US20190024068A1 - Aglycosylated enzyme and uses thereof - Google Patents

Aglycosylated enzyme and uses thereof Download PDF

Info

Publication number
US20190024068A1
US20190024068A1 US16/151,690 US201816151690A US2019024068A1 US 20190024068 A1 US20190024068 A1 US 20190024068A1 US 201816151690 A US201816151690 A US 201816151690A US 2019024068 A1 US2019024068 A1 US 2019024068A1
Authority
US
United States
Prior art keywords
polypeptide
amino acid
biomass
enzyme
acid position
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/151,690
Inventor
Marshall Medoff
Natasha Kreder
James J. Lynch
Sean Landry
Aiichiro YOSHIDA
Desiree Pangilinan
Thomas Craig Masterman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xyleco Inc
Original Assignee
Xyleco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xyleco Inc filed Critical Xyleco Inc
Priority to US16/151,690 priority Critical patent/US20190024068A1/en
Publication of US20190024068A1 publication Critical patent/US20190024068A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2445—Beta-glucosidase (3.2.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/02—Monosaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01021—Beta-glucosidase (3.2.1.21)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Definitions

  • the present invention relates generally to compositions having cellobiase activity and methods for producing the compositions described herein.
  • the present invention also provides methods for using such compositions, e.g., to process biomass materials.
  • Biomass-degrading enzymes such as cellulases, xylanases, and ligninases, are important for the degradation of biomass, such as feedstock.
  • Cellulosic and lignocellulosic materials are produced, processed, and used in large quantities in a number of applications. Often such materials are used once, and then discarded as waste, or are simply considered to be wasted materials, e.g., sewage, bagasse, sawdust, and stover
  • the present invention is based, at least in part, on the surprising discovery that a cellobiase from T. reesei that was expressed in a non-fungal cell line and isolated from a host cell that does not significantly glycosylate the enzyme had higher specific activity on pure substrate than the endogenous cellobiase (glycosylated and secreted) from T. reesei. Furthermore, when the aglycosylated cellobiase was used in a saccharification reaction with an enzyme mixture containing other saccharifying enzymes, a substantial increase in yield of sugar products was observed compared to the reaction without the aglycosylated cellobiase.
  • an aglycosylated polypeptide having enzymatic activity e.g., cellobiase activity
  • compositions comprising the aglycosylated polypeptide and methods for producing and using the compositions described herein.
  • the disclosure features an aglycosylated polypeptide having cellobiase activity.
  • the aglycosylated polypeptide has increased cellobiase activity as compared to glycosylated Cel3A enzyme from wild-type T. reesei or a mutant thereof, such as T. reesei RUTC30.
  • the aglycosylated polypeptide can have increased substrate recognition or a more active substrate recognition site as compared to glycosylated Cel3A enzyme from wild-type T. reesei.
  • the aglycosylated polypeptide has reduced steric hindrance as compared to glycosylated Cel3A enzyme from wild-type T. reesei.
  • the aglycosylated polypeptide comprises at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO: 1, or a functional fragment thereof.
  • the aglycosylated polypeptide comprises (e.g., consists of) the amino acid sequence SEQ ID NO: 1.
  • the aglycosylated polypeptide differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 amino acids from the amino acid sequence of SEQ ID NO: 1.
  • the polypeptide comprises a Cel3A enzyme from wild-type T. reesei, or a mutant thereof, such as T. reesei RUTC30, or a functional variant or fragment thereof.
  • the aglycosylated polypeptide is encoded by a nucleic acid sequence, wherein the nucleic acid sequence comprises (e.g., consists of) at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO: 2 or SEQ ID NO: 3.
  • the aglycosylated polypeptide is encoded by a nucleic acid sequence comprising (e.g., consisting of) SEQ ID NO: 2 or SEQ ID NO: 3.
  • the aglcyosylated polypeptide is expressed by a gene that comprises a mutation proximal to or a mutation at one or more glycosylation site, wherein the mutation prevents glycosylation at the glycosylation site.
  • the mutation is at one or more of the threonine at amino acid position 78, the threonine at amino acid position 241, the serine at amino acid position 343, the serine at amino acid position 450, the threonine at amino acid position 599, the serine at amino acid position 616, the threonine at amino acid position 691, the serine at amino acid position 21, the threonine at amino acid position 24, the serine at amino acid position 25, the serine at amino acid position 28, the threonine at amino acid position 38, the threonine at amino acid position 42, the threonine at amino acid position 303, the serine at amino acid position at 398, the at serine amino acid position 435, the serine at amino acid position 436, the threonine at amino acid position 439, threonine at amino acid position 442, the threonine at amino acid position 446, the serine at amino acid position 451, the serine at amino acid position 619, the serine at
  • a mutation proximal to one or more glycosylation site can prevent glycosylation at that site, e.g., by changing the conformation of the polypeptide or changing the consensus site recognized by the glycosylating enzyme such that glycosylation would not occur at the glycosylation site.
  • the aglycosylated polypeptide hydrolyzes a carbohydrate, such as a dimer, a trimer, a tetramer, a pentamer, a hexamer, a heptamer, an octamer, or an oligomer of glucose; or an oligomer of glucose and xylose, into one or more monosaccharide, e.g., glucose.
  • the cellobiase activity comprises hydrolysis of a beta 1,4 glycosidic linkage of cellobiose.
  • the disclosure features a nucleic acid sequence encoding an aglycosylated polypeptide described herein.
  • the nucleic acid sequence encodes a Cel3A enzyme or functional fragment thereof, wherein the nucleic acid sequence comprises (e.g., consists of) at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO: 2 or SEQ ID NO: 3.
  • the nucleic acid sequence encodes a Cel3A enzyme, wherein the nucleic acid sequence comprises (e.g., consists of) SEQ ID NO: 2 or SEQ ID NO: 3.
  • the disclosure features a nucleic acid molecule that includes a nucleic acid sequence described herein.
  • the nucleic acid molecule further includes a promoter, e.g., a promoter for prokaryotic cell expression, e.g., bacterial cell expression, e.g., expression in E. coli.
  • a promoter e.g., a promoter for prokaryotic cell expression, e.g., bacterial cell expression, e.g., expression in E. coli.
  • the promoter sequence is a constitutive promoter sequence, inducible promoter sequence, or a repressible promoter sequence.
  • the promoter is a T7 promoter.
  • the nucleic acid molecule further comprises a nucleic acid sequence encoding a tag, e.g., a tag for detection and/or purification and/or for linkage to another molecule, e.g., a His tag.
  • a tag e.g., a tag for detection and/or purification and/or for linkage to another molecule, e.g., a His tag.
  • the nucleic acid molecule further comprises a nucleic acid encoding one or more signal sequences, e.g., a secretion signal sequence.
  • the disclosure features an expression vector comprising the nucleic acid sequence described herein or a nucleic acid molecule described herein.
  • the vector further comprises a nucleic acid sequence encoding a selection marker, e.g., a kanamycin or an ampicillin marker.
  • a selection marker e.g., a kanamycin or an ampicillin marker.
  • the disclosure features a cell comprising a vector described herein.
  • the cell is a prokaryotic cell/bacterial cell, e.g., an E. coli cell, e.g., an Origami E. coli cell.
  • the cell expresses an aglycosylated polypeptide described herein.
  • the cell is impaired for glycosylation.
  • the disclosure features a method for producing the aglycosylated polypeptide described herein, comprising culturing a cell expressing a polypeptide described herein, under conditions suitable for the expression of the polypeptide, wherein the cell does not glycosylate the polypeptide, e.g., a bacterial cell, e.g., an E. coli cell, e.g., an origami E. coli cell.
  • a bacterial cell e.g., an E. coli cell, e.g., an origami E. coli cell.
  • the disclosure features a method for producing the aglycosylated polypeptide described herein, comprising treating a polypeptide comprising an amino acid sequence of SEQ ID NO:1, or an amino acid sequence with at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO: 1 with a deglycosylating enzyme.
  • a deglycosylating enzyme can be PGNase or EndoH.
  • the disclosure features a method for producing the aglycosylated polypeptide described herein, comprising culturing a cell that comprises a nucleic acid sequence encoding a polypeptide having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO: 1, wherein the nucleic acid has one or more mutations which prevent glycosylation of the encoded polypeptide, and optionally obtaining the aglycosylated polypeptide from the culture.
  • the disclosure features a method for culturing a cell expressing the aglycosylated polypeptide described herein in the presence of a glycosylation inhibitor.
  • the glycosylation inhibitor is tunicamycin.
  • the disclosure features an enzyme mixture comprising an aglycosylated polypeptide described herein and one or more additional enzyme, such as one or more glycosylated enzymes, e.g., cellulases from fungal cells.
  • the enzyme mixture comprises a glycosylated polypeptide comprising an amino acid sequence with at least 75%, 80%, 95%, 90%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO: 1 and an aglycosylated polypeptide described herein, wherein both of the glycosylated polypeptide and the aglycosylated peptide have cellobiase activity.
  • the enzyme mixture comprises a glycosylated polypeptide and an aglycosylated polypeptide and both the glycosylated polypeptide and the aglycosylated polypeptide both comprise Cel3A enzyme from wild-type T. reesei or a mutant thereof, such as T. reesei RUTC30.
  • the enzyme mixture further comprises at least one additional enzyme derived from a microorganism, wherein the additional enzyme has a biomass-degrading activity.
  • the additional enzyme is selected from a ligninase, an endoglucanase, a cellobiohydrolase, xylanase, and a cellobiase.
  • the reaction mixture has a ratio between the aglycosylated polypeptide and the remaining enzymes of at least 1:32, e.g., 1:32 to 1:300. In one embodiment, the reaction mixture has a ratio of the aglycosylated polypeptide to a glycosylated polypeptide is at least 1:32, e.g., 1:32 to 1:300.
  • the disclosure features a method of producing a product (e.g., hydrogen, a sugar, an alcohol, etc.) from a biomass (or converting a biomass to a product) comprising contacting a biomass, e.g., a biomass that has been treated with radiation, e.g., radiation from an electron beam, with an aglycosylated polypeptide described herein, under condiaitions suitable for the production of a sugar product.
  • the method further comprises contacting the biomass with a microorganism that produces one or more biomass-degrading enzyme or an enzyme mixture comprising biomass-degrading enzymes, e.g., an enzyme mixture described herein.
  • the disclosure features a method of producing a product (e.g., hydrogen, sugar, alcohol, etc.) from a biomass (or converting a biomass to a product) comprising contacting a biomass with an enzyme mixture described herein under conditions suitable for the production of the product.
  • a product e.g., hydrogen, sugar, alcohol, etc.
  • the product is a sugar product, e.g., a sugar product described herein.
  • the sugar product is glucose and/or xylose, or other sugar products, such as fructose, arabinose, galactose, and cellobiose.
  • the method further comprises isolating the sugar product.
  • the isolating of the sugar product comprises precipitation, crystallization, chromatography, centrifugation, and/or extraction.
  • the enzyme mixture comprises at least two of the enzymes selected from B2AF03, CIP1, CIP2, Cel1a, Cel3a, Cel5a, Cel6a, Cel7a, Cel7b, Cel12a, Cel45a, Cel74a, paMan5a, paMan26a, Swollenin, or any of the enzymes listed in Table 1.
  • the enzymes listed above are isolated from a cell that expresses the enzyme heterologously or endogenously, e.g., Trichoderma reesei or Podospora anserina.
  • the biomass comprises a starchy material or a starchy material that includes a cellulosic component.
  • the biomass comprises one or more of an agricultural product or waste, a paper product or waste, a forestry product, or a general waste, or any combination thereof; wherein: a) an agricultural product or waste comprises sugar cane jute, hemp, flax, bamboo, sisal, alfalfa, hay, arracacha, buckwheat, banana, barley, cassava, kudzu, oca, sago, sorghum, potato, sweet potato, taro, yams, beans, favas, lentils, peas, grasses, switchgrass, miscanthus, cord grass, reed canary grass, grain residues, canola straw, wheat straw, barley straw, oat straw, rice straw, corn cobs, corn stover, corn fiber, coconut hair, beet pulp, bagasse, soybean stover, grain residues,
  • the method further comprises a step of treating the biomass prior to introducing the microorganism or the enzyme mixture to reduce the recalcitrance of the biomass, e.g., by treating the biomass with bombardment with electrons, sonication, oxidation, pyrolysis, steam explosion, chemical treatment, mechanical treatment, and/or freeze grinding.
  • the microorganism that produces a biomass-degrading enzyme is from species in the genera selected from Bacillus, Coprinus, Myceliophthora, Cephalosporium, Scytalidium, Penicillium, Aspergillus, Pseudomonas, Humicola, Fusarium, Thielavia, Acremonium, Chrysosporium or Trichoderma.
  • the microorganism that produces a biomass-degrading enzyme is selected from Aspergillus, Humicola insolens ( Scytalidium thermophilum ), Coprinus cinereus, Fusarium oxysporum, Myceliophthora thermophila, Meripilus giganteus, Thielavia terrestris, Acremonium persicinum, Acremonium acremonium, Acremonium brachypenium, Acremonium dichromosporum, Acremonium obclavatum, Acremonium pinkertoniae, Acremonium roseogriseum, Acremonium incoloratum, Acremonium furatum, Chrysosporium lucknowense, Trichoderma viride, Trichoderma reesei, or Trichoderma koningii.
  • the microorganism has been induced to produce biomass-degrading enzymes by combining the microorganism with an induction biomass sample under conditions suitable for increasing production of biomass-degrading enzymes compared to an uninduced microorganism.
  • the induction biomass sample comprises paper, paper products, paper waste, paper pulp, pigmented papers, loaded papers, coated papers, filled papers, magazines, printed matter, printer paper, polycoated paper, card stock, cardboard, paperboard, cotton, wood, particle board, forestry wastes, sawdust, aspen wood, wood chips, grasses, switchgrass, miscanthus, cord grass, reed canary grass, grain residues, rice hulls, oat hulls, wheat chaff, barley hulls, agricultural waste, silage, canola straw, wheat straw, barley straw, oat straw, rice straw, jute, hemp, flax, bamboo, sisal, abaca, corn cobs, corn stover, soybean stover, corn fiber, alfal
  • FIG. 1 is a picture of purified Cel3a that was expressed in E. coli.
  • Lane 1 represents molecular weight marker (Precision Plus All Blue Protein marker, Biorad);
  • lane 2 represents purified Cel3a-His protein.
  • FIG. 2 is a chromatographic profile of the Cel3a-N′His sample, showing the detection of Cel3a-N′His at 31 minutes.
  • FIG. 3 is a profile showing no evidence of glycosylation in the mass spectral region for the peak in the chromatographic profile of the Cel3a-N′His at 31 minutes.
  • FIG. 4 is a profile showing the deconvolution of the charge state envelope, identifying the molecular weight of the major component (aglycosylated Cel3a-N′His) and the minor components (modified Cel3a-N′His).
  • FIG. 5 is a graph showing the cellobiase activity, as determined by cellobiase assay, of a purified Cel3a-N′His.
  • FIG. 6 is a graph showing a standard curve for cellobiase activity generated for a known concentration of Cel3a-N′His that can be used to determine the concentration of Cel3a of a sample with an unknown concentration of Cel3a.
  • FIG. 7 is a graph showing that specific activity of recombinant Cel3a compared to endogenous cellobiase from T. Reesei (L4196).
  • FIG. 8 is a graph showing the yield of glucose product from a saccharification reaction performed with a standard enzyme mix compared to the standard enzyme mix (L331 control) with the addition of aglycosylated cellobiase Cel3a (L331 (0.8 mg/ml Cel3a).
  • an element means one element or more than one element.
  • glycosylated refers to a molecule, e.g., a polypeptide, that is not glycosylated (i.e., it comprises a hydroxyl group or other functional group that is not attached to a glycosylate group) at one or more sites which has a glycan attached when the molecule is produced in its native environment.
  • a Cel3A enzyme is aglycosylated when one or more site in the protein that normally has a glycan group attached to it when the Cel3A enzyme is produced in T. reesei does not have a glycan attached at that site.
  • biomass refers to any non-fossilized, organic matter.
  • Biomass can be a starchy material and/or a cellulosic, hemicellulosic, or lignocellulosic material.
  • the biomass can be an agricultural product, a paper product, forestry product, or any intermediate, byproduct, residue or waste thereof, or a general waste.
  • the biomass may be a combination of such materials.
  • the biomass is processed, e.g., by a saccharification and/or a fermentation reaction described herein, to produce products, such as sugars, alcohols, organic acids, or biofuels.
  • biomass degrading enzymes refers to enzymes that break down components of the biomass matter described herein into intermediates or final products.
  • biomass-degrading enzymes include at least amylases, e.g., alpha, beta or gamma amylases, cellulases, hemicellulases, ligninases, endoglucancases, cellobiases, xylanases, and cellobiohydrolases.
  • Biomass-degrading enzymes are produced by a wide variety of microorganisms, and can be isolated from the microorganisms, such as T. reesei.
  • the biomass degrading enzyme can be endogenously expressed or heterologously expressed.
  • cellobiase activity refers to activity of a category of cellulases that catalyze the hydrolysis of cellobiose to glucose, e.g., catalyzes the hydrolysis of beta-D-glucose residues to release beta-D-glucose.
  • Cellobiase activity can be determined according to the assays described herein, e.g., in Example 6.
  • One unit of cellobiase activity can be defined as [glucose] g/L/[Cel3a] g/L/30 minutes.
  • cellobiohydrolase refers to an enzyme that hydrolyzes glycosidic bonds in cellulose.
  • the cellobiohydrolase is 1,4-beta-D-glucan cellobiohydrolase, which catalyzes the hydrolysis of 1,4-beta-D-glucosidic linkages in cellulose, cellooligosaccharides, or any beta-1,4-linked glucose containing polymer, releasing oligosaccharides from the polymer chain.
  • endoglucanase refers to an enzyme that catalyzes the hydrolysis of internal ⁇ -1,4 glucosidic bonds of cellulose.
  • the endoglucanase is endo-1,4-(1,3; 1,4)-beta-D-glucan 4-glucanohydrolase, which catalyses endohydrolysis of 1,4-beta-D-glycosidic linkages in cellulose, cellulose derivatives (such as carboxymethyl cellulose and hydroxyethyl cellulose), lichenan, beta-1,4 bonds in mixed beta-1, 3 glucans such as cereal beta-D-glucans or xyloglucans, and other plant material containing cellulosic components.
  • enzyme mixture refers to a combination of at least two different enzymes, or at least two different variants of an enzyme (e.g., a glycosylated and an aglycosylated version of an enzyme).
  • the enzyme mixture referred to herein includes at least the aglycosylated polypeptide having cellobiase activity described herein.
  • the enzyme mixture includes one or more of a cellobiase, an endoglucanase, a cellobiohydrolase, a ligninase, and/or a xylanase.
  • the enzyme mixture includes a cell, e.g., a microorganism, which expresses and, e.g., secretes, one or more of the enzymes.
  • the enzyme mixture can include an aglycosylated polypeptide described herein and a cell, e.g., a microorganism, which expresses and, e.g., secretes, one or more additional enzymes and/or variants of the polypeptide.
  • ligninase refers to an enzyme that catalyzes the breakdown of lignin, commonly found in the cell walls of plants, such as by an oxidation reaction.
  • nucleic acid or “polynucleotide” are used interchangeable, and refer to deoxyribonucleic acids (DNA) or ribonucleic acids (RNA) and polymers thereof in either single- or double-stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences as well as the sequence explicitly indicated.
  • DNA deoxyribonucleic acids
  • RNA ribonucleic acids
  • degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).
  • operably linked refers to a configuration in which a control or regulatory sequence is placed at a position relative to a nucleic acid sequence that encodes a polypeptide, such that the control sequence influences the expression of a polypeptide (encoded by the DNA sequence).
  • the control or regulatory sequence is upstream of a nucleic acid sequence that encodes a polypeptide with cellobiase activity.
  • the control or regulatory sequence is downstream of a nucleic acid sequence that encodes a polypeptide with cellobiase activity.
  • polypeptide refers to a compound comprised of amino acid residues covalently linked by peptide bonds.
  • a protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that can comprise a protein's or peptide's sequence.
  • Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds.
  • Polypeptides include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others.
  • a polypeptide includes a natural peptide, a recombinant peptide, or a combination thereof.
  • promoter refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a polynucleotide sequence.
  • regulatory sequence refers to a nucleic acid sequence which is required for expression of a nucleic acid product.
  • this sequence may be a promoter sequence and in other instances, this sequence may also include an enhancer sequence and other regulatory elements which are required for expression of the gene product.
  • the regulatory/control sequence may, for example, be one which expresses the nucleic acid product in a regulated manner, e.g., inducible manner.
  • constitutive promoter refers to a nucleotide sequence which, when operably linked with a polynucleotide which encodes a polypeptide, causes the polypeptide to be produced in a cell under most or all physiological conditions of the cell.
  • the polypeptide is a polypeptide having cellobiase activity.
  • inducible promoter refers to a nucleotide sequence which, when operably linked with a polynucleotide which encodes a polypeptide, causes the polypeptide to be produced in a cell substantially only when an inducer which corresponds to the promoter is present in the cell.
  • the polypeptide is a polypeptide having cellobiase activity.
  • repressible promoter refers to a nucleotide sequence, which when operably linked with a polynucleotide which encodes a polypeptide, causes the polypeptide to be produced in a cell substantially only until a repressor which corresponds to the promoter is present in the cell.
  • the polypeptide is a polypeptide having cellobiase activity.
  • xylanase refers to enzymes that hydrolyze xylan-containing material.
  • Xylan is polysaccharide comprising units of xylose.
  • a xylanase can be an endoxylanase, a beta-xylosidase, an arabinofuranosidase, an alpha-glucuronidase, an acetylxylan esterase, a feruloyl esterase, or an alpha-glucuronyl esterase.
  • Glycosylation is thought to play a critical role in enzyme structure and function, such as enzyme activity, solubility, stability, folding, and/or secretion. Accordingly, processes for converting biomass into biofuels and other products have focused on producing and utilizing glycosylated enzymes, e.g., cellobiases, for use in saccharification of cellulosic and/or lignocellulosic materials. Enzymes for use in saccharification are typically produced in eukaryote host cell lines that properly glycosylate, fold, and secrete the proteins, such as Pichia pastoris.
  • glycosylated enzymes e.g., cellobiases
  • the present invention is based, at least in part, on the surprising discovery that a cellobiase from T. reesei that was expressed in a non-fungal cell line and isolated from a host cell that does not significantly glycosylate the enzyme had higher specific activity on pure substrate than the endogenous cellobiase (glycosylated and secreted) from T. reesei. Furthermore, when the aglycosylated cellobiase was used in a saccharification reaction with an enzyme mixture containing other saccharifying enzymes, a substantial increase in yield of sugar products was observed compared to the reaction without the aglycosylated cellobiase.
  • an aglycosylated polypeptide having enzymatic activity e.g., cellobiase activity
  • compositions comprising the aglycosylated polypeptide and methods for producing and using the compositions described herein.
  • the present disclosure provides an aglycosylated polypeptide with cellobiase activity.
  • the aglycosylated polypeptide is a cellobiase.
  • a cellobiase is an enzyme that hydrolyzes beta-1,4 bonds in its substrate, cellobiose, to release two glucose molecules.
  • Cellobiose is a water soluble 1,4-linked dimer of glucose.
  • Cel3a (also known as BglI) is a cellobiase that was identified in Trichoderma reesei.
  • the amino acid sequence for Cel3a (GenBank Accession No. NW_006711153) is provided below:
  • a functional variant has an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a Cel3a described herein, or a functional fragment thereof, e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a Cel3a described herein, or a functional fragment thereof.
  • a functional variant has an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91% identity, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to SEQ ID NO: 1, or a functional fragment thereof.
  • Percent identity in the context of two or more amino acid or nucleic acid sequences refers to two or more sequences that are the same. Two sequences are “substantially identical” if two sequences have a specified percentage of amino acid residues or nucleotides that are the same (e.g., 60% identity, optionally 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity over a specified region, or, when not specified, over the entire sequence), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection.
  • the identity exists over a region that is at least about 50 nucleotides, 100 nucleotides, 150 nucleotides, in length. More preferably, the identity exists over a region that is at least about 200 or more amino acids, or at least about 500 or 1000 or more nucleotides, in length.
  • sequence comparison For sequence comparison, one sequence typically acts as a reference sequence, to which one or more test sequences are compared.
  • test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated.
  • sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters. Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman, (1970) Adv. Appl. Math.
  • BLAST and BLAST 2.0 algorithms Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., (1977) Nuc. Acids Res. 25:3389-3402; and Altschul et al., (1990) J. Mol. Biol. 215:403-410, respectively.
  • Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.
  • Functional variants may comprise one or more mutations, such that the variant retains cellobiase activity that is better, e.g., increased in comparison to, than the cellobiase activity of an ezyme of SEQ ID NO:1 produced by T. reesei.
  • the functional variant has at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, or at least 99%) of the cellobiase activity as an aglycosylated version of SEQ ID NO: 1 as produced by E. coli. Cellobiase activity can be tested using the functional assays described herein.
  • the aglycosylated polypeptide differs by no more than 1, no more than 2, no more than 3, no more than 4, no more than 5, no more than 6, no more than 7, no more than 8, no more than 9, no more than 10, no more than 15, no more than 20, no more than 30, no more than 40, or no more than 50 amino acids from a reference amino acid sequence, e.g., the amino acid sequence of SEQ ID NO: 1.
  • the mutations present in a functional variant include amino acid substitutions, additions, and deletions. Mutations can be introduced by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. The mutation may be a conservative amino acid substitution, in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art.
  • amino acids with basic side chains e.g., lysine, arginine, histidine
  • acidic side chains e.g., aspartic acid, glutamic acid
  • uncharged polar side chains e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan
  • nonpolar side chains e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine
  • beta-branched side chains e.g., threonine, valine, isoleucine
  • aromatic side chains e.g., tyrosine, phenylalanine, tryptophan, histidine
  • one or more amino acid residues within the polypeptide having cellobiase activity of the disclosure can be replaced with other amino acids from the same side chain family, and the resultant polypeptide retains cellobiase activity comparable (e.g., at least 80%, 85%, 90%, 95%, or 99% of the cellobiase activity) to that of the wild-type polypeptide.
  • the mutation may be an amino acid substitution in which an amino acid residue is replaced with an amino acid residue having a different side chain.
  • Such mutations may alter or affect various enzymatic characteristics of the cellobiase. For example, such mutations may alter or affect the cellobiase activity, thermostability, optimal pH for reaction, enzyme kinetics, or substrate recognition of the cellobiase.
  • a mutation increases the cellobiase activity of the variant in comparison to the cellobiase produced by T. reesei and/or SEQ ID NO:1 produced in E.coli.
  • a mutation increases or decreases the thermostability of the variant in comparison to wild-type cellobiase and/or SEQ ID NO:1 produced in E.coli.
  • a mutation changes the pH range at which the variant optimally performs the cellobiase reaction in comparison to wild-type cellobiase and/or SEQ ID NO:1 produced in E.coli.
  • a mutation increases or decreases the kinetics of the cellobiase reaction (e.g., k cat , K M or K D ) in comparison to wild-type cellobiase and/or SEQ ID NO:1 produced in E.coli.
  • a mutation increases or decreases the ability of the cellobiase to recognize or bind to the substrate (e.g., cellobiose) in comparison to wild-type cellobiase and/or SEQ ID NO:1 produced in E.coli.
  • the present invention also provides functional fragments of a polypeptide having cellobiase activity as described herein, e.g., Cel3a or SEQ ID NO: 1.
  • a fragment of a polypeptide having cellobiase activity as described herein that contains the functional domains responsible for enzymatic activity would retain functional activity, e.g., cellobiase activity, and therefore, such fragments are encompassed in the present invention.
  • the functional fragment is at least 700 amino acids, at least 650 amino acids, at least 600 amino acids, at least 550 amino acids, at least 500 amino acids, at least 450 amino acids, at least 400 amino acids, at least 350 amino acids, at least 300 amino acids, at least 250 amino acids, at least 200 amino acids, at least 150 amino acids, at least 100 amino acids, or at least 50 amino acids in length.
  • the functional fragment is 700 to 744 amino acids, 650 to 699 amino acids, 600 to 649 amino acids, 550 to 599 amino acids, 500 to 549 amino acids, 450 to 499 amino acids, 400 to 449 amino acids, 350 to 399 amino acids, 300 to 349 amino acids, 250 to 299 amino acids, 200 to 249 amino acids, 150 to 199 amino acids, 100 to 149 amino acids, or 50 to 99 amino acids.
  • the ranges of amino acid length described above the lowest and highest values of amino acid length are included within each disclosed range.
  • the functional fragment has at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% of the cellobiase activity as wild-type Cel3a or the polypeptide comprising SEQ ID NO: 1 produced in E.coli.
  • Assays for detecting cellobiase activity are known in the art. For example, detection of the amount of glucose released from cellobiose can be determined by incubating purified cellobiase with substrate, e.g., cellobiose, D-(+)-cellobiose, and detecting the resultant amount of free glucose after completion of the reaction.
  • substrate e.g., cellobiose, D-(+)-cellobiose
  • the amount of free glucose can be determined using a variety of methods known in the art. For example, dilutions of purified cellobiase are prepared in a buffer containing 50 mM sodium citrate monobasic, pH 5.0 NaOH.
  • the cellobiose substrate is added to the purified cellobiase in an amount such that the final concentration of cellobiose in the reaction mixture is 30 mM.
  • the reaction mixture is incubated under conditions suitable for the reaction to occur, e.g., in a shaker (700 rpm) at 48° C. for 30 minutes. To stop the reaction, the reaction mixture is heated for 5 minutes at 100° C.
  • the reaction mixture is filtered through a 0.45 ⁇ m filter and the filtrate is analyzed to quantify the amount of glucose and/or cellobiase.
  • a YSI instrument that measures analytes such as glucose can be used to determine the concentration of glucose produced from the reaction.
  • UPLC Ultra Performance Liquid Chromatography
  • This assay can be formatted in a single reaction or in multiple reaction formats, e.g., 96 well format.
  • the multiple reaction format may be preferred to generate an activity curve representing cellobiase activity with respect to different concentrations of the purified cellobiase.
  • the concentration of the purified cellobiase can be determined using a standard Bradford assay. Dilutions of the purified cellobiase assay are prepared, e.g., 2-fold dilutions, and are aliquoted into a 96 well plate, e.g., 12 wells of 2-fold dilutions.
  • Cellobiose substrate is added as previously described, such that the final concentration of cellobiase in the reaction is 30 mM.
  • the plate is sealed and treated under conditions sufficient for the cellobiase reaction to occur, and then under conditions to stop the reaction.
  • the reaction is then filtered through a 96 well format 0.45 ⁇ m membrane (e.g., Durapore) and analyzed by YSI and/or HPLC methods, e.g., UPLC.
  • This activity assay can also be used to determine the concentration, or titer, of a Cel3a in a sample by generating a standard curve of activity of dilutions of a Cel3a sample with a known concentration. The activity of dilutions of the sample with unknown concentration is determined and compared with the standard curve to identify an approximate concentration based on the standard curve. This method is described in further detail in Example 6.
  • a colorimetric/fluorometric assay can be used.
  • the purified cellobiase is incubated with substrate cellobiose under conditions for the reaction to occur.
  • Detection of the product glucose is as follows.
  • Glucose oxidase is added to the mixture, which oxidizes glucose (the product) to gluconic acid and hydrogen peroxide.
  • Peroxidase and o-dianisidine is then added.
  • O-dianisidine reacts with the hydrogen peroxide in the presence of peroxidase to form a colored product.
  • Sulfuric acid is added, which reacts with the oxidized o-dianisidine reacts to form a more stable colored product.
  • the intensity of the color when measured is directly proportional to the glucose concentration.
  • Such colorimetric/fluorometric glucose assays are commercially available, for example from Sigma Aldrich, Catalog No. GAGO-20.
  • polypeptides having cellobiase activity described above are aglycosylated using the methods for producing aglycosylated polypeptides described herein.
  • Glycosylation is the enzymatic process by which a carbohydrate is attached to a glycosyl acceptor, e.g., the nitrogen of arginine or asparginine side chains or the hydroxyl oxygen of serine, threonine, or tyrosine side chains.
  • a glycosyl acceptor e.g., the nitrogen of arginine or asparginine side chains or the hydroxyl oxygen of serine, threonine, or tyrosine side chains.
  • N-linked glycosylation occurs at consensus site Asn-X-Ser/Thr, wherein the X can be any amino acid except a proline.
  • O-linked glycosylation occurs at Ser/Thr residues.
  • Glycosylation sites can be predicted using various algorithms known in the art, such as Prosite, publicly available by the Swiss Institute of Bioinformatics, and NetNGlyc 1.0 or NetOGlyc 4.0, publicly available by the Center for Biological Sequence Analysis.
  • the functional variant contains one or more mutations wherein one or more glycoslyation sites present in the Cel3a polypeptide expressed by a nucleic acid sequence described herein that has been mutated such that a glycan can no longer be attached or linked to the glycosylation site.
  • the functional variant contains one or more mutations proximal to one or more glycosylation sites present in the Cel3a polypeptide expressed by a nucleic acid sequence described herein that has been mutated such that a glycan can no longer be attached or linked to the glycosylation site.
  • the mutation proximal to a glycosylation site mutates the consensus motif recognized by the glycosylating enzyme, or changes the conformation of the polypeptide such that the polypeptide cannot be glycosylated, e.g., the glycoslation site is hidden or steric hindrance due to the new conformation prevents the glycosylating enzymes from accessing the glycosylation site.
  • a mutation proximal to a glycosylation site in the Cel3a polypeptide is directly adjacent to, or at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 30 or at least 40 amino acids from the glycosylation site that, as a result of the proximal mutation, will not be glycosylated.
  • one or more of the following glycosylation sites of Cel3a, or SEQ ID NO: 1, are mutated: the threonine at amino acid position 78, the threonine at amino acid position 241, the serine at amino acid position 343, the serine at amino acid position 450, the threonine at amino acid position 599, the serine at amino acid position 616, the threonine at amino acid position 691, the serine at amino acid position 21, the threonine at amino acid position 24, the serine at amino acid position 25, the serine at amino acid position 28, the threonine at amino acid position 38, the threonine at amino acid position 42, the threonine at amino acid position 303, the serine at amino acid position at 398, the at serine amino acid position 435, the serine at amino acid position 436, the threonine at amino acid position 439, threonine at amino acid position 442, the threonine at amino acid position 446, the serine
  • the glycosylation site is mutated from a serine or threonine to an alanine.
  • the aglycosylated polypeptide described herein has one or more of the following mutations: T78A, T241A, S343A, S450A, T599A, S616A, T691A, S21A, T24A, S25A, S28A, T38A, T42A, T303A, T398A, S435A, S436A, T439A, T442A, T446A, S451A, S619A, S622A, T623A, S626A, or T630A, or any combination thereof.
  • one or more amino acids proximal to the glycosylation sites described above is mutated.
  • Assays to detect whether a polypeptide is modified by a glycan are known in the art.
  • the polypeptide can be purified or isolated and can be stained for detection and quantification of glycan moieties, or the polypeptide can be analyzed by mass spectrometry, and compared to a corresponding reference polypeptide.
  • the reference polypeptide has the same primary sequence as the test polypeptide (of which the glycosylation state is to be determined), but is either glycosylated or aglycosylated.
  • the aglycosylated polypeptides described herein have increased cellobiase activity compared to a corresponding glycosylated polypeptide, e.g., glycosylated Cel3a polypeptide.
  • the aglycosylated polypeptide having cellobiase activity has at least 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or 200% cellobiase activity compared to the glyocyosylated polypeptide.
  • the present invention also provides a nucleic acid sequence encoding a polypeptide having cellobiase activity of the present invention.
  • the nucleic acid sequence encodes a Cel3a enzyme or a functional fragment thereof with the amino acid sequence described herein.
  • nucleic acid sequence that encodes Cel3a is provided below:
  • the nucleic acid sequence encoding the polypeptide with cellobiase activity described herein can be codon-optimized for increased expression in host cells. Codon optimization includes changing the nucleic acid sequence to take into consideration factors including codon usage bias, cryptic splicing sites, mRNA secondary structure, premature polyA sites, interaction of codon and anti-codon, and RNA instability motifs, to increase expression of the encoded polypeptide in the host.
  • Codon optimization includes changing the nucleic acid sequence to take into consideration factors including codon usage bias, cryptic splicing sites, mRNA secondary structure, premature polyA sites, interaction of codon and anti-codon, and RNA instability motifs, to increase expression of the encoded polypeptide in the host.
  • Various algorithms and commercial services for codon-optimization are known and available in the art.
  • the nucleic acid sequence encoding a Cel3a enzyme or functional variant thereof comprises at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to SEQ ID NO: 2.
  • the nucleic acid sequence encoding a Cel3a enzyme or functional variant thereof comprises at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to SEQ ID NO:2 or SEQ ID NO: 3.
  • aglycosylated polypeptide e.g., Cel3a polypeptide, as described above, in which one or more glycoslyation sites present in the polypeptide has been mutated such that a glycan can no longer be attached or linked to the glycosylation site.
  • nucleic acid sequence described herein encoding an aglycosylated polypeptide, e.g., a Cel3a polypeptide, as described above, in which one or more mutations proximal to one or more glycosylation sites present in the polypeptide has been mutated such that a glycan can no longer be attached or linked to the glycosylation site, as previously described.
  • aglycosylated polypeptide e.g., a Cel3a polypeptide
  • the nucleic acid sequence encodes a polypeptide comprising one or more mutations at one or more of the following glycosylation sites of Cel3a, or SEQ ID NO: 1: the threonine at amino acid position 78, the threonine at amino acid position 241, the serine at amino acid position 343, the serine at amino acid position 450, the threonine at amino acid position 599, the serine at amino acid position 616, the threonine at amino acid position 691, the serine at amino acid position 21, the threonine at amino acid position 24, the serine at amino acid position 25, the serine at amino acid position 28, the threonine at amino acid position 38, the threonine at amino acid position 42, the threonine at amino acid position 303, the serine at amino acid position at 398, the at serine amino acid position 435, the serine at amino acid position 436, the threonine at amino acid position 439, threonine at amino acid position 44
  • the glycosylation site is mutated from a serine or threonine to an alanine.
  • the nucleic acid sequence of the invention encodes an aglycosylated polypeptide comprising one or more of the following mutations: T78A, T241A, S343A, S450A, T599A, S616A, T691A, S21A, T24A, S25A, S28A, T38A, T42A, T303A, T398A, S435A, S436A, T439A, T442A, T446A, S451A, S619A, S622A, T623A, S626A, or T630A, or any combination thereof.
  • the ordinarily skilled artisan could readily modify the nucleic acid sequence of wild-type Cel3a (SEQ ID NO: 2) to encode a polypeptide with one or more glycosylation site mutation by using methods known in the art, such as site-directed mutagenesis.
  • the techniques used to isolate or clone a nucleic acid sequence encoding a polypeptide include isolation from genomic DNA, preparation from cDNA, or a combination thereof.
  • the cloning of the nucleic acid sequences of the present invention from such genomic DNA can be effected, e.g., by using the well known polymerase chain reaction (PCR) or antibody screening of expression libraries to detect cloned DNA fragments with shared structural features. See, e.g., Innis et al., 1990, PCR: A Guide to Methods and Application, Academic Press, New York.
  • amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and nucleotide sequence-based amplification (NASBA) may be used.
  • LCR ligase chain reaction
  • LAT ligated activated transcription
  • NASBA nucleotide sequence-based amplification
  • the nucleic acid sequence may be cloned from a strain of Trichoderma reesei, e.g., wild-type T. reesei, or T. reesei RUTC30, or another or related organism and thus, for example, may be an allelic or species variant of the polypeptide encoding region of the nucleic acid sequence.
  • the nucleic acid sequence may be obtained by standard cloning procedures used in genetic engineering to relocate the nucleic acid sequence from its natural location to a different site where it will be reproduced.
  • the cloning procedures may involve excision and isolation of a desired fragment comprising the nucleotide sequence encoding the polypeptide, insertion of the fragment into a vector molecule, and incorporation of the recombinant vector into a host cell where multiple copies or clones of the nucleotide sequence will be replicated.
  • the nucleotide sequence may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.
  • the present invention also provides nucleic acid constructs comprising a nucleic acid sequence encoding the polypeptide having cellobiase activity described herein operably linked to one or more control sequences that direct the expression, secretion, and/or isolation of the expressed polypeptide.
  • an “expression vector” is a nucleic acid construct for introducing and expressing a nucleic acid sequence of interest into a host cell.
  • the vector comprises a suitable control sequence operably linked to and capable of effecting the expression of the polypeptide encoded in the nucleic acid sequence of interest.
  • the control sequence may be an appropriate promoter sequence, recognized by a host cell for expression of the nucleic acid sequence.
  • the nucleic acid sequence of interest is a nucleic acid sequence encoding a polypeptide having cellobiase activity as described herein.
  • a promoter in the expression vector of the invention can include promoters obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell, mutant promoters, truncated promoters, and hybrid promoters.
  • suitable promoters for directing transcription of the nucleic acid constructs of the present invention in a bacterial host cell are the promoters obtained from the E. coli lac operon, E. coli tac promoter (hybrid promoter, DeBoer et al, PNAS, 1983, 80:21-25), E. coli rec A, E. coli araBAD, E. coli tetA, and prokaryotic beta-lactamase.
  • Other examples of suitable promoters include viral promoters, such as promoters from bacteriophages, including a T7 promoter, a T5 promoter, a T3 promoter, an M13 promoter, and a SP6 promoter.
  • more than one promoter controls the expression of the nucleic acid sequence of interest, e.g., an E. coli lac promoter and a T7 promoter.
  • E. coli lac promoter e.g., E. coli lac promoter and a T7 promoter.
  • T7 promoter e.g., E. coli lac promoter
  • the promoter is inducible, where the addition of a molecule stimulates the transcription and expression of the downstream reading frame.
  • promoters for directing transcription of the nucleic acid constructs of the present invention in a eukaryotic host cell e.g., in a fungal or yeast cell
  • AOX promoter methanol-inducible alcohol oxidase
  • trpC promoter Aspergillus nidulans tryptophan biosynthesis
  • glaA Saccharomyces cerevisiae galactokinase
  • GAL1 Saccharomyces cerevisiae gal
  • a control sequence present in the expression vector of the present invention may also be a signal sequence that codes for an amino acid sequence linked to the amino terminus of a polypeptide and directs the encoded polypeptide into the cell's secretory pathway, e.g., a secretion signal sequence.
  • the signal sequence may be an endogenous signal sequence, e.g., where the signal sequence is present at the N-terminus of the wild-type polypeptide when endogenously expressed by the organism from which the polypeptide of interest originates from.
  • the signal sequence may be a foreign, or heterologous, signal peptide, in which the signal sequence is from a different organism or a different polypeptide than that of the polypeptide of interest being expressed. Any signal sequence which directs the expressed polypeptide into the secretory pathway of a host cell may be used in the present invention.
  • signal sequences are composed of between 6 and 136 basic and/or hycrophobic amino acids.
  • signal sequences suitable for the present invention include the signal sequence from Saccharomyces cerevisiae alpha-factor.
  • Fusion tags may also be used in the expression vector of the present invention to facilitate the detection and purification of the expressed polypeptide.
  • suitable fusion tags include His-tag (e.g., 3 ⁇ His, 6 ⁇ His (SEQ ID NO: 6), or 8 ⁇ His (SEQ ID NO: 7)), GST-tag, HSV-tag, S-tag, T7 tag.
  • Other suitable fusion tags include myc tag, hemagglutinin (HA) tag, and fluorescent protein tags (e.g., green fluorescent protein).
  • the fusion tag is typically operably linked to the N or C terminus of the polypeptide to be expressed.
  • the linker region comprises a sequence between 1 to 20 amino acids, that does not affect or alter the expression or function of the expressed polypeptide.
  • fusion tags described herein allows detection of the expressed protein, e.g., by western blot by using antibodies that specifically recognize the tag.
  • the tags also allows for purification of the expressed polypeptide from the host cell, e.g., by affinity chromatography.
  • an expressed polypeptide fused to a His-tag can be purified by using nickel affinity chromatography.
  • the His tag has affinity for the Nickel ions, and a nickel column will retain the his-tagged polypeptide, while allowing all other proteins and cell debris to flow through the column.
  • Elution of the His-tagged polypeptide using an elution buffer, e.g., containing imidazole releases the His-tagged polypeptide from the column, resulting in substantially purified polypeptide.
  • the expression vector of the invention may further comprise a selectable marker gene to enable isolation of a genetically modified microbe transformed with the construct as is commonly known to those of skill in the art.
  • the selectable marker gene may confer resistance to an antibiotic or the ability to grow on medium lacking a specific nutrient to the host organism that otherwise could not grow under these conditions.
  • the present invention is not limited by the choice of selectable marker gene, and one of skill in the art may readily determine an appropriate gene.
  • the selectable marker gene may confer resistance to ampicillin, chloramphenicol, tetracycline, kanamycin, hygromycin, phleomycin, geneticin, or G418, or may complement a deficiency of the host microbe in one of the trp, arg, leu, pyr4, pyr, ura3, ura5, his, or ade genes or may confer the ability to grow on acetamide as a sole nitrogen source.
  • the expression vector of the invention may further comprise other nucleic acid sequences, e.g., additional control sequences, as is commonly known to those of skill in the art, for example, transcriptional terminators, synthetic sequences to link the various other nucleic acid sequences together, origins of replication, ribosome binding sites, a multiple cloning site (or polylinker site), a polyadenylation signal and the like.
  • additional control sequences as is commonly known to those of skill in the art, for example, transcriptional terminators, synthetic sequences to link the various other nucleic acid sequences together, origins of replication, ribosome binding sites, a multiple cloning site (or polylinker site), a polyadenylation signal and the like.
  • the ribosomal binding site suitable for the expression vector depends on the host cell used, for example, for expression in a prokaryotic host cell, a prokaryotic RBS, e.g., a T7 phage RBS can be used.
  • a multiple cloning site, or polylinker site contains one or more restriction enzyme sites that are preferably not present in the remaining sequence of the expression vector.
  • the restriction enzyme sites are utilized for the insertion of a nucleic acid sequence encoding a polypeptide having cellobiase activity or other desired control sequences.
  • the practice of the present invention is not limited by the presence of any one or more of these other nucleic acid sequences, e.g., other control sequences.
  • suitable expression vectors for use in the present invention include vectors for expression in prokaryotes, e.g., bacterial expression vectors.
  • a bacterial expression vector suitable for use in the present invention in the pET vector which contains the following: a viral T7 promoter which is specific to only T7 RNA polymerase (not bacterial RNA polymerase) and also does not occur anywhere in the prokaryotic genome, a lac operator comprising a lac promoter and coding sequence for the lac repressor protein (lacI gene), a polylinker, an f1 origin of replication (so that a single-stranded plasmid can be produced when co-infected with M13 helper phage), an ampicillin resistance gene, and a ColE1 origin of replication (Blaber, 1998).
  • Both the promoter and the lac operator are located 5′, or upstream, of the polylinker in which the nucleic acid sequence encoding a polypeptide described herein is inserted.
  • the lac operator confers inducible expression of the nucleic acid sequence encoding a polypeptide having cellobiase activity.
  • Addition of IPTG (Isopropyl ⁇ -D-1-thiogalactopyranoside), a lactose metabolite triggers transcription of the lac operon and induces protein expression of the nucleic acid sequence under control of the lac operator.
  • Use of this system requires the addition of T7 RNA polymerase to the host cell for vector expression.
  • the T7 RNA polymerase can be introduced via a second expression vector, or a host cell strain that is genetically engineered to express T7 RNA polymerase can be used.
  • An exemplary expression vector for use with the invention is a pET vector, commercially available from Novagen.
  • the pET expression system is described in U.S. Pat. Nos. 4,952,496; 5,693,489; and 5,869,320.
  • the pET vector is a pET-DUET vector, e.g., pET-Duet1, commercially available from Novagen.
  • Other vectors suitable for use in the present invention include vectors containing His-tag sequences, such as those described in U.S. Pat. Nos. 5,310,663 and 5,284,933; and European Patent No. 282042.
  • the present invention also relates to a host cell comprising the nucleic acid sequence or expression vector of the invention, which are used in the recombinant production of the polypeptides having cellobiase activity.
  • An expression vector comprising a nucleic acid sequence of the present invention is sintroduced into a host cell so that the vector is maintained (e.g., by chromosomal integration or as a self-replicating extra-chromosomal vector) such that the polypeptide is expressed.
  • the host cell may be a prokaryote or a eukaryote.
  • the host cell may be a bacteria, such as an E. coli strain, e.g., K12 strains NovaBlue, NovaBlue T1R, JM109, and DH5 ⁇ .
  • the bacteria cell has the capability to fold, or partially fold, exogenously expressed proteins, such as E. coli Origami strains, e.g., Origami B, Origami B (DE3), Origami 2, and Origami 2(DE3) strains.
  • the host cell may be a yeast or a filamentous fungus, particularly those classified as Ascomycota.
  • Genera of yeasts useful as host microbes for the expression of modified TrCel3A beta-glucosidases of the present invention include Saccharomyces, Pichia, Hansenula, Kluyveromyces, Yarrowia, and Arxula.
  • Genera of fungi useful as microbes for the expression of the polypeptides of the present invention include Trichoderma, Hypocrea, Aspergillus, Fusarium, Humicola, Neurospora, Chrysosporium, Myceliophthora, Thielavia, Sporotrichum and Penicillium.
  • the host cell may be Pichia pastoris.
  • the host cell may be an industrial strain of Trichoderma reesei, or a mutant thereof, e.g., T. reesei RUTC30.
  • the host cell is one which does not express a parental cellobiase or Cel3a.
  • the selection of the particular host cell depends on the expression vector (e.g., the control sequences) and/or the method utilized for producing an aglycosylated polypeptide of the invention, as described in further detail below.
  • the expression vector of the invention may be introduced into the host cell by any number of methods known by one skilled in the art of microbial transformation, including but not limited to, transformation, treatment of cells with CaCl 2 , electroporation, biolistic bombardment, lipofection, and PEG-mediated fusion of protoplasts (e.g. White et al., WO 2005/093072, which is incorporated herein by reference).
  • transformation transformation, treatment of cells with CaCl 2 , electroporation, biolistic bombardment, lipofection, and PEG-mediated fusion of protoplasts
  • the recombinant host cells may be cultured under conditions that induce the expression of the polypeptide having cellobiase activity of the invention.
  • the present invention further provides methods for producing an aglycosylated polypeptide having cellobiase activity, as described herein.
  • the method comprises culturing the recombinant host cell expressing the polypeptide of the present invention under conditions suitable for the expression of the polypeptide.
  • the method may also comprise recovering the aglycosylated polypeptide from the recombinant host cell.
  • the method for recovering the polypeptide comprises lysing the cells, e.g., by mechanical, chemical, or enzymatic means.
  • cells can be physically broken apart, e.g., by sonication, milling (shaking with beads), or shear forces.
  • Cell membranes can be treated such that they are permeabilized such that the contents of the cells are released, such as treatment with detergents, e.g., Triton, NP-40, or SDS.
  • Cells with cell walls can be permeabilized using enzymes, such as a lysozyme or lysonase. Any combination of the mechanical, chemical, and enzymatic techniques described above are also suitable for recovering expressed polypeptides of interest from the host cell in the context of this invention.
  • enzymes such as a lysozyme or lysonase.
  • Any combination of the mechanical, chemical, and enzymatic techniques described above are also suitable for recovering expressed polypeptides of interest from the host cell in the context of this invention.
  • a bacterial cell e.g., an E. coli cell
  • the cell is typically lysed by centrifuging and pelleting the cell culture, and resuspending in a lysis buffer containing lysozyme.
  • the resuspended cells are subjected to one of the following methods: sonication, milling, or homogenization.
  • the expressed aglycosylated polypeptides having cellobiase activity described herein are not lysed before addition to the biomass for the saccharification reaction.
  • the methods for lysing host cells can result in protein denaturation and/or decreased enzyme activity, which leads to increased cost of downstream processing.
  • the present invention also provides methods for directly adding the host cells expressing an aglycosylated polypeptide having cellobiase activity described herein to the biomass prior to the saccharification step.
  • the host cell e.g., the E. coli cell, expressing the aglycosylated polypeptide having cellobiase activity described herein is isolated, e.g., by centrifugation, and added to the saccharification reaction, e.g., the saccharification reactor containing biomass.
  • the cells are lysed by a combination of shear from the biomass, the impellers, and the increased temperature.
  • the culture of host cell, e.g., the E. coli cell, expressing the aglycosylated polypeptide having cellobiase activity described herein is added directly from the fermentation tank directly to the saccharification tank and eliminating the need to pellet cells by centrifugation.
  • the expression vector comprises a nucleic acid sequence encoding a polypeptide having cellobiase activity described herein operably linked to a fusion tag is introduced to and expressed in a cell that does not significantly glycosylate proteins expressed in the cell, e.g., a bacterial host cell.
  • the recombinant host cell is cultured under conditions for expression of the polypeptide, resulting in the production of an aglycosylated polypeptide having cellobiase activity.
  • the aglycosylated polypeptide can be purified or isolated from the host cell using affinity chromatography methods for the fusion tag as described herein.
  • the expression vector contains a lac operator and a T7 promoter upstream of the nucleic acid sequence encoding a polypeptide having cellobiase activity, and the host cell has the capacity to express T7 RNA polymerase. Expression of the polypeptide having cellobiase activity is induced by addition of IPTG.
  • the host cell is an E. coli cell, preferably an E. coli Origami cell.
  • the fusion tag is a His-tag, and the purification of the expressed aglycosylated polypeptide comprises nickel affinity chromatography.
  • an expression vector comprising a nucleic acid sequence encoding a polypeptide comprising one or more glycosylation site mutations such that the polypeptide is not glyscosylated, as described herein, is expressed in a host cell, wherein the host cell is capable of glycosylating proteins expressed within the cell, e.g., a yeast or fungal host cell. Alternatively, the host cell is not capable of glycosylating proteins expressed within the cell, e.g., a bacterial host cell.
  • the polypeptide is operably linked to a fusion tag.
  • the aglycosylated polypeptide can be purified or isolated from the bacterial host cell using affinity chromatography methods for the fusion tag as described herein.
  • an expression vector comprising a nucleic acid sequence encoding a polypeptide having cellobiase activity described herein is expressed in a host cell, wherein the host cell is capable of glycosylating proteins expressed within the cell.
  • the cells are cultured under conditions sufficient for expression and glycosylation of the polypeptide.
  • the polypeptide is operably linked to a fusion tag.
  • the glycosylated polypeptide can be purified or isolated from the bacterial host cell using affinity chromatography methods for the fusion tag as described herein.
  • the glycans of the isolated glycosylated polypeptide can be removed by incubation with deglycosylating enzymes.
  • Deglycosylating enzymes include PNGase F, PNGase A, EndoH (endoglycosidase H), EndoS (endoglycosidase S), EndoD (endoglycosidase D), EndoF (endoglycosidase F), EndoF1 (endoglycosidase F1), or EndoF2 (endoglycosidase F2).
  • Protein deglycosylation mixes containing enzymes sufficient for the complete removal of glycans are commercially available, e.g., from New England Biolabs.
  • the isolated polypeptide is incubated with one or more deglycosylating enzyme under conditions sufficient for the removal of all of the glycans from the polypeptide.
  • Other methods are known in the art for removing glycans from a polypeptide, e.g., ⁇ -elimination with mild alkali or mild hydrazinolysis.
  • Assessment of the glycosylation state of the polypeptide can be determined using methods for staining and visualization of glycans known in the art, or mass spectrometry.
  • an expression vector comprising a nucleic acid sequence encoding a polypeptide having cellobiase activity described herein is expressed in a host cell, wherein the host cell is capable of glycosylating proteins expressed within the cell.
  • the cells are cultured under conditions sufficient for expression of the polypeptide, but in the presence of glycosylation inhibitors.
  • the glycosylation inhibitors are present at a concentration and for a sufficient time such that the expressed polypeptides are not glycosylated.
  • the polypeptide is operably linked to a fusion tag.
  • the resulting aglycosylated polypeptide can be purified or isolated from the bacterial host cell using affinity chromatography methods for the fusion tag as described herein.
  • glycosylation inhibitors for use in this embodiment include tunicamycin, Benzyl-GalNAc (Benzyl 2-acetamido-2-deoxy- ⁇ -D-galactopyranoside), 2-Fluoro-2-deoxy-D-glucose, and 5′CDP (5′ cytidylate diphosphate).
  • a combination of glycosylation inhibitors is used.
  • the concentration of glycosylation inhibitors used in this embodiment is sufficient to inhibit glycosylation of the polypeptide, but do not cause cytotoxicity or inhibition of protein expression of the host cell.
  • the present invention provides methods and compositions for converting or processing a biomass into products, using an aglycosylated polypeptide having cellobiase activity, as described herein.
  • Methods for converting a biomass to products, such as sugar products are known in the art, for example, as described in US Patent Application 2014/0011258, the contents of which are incorporated by reference in its entirety.
  • a biomass is optimally pretreated, e.g., to reduce the recalcitrance, and saccharified by a saccharification process that involves incubating the treated biomass with biomass-degrading, or cellulolytic, enzymes to produce sugars (e.g., glucose and/or xylose).
  • the sugar products can then be further processed to produce a final product, e.g., by fermentation or distillation.
  • Final products include alcohols (e.g., ethanol, isobutanol, or n-butanol), sugar alcohols (e.g., erythritol, xylitol, or sorbitol), or organic acids (e.g., lactic acid, pyurvic acid, succinic acid).
  • the biomass material can be converted to one or more products, such as energy, fuels, foods and materials.
  • products include, but are not limited to, hydrogen, sugars (e.g., glucose, xylose, arabinose, mannose, galactose, fructose, cellobiose, disaccharides, oligosaccharides and polysaccharides), alcohols (e.g., monohydric alcohols or dihydric alcohols, such as ethanol, n-propanol, isobutanol, sec-butanol, tert-butanol or n-butanol), hydrated or hydrous alcohols (e.g., containing greater than 10%, 20%, 30% or even greater than 40% water), biodiesel, organic acids, hydrocarbons (e.g., methane, ethane, propane, isobutene, pentane, n-hexane, biodiesel, bio-gasoline and mixture
  • hydrocarbons e.
  • carboxylic acids examples include carboxylic acids, salts of a carboxylic acid, a mixture of carboxylic acids and salts of carboxylic acids and esters of carboxylic acids (e.g., methyl, ethyl and n-propyl esters ketones (e.g., acetone), aldehydes (e.g., acetaldehyde), alpha and beta unsaturated acids (e.g., acrylic acid) and olefins (e.g., ethylene).
  • carboxylic acids e.g., methyl, ethyl and n-propyl esters ketones (e.g., acetone), aldehydes (e.g., acetaldehyde), alpha and beta unsaturated acids (e.g., acrylic acid) and olefins (e.g., ethylene).
  • ketones e.g., acetone
  • aldehydes e.g., acetal
  • Alcohols and alcohol derivatives include propanol, propylene glycol, 1,4-butanediol, 1,3-propanediol, sugar alcohols and polyols (e.g., glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol, and polyglycitol and other polyols), and methyl or ethyl esters of any of these alcohols.
  • sugar alcohols and polyols e.g., glycol, glycerol, erythritol, threitol, arabitol, xylitol, rib
  • Other products include methyl acrylate, methylmethacrylate, lactic acid, citric acid, formic acid, acetic acid, propionic acid, butyric acid, succinic acid, valeric acid, caproic acid, 3-hydroxypropionic acid, palmitic acid, stearic acid, oxalic acid, malonic acid, glutaric acid, oleic acid, linoleic acid, glycolic acid, gamma-hydroxybutric acid, and mixtures thereof, salts of any of these acids, mixtures of any of the acids and their respective salts.
  • the biomass to be processed using the methods described herein is a starchy material and/or a cellulosic material comprising cellulose, e.g., a lignocellulosic material.
  • the biomass may also comprise hemicellulose and/or lignin.
  • the biomass can comprise one or more of an agricultural product or waste, a paper product or waste, a forestry product, or a general waste, or any combination thereof.
  • An agricultural product or waste comprises material that can be cultivated, harvested, or processed for use or consumption, e.g., by humans or animals, or any intermediate, byproduct, or waste that is generated from the cultivation, harvest, or processing methods.
  • Agricultural products or waste include, but are not limited to, sugar cane, jute, hemp, flax, bamboo, sisal, alfalfa, hay, arracacha, buckwheat, banana, barley, cassava, kudzu, oca, sago, sorghum, potato, sweet potato, taro, yams, beans, favas, lentils, peas, grasses, switchgrass, miscanthus, cord grass, reed canary grass, grain residues, canola straw, wheat straw, barley straw, oat straw, rice straw, corn cobs, corn stover, corn fiber, coconut hair, beet pulp, bagasse, soybean stover, grain residues, rice hulls, oat hulls, wheat chaff, barley hulls, or beeswing, or a combination thereof.
  • a paper product or waste comprises material that is used to make a paper product, any paper product, or any intermediate, byproduct or waste that is generated from making or breaking down the paper product.
  • Paper products or waste include, but are not limited to, paper, pigmented papers, loaded papers, coated papers, corrugated paper, filled papers, magazines, printed matter, printer paper, polycoated paper, cardstock, cardboard, paperboard, or paper pulp, or a combination thereof.
  • a forestry product or waste comprises material that is produced by cultivating, harvesting, or processing of wood, or any intermediate, byproduct, or waste that is generated from the cultivation, harvest, or processing of the wood.
  • Forestry products or waste include, but are not limited to, aspen wood, wood from any genus or species of tree, particle board, wood chips, or sawdust, or a combination thereof.
  • a general waste includes, but is not limited to, manure, sewage, or offal, or a combination thereof.
  • the biomass comprises agriculture waste, such as corn cobs, e.g., corn stover. In another embodiment, the biomass comprises grasses.
  • the biomass is treated prior to contact with the compositions described herein.
  • the biomass is treated to reduce the recalcitrance of the biomass, to reduce its bulk density, and/or increase its surface area.
  • Suitable biomass treatment process may include, but are not limited to: bombardment with electrons, sonication, oxidation, pyrolysis, steam explosion, chemical treatment, mechanical treatment, and freeze grinding.
  • the treatment method is bombardment with electrons.
  • electron bombardment is performed until the biomass receives a total dose of at least 0.5 Mrad, e.g. at least 5, 10, 20, 30, or at least 40 Mrad.
  • the treatment is performed until the biomass receives a dose a of from about 0.5 Mrad to about 150 Mrad, about 1 Mrad to about 100 Mrad, about 5 Mrad to about 75 Mrad, about 2 Mrad to about 75 Mrad, about 10 Mrad to about 50 Mrad, e.g., about 5 Mrad to about 50 Mrad, about 20 Mrad to about 40 Mrad, about 10 Mrad to about 35 Mrad, or from about 20 Mrad to about 30 Mrad.
  • a total dose of 25 to 35 Mrad is preferred, applied ideally over a couple of seconds, e.g., at 5 Mrad/pass with each pass being applied for about one second. Applying a dose of greater than 7 to 9 Mrad/pass can in some cases cause thermal degradation of the feedstock material.
  • the biomass material e.g., plant biomass, animal biomass, paper, and municipal waste biomass
  • useful intermediates and products such as organic acids, salts of organic acids, anhydrides, esters of organic acids and fuels, e.g., fuels for internal combustion engines or feedstocks for fuel cells.
  • Systems and processes are described herein that can use as feedstock cellulosic and/or lignocellulosic materials that are readily available, but often can be difficult to process, e.g., municipal waste streams and waste paper streams, such as streams that include newspaper, kraft paper, corrugated paper or mixtures of these.
  • the glucan- or xylan-containing cellulose in the feedstock can be hydrolyzed to low molecular weight carbohydrates, such as sugars, by a saccharifying agent, e.g., an enzyme or acid, a process referred to as saccharification.
  • a saccharifying agent e.g., an enzyme or acid
  • the low molecular weight carbohydrates can then be used, for example, in an existing manufacturing plant, such as a single cell protein plant, an enzyme manufacturing plant, or a fuel plant, e.g., an ethanol manufacturing facility.
  • the biomass can be hydrolyzed using an enzyme, e.g., a biomass degrading enzyme, by combining the materials and the enzyme in a solvent, e.g., in an aqueous solution.
  • an enzyme e.g., a biomass degrading enzyme
  • the enzymes can be made/induced according to the methods described herein.
  • the biomass degrading enzyme can be supplied by organisms, e.g., a microorganism, that are capable of breaking down biomass (such as the cellulose and/or the lignin portions of the biomass), or that contain or manufacture various cellulolytic enzymes (cellulases), ligninases or various small molecule biomass-degrading metabolites. These enzymes may be a complex of enzymes that act synergistically to degrade crystalline cellulose or the lignin portions of biomass. Examples of cellulolytic enzymes include: endoglucanases, cellobiohydrolases, and cellobiases (beta-glucosidases).
  • a cellulosic substrate can be initially hydrolyzed by endoglucanases at random locations producing oligomeric intermediates. These intermediates are then substrates for exo-splitting glucanases such as cellobiohydrolase to produce cellobiose from the ends of the cellulose polymer.
  • Cellobiose is a water-soluble 1,4-linked dimer of glucose.
  • cellobiase cleaves cellobiose to yield glucose. The efficiency (e.g., time to hydrolyze and/or completeness of hydrolysis) of this process depends on the recalcitrance of the cellulosic material.
  • the reduced-recalcitrance biomass is treated with the biomass-degrading enzymes discussed above, generally by combining the reduced-recalcitrance biomass and the biomass-degrading enzymes in a fluid medium, e.g., an aqueous solution.
  • a fluid medium e.g., an aqueous solution.
  • the feedstock is boiled, steeped, or cooked in hot water prior to saccharification, as described in U.S. Pat. App. Pub. 2012/0100577 A1 by Medoff and Masterman, published on Apr. 26, 2012, the entire contents of which are incorporated herein.
  • mixtures of enzymes that are capable of degrading the biomass e.g., an enzyme mixture of biomass-degrading enzymes, for use in the saccharification process described herein.
  • the saccharification process can be partially or completely performed in a tank (e.g., a tank having a volume of at least 4000, 40,000, or 500,000 L) in a manufacturing plant, and/or can be partially or completely performed in transit, e.g., in a rail car, tanker truck, or in a supertanker or the hold of a ship.
  • a tank e.g., a tank having a volume of at least 4000, 40,000, or 500,000 L
  • the time required for complete saccharification will depend on the process conditions and the biomass material and enzyme used. If saccharification is performed in a manufacturing plant under controlled conditions, the cellulose may be substantially entirely converted to sugar, e.g., glucose in about 12-96 hours. If saccharification is performed partially or completely in transit, saccharification may take longer.
  • the saccharification reaction occurs at a pH optimal for the enzymatic reactions to occur, e.g., at the pH optimal for the activity of the biomass-degrading enzymes.
  • the pH of the saccharification reaction is at pH 4-4.5.
  • the saccharification reaction occurs at a temperature optimal for the enzymatic reactions to occur, e.g., at the temperature optimal for the activity of the biomass-degrading enzymes.
  • the temperature of the saccharification reaction is at 42° C.-52° C.
  • tank contents be mixed during saccharification, e.g., using jet mixing as described in International App. No. PCT/US2010/035331, filed May 18, 2010, which was published in English as WO 2010/135380 and designated the United States, the full disclosure of which is incorporated by reference herein.
  • surfactants can enhance the rate of saccharification.
  • surfactants include non-ionic surfactants, such as a Tween® 20 or Tween® 80 polyethylene glycol surfactants, ionic surfactants, or amphoteric surfactants.
  • the concentration of the sugar solution resulting from saccharification be relatively high, e.g., greater than 40%, or greater than 50, 60, 70, 80, 90 or even greater than 95% by weight.
  • Water may be removed, e.g., by evaporation, to increase the concentration of the sugar solution. This reduces the volume to be shipped, and also inhibits microbial growth in the solution.
  • sugar solutions of lower concentrations may be used, in which case it may be desirable to add an antimicrobial additive, e.g., a broad spectrum antibiotic, in a low concentration, e.g., 50 to 150 ppm.
  • an antimicrobial additive e.g., a broad spectrum antibiotic
  • suitable antibiotics include amphotericin B, ampicillin, chloramphenicol, ciprofloxacin, gentamicin, hygromycin B, kanamycin, neomycin, penicillin, puromycin, streptomycin.
  • Antibiotics will inhibit growth of microorganisms during transport and storage, and can be used at appropriate concentrations, e.g., between 15 and 1000 ppm by weight, e.g., between 25 and 500 ppm, or between 50 and 150 ppm.
  • an antibiotic can be included even if the sugar concentration is relatively high.
  • other additives with anti-microbial of preservative properties may be used.
  • the antimicrobial additive(s) are
  • a relatively high concentration solution can be obtained by limiting the amount of water added to the biomass material with the enzyme.
  • the concentration can be controlled, e.g., by controlling how much saccharification takes place.
  • concentration can be increased by adding more biomass material to the solution.
  • a surfactant can be added, e.g., one of those discussed above.
  • Solubility can also be increased by increasing the temperature of the solution. For example, the solution can be maintained at a temperature of 40-50° C., 60-80° C., or even higher.
  • sugars e.g., glucose and xylose
  • sugars can be isolated by precipitation, crystallization, chromatography (e.g., simulated moving bed chromatography, high pressure chromatography), centrifugation, extraction,any other isolation method known in the art, and combinations thereof.
  • the present invention provides an enzyme mixture comprising a glycosylated polypeptide comprising at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 1, and an aglycosylated polypeptide comprising at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 1, wherein both the glycosylated polypeptide and the aglyscosylated polypeptide have cellobiase activity.
  • the aglycosylated polypeptide having cellobiase activity is any of the aglycosylated polypeptides described herein, e.g., produced using the methods described herein.
  • the glycosylated polypeptide comprising at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 1 can be isolated or obtained from a microorganism that endogenously expresses the polypeptide.
  • the glysocylated polypeptide and the aglycosylated polypeptide are both the Cel3A enzyme from wild-type T. reesei, e.g., comprising SEQ ID NO: 1.
  • the enzyme mixture further comprises at least one additional enzyme derived from a microorganism, wherein the additional enzyme has biomass or cellulose-based material-degrading activity, e.g., the additional enzyme is a cellulolytic enzyme, e.g., a cellulase.
  • the additional enzyme is a ligninase, an endoglucanase, a cellobiohydrolase, a xylanase, and a cellobiase.
  • the mixture further comprises one or more ligninase, one or more endogluconase, one or more cellobiohydrolase, and one or more xylanase.
  • the additional biomass-degrading enzyme is glycosylated.
  • the enzyme mixture further comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 additional biomass-degrading enzymes described herein.
  • the enzyme mixture further comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or all of the enzymes listed in Table 1.
  • the enzyme mixture further comprises a mixture of additional biomass-degrading enzymes produced by a microorganism, e.g., a fungal cell, such as wild-type T. reesei, or a mutant thereof, e.g., T. Reesei RUTC30.
  • the additional biomass-degrading enzymes are isolated from the microorganisms.
  • the mixture comprises one or more of the following biomass-degrading enzymes: B2AF03, CIP1, CIP2, Cel1a, Cel3a, Cel5a, Cel6a, Cel7a, Cel7b, Cel12a, Cel45a, Cel74a, paMan5a, paMan26a, or Swollenin, or any combination thereof.
  • the additional biomass-degrading enzymes can be endogenously expressed and isolated from the microorganism, e.g., fungal cell, from which the enzyme originates from (listed below in Table 1).
  • the additional biomass-degrading enzymes e.g., listed above, can be heterologously expressed using similar methods of expression in a host cell described herein, and isolated from the host cells.
  • the heterologously expressed additional biomass-degrading enzymes are tagged with a His tag at the C or N terminus of the enzyme and are isolated using nickel affinity chromatography techniques known in the art.
  • the additional biomass-degrading enzymes can be selected from Table 1 below.
  • B2AF03 ( Podospora anserina ) (SEQ ID NO: 9) MKSSVFWGASLTSAVVRAIDLPFQFYPNCVDDLLSTNQVCNTTLSPPERAAALVAALTPEE KLQNIVSKSLGAPRIGLPAYNWWSEALHGVAYAPGTQFWQGDGPFNSSTSFPMPLLMAATFDDELLEKI AEVIGIEGRAFGNAGFSGLDYWTPNVNPFKDPRWGRGSETPGEDVLLVKRYAAAMIKGLEGPVPEKERR VVATCKHYAANDFEDWNGATRHNFNAKISLQDMAEYYFMPFQQCVRDSRVGSIMCAYNAVNGVPSCASP YLLQTILREHWNWTEHNNYITSDCEAVLDVSLNHKYAATNAEGTAISFEAGMDTSCEYEGSSDIPGAWS QGLLKESTVDRALLRLYEGIVRAGYFDGKQSLYSSLGWADVNKPSAQKLSLQAAVDGTVLLKNDG
  • the ratio between the aglycosylated polypeptide described herein to the other biomass-degrading enzymes in the mixture can be, for example, at least 1:1; 1:2; 1:4; 1:8; 1:16; 1:32; 1:50; 1:75; 1:100, 1:150; 1:200; 1:300, 1:400 or 1:500.
  • the ratio of aglycosylated polypeptide described herein to the other enzymes in the mixture is 1:32.
  • the ratio between the aglycosylated polypeptide described herein to the glycosylated polypeptide is, for example, at least 1:1; 1:2; 1:4; 1:8; 1:16; 1:32; 1:50; 1:75; 1:100, 1:150; 1:200; 1:300, 1:400, or 1:500.
  • Coprinus cinereus Coprinus cinereus, Fusarium oxysporum, Myceliophthora thermophila, Meripilus giganteus, Thielavia terrestris, Acremonium sp. (including, but not limited to, A. persicinum, A. acremonium, A. brachypenium, A. dichromosporum, A. obclavatum, A. pinkertoniae, A. roseogriseum, A. incoloratum, and A. furatum ).
  • Preferred strains include Humicola insolens DSM 1800, Fusarium oxysporum DSM 2672, Myceliophthora thermophila CBS 117.65, Cephalosporium sp.
  • Biomass-degrading enzymes may also be obtained from Chrysosporium, preferably a strain of Chrysosporium lucknowense. Additional strains that can be used include, but are not limited to, Trichoderma (particularly T. viride, T. reesei, and T. koningii ), alkalophilic Bacillus (see, for example, U.S. Pat. No. 3,844,890 and EP Pub. No. 0 458 162), and Streptomyces (see, e.g., EP Pub. No. 0 458 162).
  • the microorganism is induced to produce the biomass-degrading enzymes described herein under conditions suitable for increasing production of biomass-degrading enzymes compared to an uninduced microorganism.
  • an induction biomass sample comprising biomass as described herein is incubated with the microorganism to increase production of the biomass-degrading enzymes.
  • biomass-degrading enzymes produced and/or secreted by the aforementioned microorganisms can be isolated and added to the enzyme mixture of the present invention.
  • the aforementioned microorganisms or host cells expressing the biomass-degrading enzymes described herein and above are not lysed before addition to the saccharification reaction.
  • the enzyme mixture comprises the host cell expressing an aglycosylated polypeptide having cellobiase activity as described herein, and one or more additional biomass-degrading enzymes described herein.
  • the enzyme mixture comprises a host cell expressing an aglycosylated polypeptide having cellobiase activity as described herein, and one or more host cells expressing one or more additional biomass-degrading enzymes described herein.
  • Use of the enzyme mixture described herein comprising an aglycosylated polypeptide having cellobiase activity results in increased yield of sugar products from saccharification compared to the yield of sugar products from saccharification using the standard mixture of biomass-degrading enzymes (e.g., RUTC30 cocktail, e.g., without addition of an aglycosylated polypeptide having cellobiase activity).
  • the standard mixture of biomass-degrading enzymes e.g., RUTC30 cocktail, e.g., without addition of an aglycosylated polypeptide having cellobiase activity.
  • the yield of sugar products increases at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100% when an aglycosylated polypeptide having cellobiase activity is added to the saccharification process.
  • sugars produced by saccharification may be hydrogenated, fermented, or treated with other chemicals to produce other products.
  • Glucose can be hydrogenated to sorbitol.
  • Xylose can be hydrogenated to xylitol.
  • Hydrogenation can be accomplished by use of a catalyst (e.g., Pt/gamma-Al 2 O 3 , Ru/C, Raney Nickel, or other catalysts know in the art) in combination with H 2 under high pressure (e.g., 10 to 12000 psi).
  • a catalyst e.g., Pt/gamma-Al 2 O 3 , Ru/C, Raney Nickel, or other catalysts know in the art
  • high pressure e.g. 10 to 12000 psi.
  • the sorbitol and/or xylitol products can be isolated and purified using methods known in the art.
  • Sugar products from saccharification can also be fermented to produce alcohols, sugar alcohols, such as erythritol, or organic acids, e.g., lactic, glutamic or citric acids or amino acids.
  • Yeast and Zymomonas bacteria can be used for fermentation or conversion of sugar(s) to alcohol(s). Other microorganisms are discussed below.
  • the optimum pH for fermentations is about pH 4 to 7.
  • the optimum pH for yeast is from about pH 4 to 5
  • the optimum pH for Zymomonas is from about pH 5 to 6.
  • Typical fermentation times are about 24 to 168 hours (e.g., 24 to 96 hrs) with temperatures in the range of 20° C. to 40° C. (e.g., 26° C. to 40° C.), however thermophilic microorganisms prefer higher temperatures.
  • At least a portion of the fermentation is conducted in the absence of oxygen, e.g., under a blanket of an inert gas such as N 2 , Ar, He, CO 2 or mixtures thereof.
  • the mixture may have a constant purge of an inert gas flowing through the tank during part of or all of the fermentation.
  • anaerobic conditions can be achieved or maintained by carbon dioxide production during the fermentation and no additional inert gas is needed.
  • all or a portion of the fermentation process can be interrupted before the low molecular weight sugar is completely converted to a product (e.g., ethanol).
  • the intermediate fermentation products include sugar and carbohydrates in high concentrations.
  • the sugars and carbohydrates can be isolated via any means known in the art.
  • These intermediate fermentation products can be used in preparation of food for human or animal consumption. Additionally or alternatively, the intermediate fermentation products can be ground to a fine particle size in a stainless-steel laboratory mill to produce a flour-like substance.
  • Jet mixing may be used during fermentation, and in some cases saccharification and fermentation are performed in the same tank.
  • Nutrients for the microorganisms may be added during saccharification and/or fermentation, for example the food-based nutrient packages described in U.S. Pat. App. Pub. 2012/0052536, filed Jul. 15, 2011, the complete disclosure of which is incorporated herein by reference.
  • “Fermentation” includes the methods and products that are disclosed in U.S. Prov. App. No. 61/579,559, filed Dec. 22, 2012, and U.S. Prov. App. No. 61/579,576, filed Dec. 22, 2012, the contents of both of which are incorporated by reference herein in their entirety.
  • Mobile fermenters can be utilized, as described in International App. No. PCT/US2007/074028 (which was filed Jul. 20, 2007, was published in English as WO 2008/011598 and designated the United States), the contents of which is incorporated herein in its entirety.
  • the saccharification equipment can be mobile. Further, saccharification and/or fermentation may be performed in part or entirely during transit.
  • the microorganism(s) used in fermentation can be naturally-occurring microorganisms and/or engineered microorganisms.
  • the microorganism can be a bacterium (including, but not limited to, e.g., a cellulolytic bacterium), a fungus, (including, but not limited to, e.g., a yeast), a plant, a protist, e.g., a protozoa or a fungus-like protest (including, but not limited to, e.g., a slime mold), or an algae.
  • a bacterium including, but not limited to, e.g., a cellulolytic bacterium
  • a fungus including, but not limited to, e.g., a yeast
  • a plant e.g., a protist, e.g., a protozoa or a fungus-like protest (including, but not limited to, e.g.
  • Suitable fermenting microorganisms have the ability to convert carbohydrates, such as glucose, fructose, xylose, arabinose, mannose, galactose, oligosaccharides or polysaccharides into fermentation products.
  • Fermenting microorganisms include strains of the genus Saccharomyces spp. (including, but not limited to, S. cerevisiae (baker's yeast), S. distaticus, S. uvarum ), the genus Kluyveromyces, (including, but not limited to, K. marxianus, K. fragilis ), the genus Candida (including, but not limited to, C. pseudotropicalis, and C.
  • brassicae Pichia stipitis (a relative of Candida shehatae ), the genus Clavispora (including, but not limited to, C. lusitaniae and C. opuntiae ), the genus Pachysolen (including, but not limited to, P. tannophilus ), the genus Bretannomyces (including, but not limited to, e.g., B. clausenii (Philippidis, G. P., 1996, Cellulose bioconversion technology, in Handbook on Bioethanol: Production and Utilization, Wyman, C. E., ed., Taylor & Francis, Washington, D.C., 179-212)).
  • B. clausenii Philippidis, G. P., 1996, Cellulose bioconversion technology, in Handbook on Bioethanol: Production and Utilization, Wyman, C. E., ed., Taylor & Francis, Washington, D.C., 179-212
  • Suitable microorganisms include, for example, Zymomonas mobilis, Clostridium spp. (including, but not limited to, C. thermocellum (Philippidis, 1996, supra), C. saccharobutylacetonicum, C. saccharobutylicum, C. Puniceum, C. beijernckii, and C. acetobutylicum ), Moniliella pollinis, Moniliella megachiliensis, Lactobacillus spp.
  • Yarrowia lipolytica Aureobasidium sp., Trichosporonoides sp., Trigonopsis variabilis, Trichosporon sp., Moniliellaacetoabutans sp., Typhula variabilis, Candida magnoliae, Ustilaginomycetes sp., Pseudozyma tsukubaensis, yeast species of genera Zygosaccharomyces, Debaryomyces, Hansenula and Pichia, and fungi of the dematioid genus Torula.
  • Clostridium spp. can be used to produce ethanol, butanol, butyric acid, acetic acid, and acetone. Lactobacillus spp. can be used to produce lactic acid.
  • microbial strains are publicly available, either commercially or through depositories such as the ATCC (American Type Culture Collection, Manassas, Va., USA), the NRRL (Agricultural Research Sevice Culture Collection, Peoria, Ill., USA), or the DSMZ (Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH, Braunschweig, Germany), to name a few.
  • ATCC American Type Culture Collection, Manassas, Va., USA
  • NRRL Agricultural Research Sevice Culture Collection, Peoria, Ill., USA
  • DSMZ Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH, Braunschweig, Germany
  • yeasts include, for example, Red Star®/Lesaffre Ethanol Red (available from Red Star/Lesaffre, USA), FALI® (available from Fleischmann's Yeast, a division of Burns Philip Food Inc., USA), SUPERSTART® (available from Alltech, now Lalemand), GERT STRAND® (available from Gert Strand AB, Sweden) and FERMOL® (available from DSM Specialties).
  • microorganisms that can be used to saccharify biomass material and produce sugars can also be used to ferment and convert those sugars to useful products.
  • the resulting fluids can be distilled using, for example, a “beer column” to separate ethanol and other alcohols from the majority of water and residual solids.
  • the vapor exiting the beer column can be, e.g., 35% by weight ethanol and can be fed to a rectification column.
  • a mixture of nearly azeotropic (92.5%) ethanol and water from the rectification column can be purified to pure (99.5%) ethanol using vapor-phase molecular sieves.
  • the beer column bottoms can be sent to the first effect of a three-effect evaporator.
  • the rectification column reflux condenser can provide heat for this first effect. After the first effect, solids can be separated using a centrifuge and dried in a rotary dryer.
  • a portion (25%) of the centrifuge effluent can be recycled to fermentation and the rest sent to the second and third evaporator effects. Most of the evaporator condensate can be returned to the process as fairly clean condensate with a small portion split off to waste water treatment to prevent build-up of low-boiling compounds.
  • the mature sequence for Cel3a (amino acids 20-744) was synthesized and codon-optimized for E. coli expression by Genewiz.
  • the Cel3a-C′His referred to in the following examples refers to the codon-optimized mature sequence for Cel3a (aas 20-744) with an 8 ⁇ His (SEQ ID NO: 7) tag at the C-terminus.
  • the below primers were used to clone the Cel3a-C′His into pET-Duet (Novagen, Catalog No. 71146):
  • the amplified DNA was cloned by restriction digestion using NcoI restriction enzyme (New England Biolabs, R3193) and HindIII restriction enzyme (New England Biolabs, R3104) under conditions suggested by the manufacturer.
  • the digested amplified DNA was ligated into the NcoI-HindIII sites in the pETDuet vector using T4 DNA ligase (New England Biolabs, M0202), followed by transformation of E. coli cloning host Top10 One Shot (Invitrogen). Plasmid purification was carried out using Qiagen's plasmid purification kit.
  • the Cel3A-C′His constructs were transformed into the E. coli expression host Origami B (DE3) (EMD Millipore, Catalog No. 70837) and streaked on plates containing LB medium and 100 ⁇ g/ml ampicillin (Fisher Scientific, Catalog No. BP1760), 15 ⁇ g/ml kanamysin (Fisher Scientific, Catalog No. BP906) and 12.5 ⁇ g/ml tetracycline (Fisher Scientified, Catalog No. BP912).
  • Colonies carrying the recombinant DNA were picked from plates for the inoculation of 2 ml starter cultures, and grown overnight at 37° C., then subsequently used to inoculate 100 ml of LB media containing the appropriate antibiotics. Cultures were grown at 37° C. until OD600 reached 0.8.
  • IPTG Isopropyl-b-D-thiogalactopyranoside
  • RT room temperature
  • the cell pellet was thawed on ice and resuspended in 2 ml of native lysis buffer containing 50 mM Tris-HCl pH 7.5, 0.1% Triton X-100, 5 mM imidazole (Fisher Scientific, Catalog No. 03196), and 1 mg/ml lysozyme (Fisher Scientific, Catalog No. BP535), then incubated on ice for 20 minutes.
  • 2 ⁇ l of lysonase EMD Millipore, Catalog No. 71230 was added and incubated for another 10 minutes. The sample was then spun in a microcentrifuge at maximum speed for 10 minutes at 4° C.
  • the clarified lysate was transferred to a fresh tube containing 100 ⁇ l of pre-equilibrated Profinity (Biorad) Ni-charged IMAC resin slurry (Biorad, Catalog No. 732-4614).
  • the native binding buffer consisted of 50 mM Tris HCl pH 7.5, 150 mM NaCl, 0.1% Triton X-100, and 5 ⁇ M imidazole.
  • the protein was batch-bound for 1 hour at RT, and then washed with native buffer containing 25 ⁇ M imidazole. The protein was eluted in 300 ml of native buffer containing 200 ⁇ M imidazole.
  • Purified Cel3a protein from the expression and purification process described above is shown in FIG. 1 .
  • Cel3a is scaled up to 3 liter and 5 liter bioreactors.
  • the skilled artisan could readily use the process described herein to scale the production further, for example, to 3 L and 7 L bioreactors.
  • the pET Duet-1 Cel3a-C′His construct is transformed into E. Coli Origami B (DE3) host cell line, and streaked on plates containing LB medium and 100 ⁇ g/ml ampicillin (Fisher Scientific, Catalog No. BP1760), 15 ⁇ g/ml kanamysin (Fisher Scientific, Catalog No. BP906) and 12.5 ⁇ g/ml tetracycline (Fisher Scientific, Catalog No. BP912).
  • the OD of the overnight inoculums was measured by a spectrophotometer at 600 nM.
  • the spectrophotometer can be blanked by using LB media.
  • the bioreactors were set to 37° C., 300 rpm, and 2.5 vvm. Once the bioreactors reach 37° C., the appropriate mls of overnight inoculums was added to each 1.5 L and to each 4 L culture for a target starting OD value of 0.05.
  • the OD of the reactors were measured occasionally by sampling out of the top with ethanol and a sterile pipet. As the OD approaches 0.8, samples were taken more frequently.
  • the temperature of the bioreactors was reduced to 20° C., and the cultures were induced with IPTG for Cel3a-C′His protein expression. 750 ml of IPTG was added to each 1.5 L reactor and 1.5 ml of IPTG was added to each 5 L reactor. The reactors were run overnight.
  • the cells were harvested into clean 2 L centrifuge bottles and spun at 4200 rpm for 45 minutes. The supernatant was discarded, and the pellet was saved and the weight of the pellet was recorded. Using PBS buffer, the pellet was transferred to 50 mL conical centrifuge tubes. The 50 mL tubes were spun at 4500 rpm for 45 minutes in the Sorvall St-16 tabletop centrifuge. Supernatant was discarded and the pellet was frozen at ⁇ 20° C. until ready for purification, or processed immediately for purification.
  • Lysis Buffer with EDTA was prepared, containing the following: 50 mM Tris-HCl pH 7.5, 0.1% Triton X-100, 1% Glycerol, 5 mM imidazole, 1 mg/mL Lysozyme, and 1 mM EDTA in de-ionized water.
  • the cell pellet was resuspended in 5 mL volume of Lysis Buffer with EDTA. 10 ⁇ l of Lysonase (DNAse) was added to the sample. Samples were then incubated for 1 hour at room temperature.
  • samples were sonicated on ice for three 1 minute intervals (e.g., for 3 minutes total, Sorvall sonicator at setting 17).
  • sample E The supernatant was removed, and an aliquot was taken from the supernatant (satant (sample E), representing the soluble wash fraction. The remaining pellet was reserved (sample C), representing the insoluble fraction. All samples were stored in the refrigerator (e.g., 4° C.) until analysis.
  • a cellobiase activity assay was performed using the total protein aliquot (sample A), for example, as described in Example 6.
  • the samples A, C, D, and E were also analyzed by SDS-PAGE and western blotting.
  • Samples were diluted to 2.00 OD to normalize. 17.5 ⁇ l of LDS sample buffer (375 ⁇ l LDS buffer and 150 ⁇ l of NuPAGE reducing agent were mixed to prepare 525 ⁇ l of LDS sample buffer) was added to 32.5 ⁇ l of each sample. Samples were boiled for 5 minutes and 20 ⁇ l of each sample was loaded into each gel well. A standard (molecular weight ladder) was also loaded into a gel well.
  • Cel3a with a His-tag at the N-terminus was cloned, expressed in E. coli, and harvested using methods similar to those described above in Examples 1-4.
  • Cel3a-N′His was cloned into pET-Duet1 vector.
  • the expressed Cel3a-N′His was purified with an affinity column containing Profinity Ni-charge IMAC resin slurry and eluted using elution buffer containing 200 mM imidazole in the lysis buffer.
  • the purified Cel3a-N′His was dialyzed in buffer containing 50mM Tris-HCl and 0.5M EDTA. The dialyzed protein was then submitted for liquid chromatography-mass spectrometry (LCMS) intact mass analysis.
  • LCMS liquid chromatography-mass spectrometry
  • Sample concentration was determined, e.g., by Bradford assay and by Nanodrop assay. Sample concentration was at about 4 mg/mL. A 10 ⁇ and 100 ⁇ dilution sample was prepared for LCMS, with 0.1% formic acid in de-ionized water to provide 0.4 mg/mL and 0.04 mg/mL samples.
  • the chromatographic profile of the sample is shown in FIG. 2 .
  • the profile shows three areas of interest: a large peak at 31 minutes, a cluster of peaks between 38 and 40 minutes, and a smaller peak at about 45 minutes.
  • Manual deconvolution of the mass spectrum of peak at about 45 minutes and the peak cluster at about 39 minutes shows that the main peaks are not part of a charge state envelope, but rather a polymer series (with 44 amu as the repeating unit), and were thus attributed to possibly being from the Triton-X used in the lysis buffer.
  • His-tagged Cel3a e.g., Cel3a with a His-tag at the N or C-terminus
  • IMAC techniques The amount (titer) of purified His-tagged Cel3a was determined using Bradford assay and/or the nanodrop.
  • the molar extinction coefficient was estimated by inserting the amino acid sequence of the target form of Cel3a into the ExPASy ProtParam online tool.
  • the activity assay can be used to determine the titer of Cel3a.
  • a standard curve of cellobiase activity of a sample of purified Cel3a-N′His with a known concentration is generated.
  • Two-fold serial dilutions of Cel3a-N′His with a known concentration were prepared in one row of a 96 well plate, e.g., 12 two-fold serial dilutions.
  • the other rows contained two-fold serial dilutions of other remaining samples whose titer is to be determined, e.g., the crude lysate sample.
  • the dilutions were incubated with a D-(+)-Cellobiose (Fluka) substrate solution in 50 mM sodium citrate monobasic buffer at pH 5.0, at 48° C. for 30 minutes. After 30 minutes, the samples were heated to 100° C. for 10 minutes to stop the reaction. Samples were analysed for glucose and cellobiose using the YSI Biochemistry analyser (YSI Life Sciences) and/or HPLC methods. Using Cel3a-N′His samples of known concentration, a standard curve is generated using the data points within the linear range of the assay ( FIG. 6 ). The cellobiase activity detected from the samples with unknown Cel3a titer can be compared to the standard curve to determine the titer of Cel3a in the sample.
  • YSI Biochemistry analyser YSI Life Sciences
  • Units of activity are only relative if calculated using values within the linear range of the assay.
  • the linear range of the assay is defined as using glucose values that are less than 30% of the original soluble substrate load. In addition, glucose values lower than 0.05 g/L are omitted due to instrumentation reporting levels.
  • One unit of cellobiase activity is defined as the amount of glucose per the amount of Cel3a per 30 minutes: [Glucose]g/L/[Cel3a]g/L/30 min.
  • FIG. 7 show that the recombinant Cel3a (aglycosylated Cel3a purified from E. coli; labeled Cel3a in FIG. 7 ) demonstrated higher specific activity for converting cellobiose to glucose compared to the endogenous Cel3a (labeled L4196 in FIG. 7 ).
  • the recombinant Cel3a was able to produce a larger amount of glucose after 30 minutes than the endogenous Cel3a.
  • the glucose yield was compared between two saccharification reactions.
  • an enzyme mixture comprising the enzymes described in Table 1 was added to a biomass.
  • 0.8 mg/ml of aglycosylated Cel3a purified from E. coli was added to the enzyme mixture comprising the enzymes described in Table 1, and was added to a biomass.
  • the saccharification reactions were run under the conditions as described herein, with samples taken at multiple timepoints between 0 and 80 minutes of the reaction.
  • the resulting glucose was measured and quantified using methods in the art, such as by YSI instrument or HPLC, and plotted over time, as shown in FIG. 8 .

Abstract

The present invention relates to compositions comprising an aglycosylated polypeptide having cellobiase activity, and methods for producing and using the same.

Description

    RELATED APPLICATIONS
  • This application is a continuation of U.S. patent application Ser. No. 14/768,126, filed Aug. 14, 2015, which is a national stage application under 35 U.S.C. § 371 of International Application No. PCT/US2015/044136, filed Aug. 7, 2015, which claims the benefit of U.S. Provisional Application No. 62/035,346, filed Aug. 8, 2014; the entire contents of each of which are hereby incorporated by reference.
    • SEQUENCE LISTING
  • The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Aug. 5, 2015, is named X2002-7000WO_SL.txt and is 76,949 bytes in size.
    • FIELD OF THE INVENTION
  • The present invention relates generally to compositions having cellobiase activity and methods for producing the compositions described herein. The present invention also provides methods for using such compositions, e.g., to process biomass materials.
    • BACKGROUND OF THE INVENTION
  • Biomass-degrading enzymes, such as cellulases, xylanases, and ligninases, are important for the degradation of biomass, such as feedstock. Cellulosic and lignocellulosic materials are produced, processed, and used in large quantities in a number of applications. Often such materials are used once, and then discarded as waste, or are simply considered to be wasted materials, e.g., sewage, bagasse, sawdust, and stover
    • SUMMARY OF THE INVENTION
  • The present invention is based, at least in part, on the surprising discovery that a cellobiase from T. reesei that was expressed in a non-fungal cell line and isolated from a host cell that does not significantly glycosylate the enzyme had higher specific activity on pure substrate than the endogenous cellobiase (glycosylated and secreted) from T. reesei. Furthermore, when the aglycosylated cellobiase was used in a saccharification reaction with an enzyme mixture containing other saccharifying enzymes, a substantial increase in yield of sugar products was observed compared to the reaction without the aglycosylated cellobiase. Therefore, provided herein are, an aglycosylated polypeptide having enzymatic activity, e.g., cellobiase activity, compositions comprising the aglycosylated polypeptide and methods for producing and using the compositions described herein.
  • Accordingly, in one aspect, the disclosure features an aglycosylated polypeptide having cellobiase activity. In one embodiment, the aglycosylated polypeptide has increased cellobiase activity as compared to glycosylated Cel3A enzyme from wild-type T. reesei or a mutant thereof, such as T. reesei RUTC30. For example, the aglycosylated polypeptide can have increased substrate recognition or a more active substrate recognition site as compared to glycosylated Cel3A enzyme from wild-type T. reesei. In one embodiment, the aglycosylated polypeptide has reduced steric hindrance as compared to glycosylated Cel3A enzyme from wild-type T. reesei.
  • In one embodiment, the aglycosylated polypeptide comprises at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO: 1, or a functional fragment thereof. In one embodiment, the aglycosylated polypeptide comprises (e.g., consists of) the amino acid sequence SEQ ID NO: 1. In another embodiment, the aglycosylated polypeptide differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 amino acids from the amino acid sequence of SEQ ID NO: 1.
  • In one embodiment, the polypeptide comprises a Cel3A enzyme from wild-type T. reesei, or a mutant thereof, such as T. reesei RUTC30, or a functional variant or fragment thereof.
  • In one embodiment, the aglycosylated polypeptide is encoded by a nucleic acid sequence, wherein the nucleic acid sequence comprises (e.g., consists of) at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO: 2 or SEQ ID NO: 3. In one embodiment, the aglycosylated polypeptide is encoded by a nucleic acid sequence comprising (e.g., consisting of) SEQ ID NO: 2 or SEQ ID NO: 3.
  • In one embodiment, the aglcyosylated polypeptide is expressed by a gene that comprises a mutation proximal to or a mutation at one or more glycosylation site, wherein the mutation prevents glycosylation at the glycosylation site. In one embodiment, the mutation is at one or more of the threonine at amino acid position 78, the threonine at amino acid position 241, the serine at amino acid position 343, the serine at amino acid position 450, the threonine at amino acid position 599, the serine at amino acid position 616, the threonine at amino acid position 691, the serine at amino acid position 21, the threonine at amino acid position 24, the serine at amino acid position 25, the serine at amino acid position 28, the threonine at amino acid position 38, the threonine at amino acid position 42, the threonine at amino acid position 303, the serine at amino acid position at 398, the at serine amino acid position 435, the serine at amino acid position 436, the threonine at amino acid position 439, threonine at amino acid position 442, the threonine at amino acid position 446, the serine at amino acid position 451, the serine at amino acid position 619, the serine at amino acid position 622, the threonine at amino acid position 623, the serine at amino acid position 626, or the threonine at amino acid position 630 of SEQ ID NO: 1. A mutation proximal to one or more glycosylation site can prevent glycosylation at that site, e.g., by changing the conformation of the polypeptide or changing the consensus site recognized by the glycosylating enzyme such that glycosylation would not occur at the glycosylation site.
  • In one embodiment, the aglycosylated polypeptide hydrolyzes a carbohydrate, such as a dimer, a trimer, a tetramer, a pentamer, a hexamer, a heptamer, an octamer, or an oligomer of glucose; or an oligomer of glucose and xylose, into one or more monosaccharide, e.g., glucose. In one embodiment, the cellobiase activity comprises hydrolysis of a beta 1,4 glycosidic linkage of cellobiose.
  • In another aspect, the disclosure features a nucleic acid sequence encoding an aglycosylated polypeptide described herein.
  • In one embodiment, the nucleic acid sequence encodes a Cel3A enzyme or functional fragment thereof, wherein the nucleic acid sequence comprises (e.g., consists of) at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO: 2 or SEQ ID NO: 3. In one embodiment, the nucleic acid sequence encodes a Cel3A enzyme, wherein the nucleic acid sequence comprises (e.g., consists of) SEQ ID NO: 2 or SEQ ID NO: 3.
  • In one aspect, the disclosure features a nucleic acid molecule that includes a nucleic acid sequence described herein.
  • In one embodiment, the nucleic acid molecule further includes a promoter, e.g., a promoter for prokaryotic cell expression, e.g., bacterial cell expression, e.g., expression in E. coli. In one embodiment, the promoter sequence is a constitutive promoter sequence, inducible promoter sequence, or a repressible promoter sequence. In one embodiment, the promoter is a T7 promoter.
  • In one embodiment, the nucleic acid molecule further comprises a nucleic acid sequence encoding a tag, e.g., a tag for detection and/or purification and/or for linkage to another molecule, e.g., a His tag.
  • In one embodiment, the nucleic acid molecule further comprises a nucleic acid encoding one or more signal sequences, e.g., a secretion signal sequence.
  • In one aspect, the disclosure features an expression vector comprising the nucleic acid sequence described herein or a nucleic acid molecule described herein.
  • In one embodiment, the vector further comprises a nucleic acid sequence encoding a selection marker, e.g., a kanamycin or an ampicillin marker.
  • In one aspect, the disclosure features a cell comprising a vector described herein.
  • In one embodiment, the cell is a prokaryotic cell/bacterial cell, e.g., an E. coli cell, e.g., an Origami E. coli cell.
  • In one embodiment, the cell expresses an aglycosylated polypeptide described herein.
  • In one embodiment, the cell is impaired for glycosylation.
  • In one aspect, the disclosure features a method for producing the aglycosylated polypeptide described herein, comprising culturing a cell expressing a polypeptide described herein, under conditions suitable for the expression of the polypeptide, wherein the cell does not glycosylate the polypeptide, e.g., a bacterial cell, e.g., an E. coli cell, e.g., an origami E. coli cell.
  • In one aspect, the disclosure features a method for producing the aglycosylated polypeptide described herein, comprising treating a polypeptide comprising an amino acid sequence of SEQ ID NO:1, or an amino acid sequence with at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO: 1 with a deglycosylating enzyme. For example, a deglycosylating enzyme can be PGNase or EndoH.
  • In one aspect, the disclosure features a method for producing the aglycosylated polypeptide described herein, comprising culturing a cell that comprises a nucleic acid sequence encoding a polypeptide having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO: 1, wherein the nucleic acid has one or more mutations which prevent glycosylation of the encoded polypeptide, and optionally obtaining the aglycosylated polypeptide from the culture.
  • In one aspect, the disclosure features a method for culturing a cell expressing the aglycosylated polypeptide described herein in the presence of a glycosylation inhibitor. For example, the glycosylation inhibitor is tunicamycin.
  • In one aspect, the disclosure features an enzyme mixture comprising an aglycosylated polypeptide described herein and one or more additional enzyme, such as one or more glycosylated enzymes, e.g., cellulases from fungal cells. In one embodiment, the enzyme mixture comprises a glycosylated polypeptide comprising an amino acid sequence with at least 75%, 80%, 95%, 90%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO: 1 and an aglycosylated polypeptide described herein, wherein both of the glycosylated polypeptide and the aglycosylated peptide have cellobiase activity.
  • In one embodiment, the enzyme mixture comprises a glycosylated polypeptide and an aglycosylated polypeptide and both the glycosylated polypeptide and the aglycosylated polypeptide both comprise Cel3A enzyme from wild-type T. reesei or a mutant thereof, such as T. reesei RUTC30.
  • In one embodiment, the enzyme mixture further comprises at least one additional enzyme derived from a microorganism, wherein the additional enzyme has a biomass-degrading activity. In one embodiment, the additional enzyme is selected from a ligninase, an endoglucanase, a cellobiohydrolase, xylanase, and a cellobiase.
  • In one embodiment, the reaction mixture has a ratio between the aglycosylated polypeptide and the remaining enzymes of at least 1:32, e.g., 1:32 to 1:300. In one embodiment, the reaction mixture has a ratio of the aglycosylated polypeptide to a glycosylated polypeptide is at least 1:32, e.g., 1:32 to 1:300.
  • In one aspect, the disclosure features a method of producing a product (e.g., hydrogen, a sugar, an alcohol, etc.) from a biomass (or converting a biomass to a product) comprising contacting a biomass, e.g., a biomass that has been treated with radiation, e.g., radiation from an electron beam, with an aglycosylated polypeptide described herein, under condiaitions suitable for the production of a sugar product. In one embodiment, the method further comprises contacting the biomass with a microorganism that produces one or more biomass-degrading enzyme or an enzyme mixture comprising biomass-degrading enzymes, e.g., an enzyme mixture described herein.
  • In one aspect, the disclosure features a method of producing a product (e.g., hydrogen, sugar, alcohol, etc.) from a biomass (or converting a biomass to a product) comprising contacting a biomass with an enzyme mixture described herein under conditions suitable for the production of the product.
  • In one embodiment, the product is a sugar product, e.g., a sugar product described herein. In one embodiment, the sugar product is glucose and/or xylose, or other sugar products, such as fructose, arabinose, galactose, and cellobiose.
  • In one embodiment, the method further comprises isolating the sugar product. In one embodiment, the isolating of the sugar product comprises precipitation, crystallization, chromatography, centrifugation, and/or extraction.
  • In one embodiment, the enzyme mixture comprises at least two of the enzymes selected from B2AF03, CIP1, CIP2, Cel1a, Cel3a, Cel5a, Cel6a, Cel7a, Cel7b, Cel12a, Cel45a, Cel74a, paMan5a, paMan26a, Swollenin, or any of the enzymes listed in Table 1. In an embodiment, the enzymes listed above are isolated from a cell that expresses the enzyme heterologously or endogenously, e.g., Trichoderma reesei or Podospora anserina.
  • In one embodiment, the biomass comprises a starchy material or a starchy material that includes a cellulosic component. In some embodiments, the biomass comprises one or more of an agricultural product or waste, a paper product or waste, a forestry product, or a general waste, or any combination thereof; wherein: a) an agricultural product or waste comprises sugar cane jute, hemp, flax, bamboo, sisal, alfalfa, hay, arracacha, buckwheat, banana, barley, cassava, kudzu, oca, sago, sorghum, potato, sweet potato, taro, yams, beans, favas, lentils, peas, grasses, switchgrass, miscanthus, cord grass, reed canary grass, grain residues, canola straw, wheat straw, barley straw, oat straw, rice straw, corn cobs, corn stover, corn fiber, coconut hair, beet pulp, bagasse, soybean stover, grain residues, rice hulls, oat hulls, wheat chaff, barley hulls, or beeswing, or a combination thereof; b) a paper product or waste comprises paper, pigmented papers, loaded papers, coated papers, filled papers, magazines, printed matter, printer paper, polycoated paper, cardstock, cardboard, paperboard, or paper pulp, or a combination thereof; c) a forestry product comprises aspen wood, particle board, wood chips, or sawdust, or a combination thereof; and d) a general waste comprises manure, sewage, or offal, or a combination thereof. In one embodiment, the method further comprises a step of treating the biomass prior to introducing the microorganism or the enzyme mixture to reduce the recalcitrance of the biomass, e.g., by treating the biomass with bombardment with electrons, sonication, oxidation, pyrolysis, steam explosion, chemical treatment, mechanical treatment, and/or freeze grinding.
  • In one embodiment, the microorganism that produces a biomass-degrading enzyme is from species in the genera selected from Bacillus, Coprinus, Myceliophthora, Cephalosporium, Scytalidium, Penicillium, Aspergillus, Pseudomonas, Humicola, Fusarium, Thielavia, Acremonium, Chrysosporium or Trichoderma. In one embodiment, the microorganism that produces a biomass-degrading enzyme is selected from Aspergillus, Humicola insolens (Scytalidium thermophilum), Coprinus cinereus, Fusarium oxysporum, Myceliophthora thermophila, Meripilus giganteus, Thielavia terrestris, Acremonium persicinum, Acremonium acremonium, Acremonium brachypenium, Acremonium dichromosporum, Acremonium obclavatum, Acremonium pinkertoniae, Acremonium roseogriseum, Acremonium incoloratum, Acremonium furatum, Chrysosporium lucknowense, Trichoderma viride, Trichoderma reesei, or Trichoderma koningii.
  • In one embodiment, the microorganism has been induced to produce biomass-degrading enzymes by combining the microorganism with an induction biomass sample under conditions suitable for increasing production of biomass-degrading enzymes compared to an uninduced microorganism. In one embodiment, the induction biomass sample comprises paper, paper products, paper waste, paper pulp, pigmented papers, loaded papers, coated papers, filled papers, magazines, printed matter, printer paper, polycoated paper, card stock, cardboard, paperboard, cotton, wood, particle board, forestry wastes, sawdust, aspen wood, wood chips, grasses, switchgrass, miscanthus, cord grass, reed canary grass, grain residues, rice hulls, oat hulls, wheat chaff, barley hulls, agricultural waste, silage, canola straw, wheat straw, barley straw, oat straw, rice straw, jute, hemp, flax, bamboo, sisal, abaca, corn cobs, corn stover, soybean stover, corn fiber, alfalfa, hay, coconut hair, sugar processing residues, bagasse, beet pulp, agave bagasse, algae, seaweed, manure, sewage, offal, agricultural or industrial waste, arracacha, buckwheat, banana, barley, cassava, kudzu, oca, sago, sorghum, potato, sweet potato, taro, yams, beans, favas, lentils, peas, or any combination thereof.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a picture of purified Cel3a that was expressed in E. coli. Lane 1 represents molecular weight marker (Precision Plus All Blue Protein marker, Biorad); lane 2 represents purified Cel3a-His protein.
  • FIG. 2 is a chromatographic profile of the Cel3a-N′His sample, showing the detection of Cel3a-N′His at 31 minutes.
  • FIG. 3 is a profile showing no evidence of glycosylation in the mass spectral region for the peak in the chromatographic profile of the Cel3a-N′His at 31 minutes.
  • FIG. 4 is a profile showing the deconvolution of the charge state envelope, identifying the molecular weight of the major component (aglycosylated Cel3a-N′His) and the minor components (modified Cel3a-N′His).
  • FIG. 5 is a graph showing the cellobiase activity, as determined by cellobiase assay, of a purified Cel3a-N′His.
  • FIG. 6 is a graph showing a standard curve for cellobiase activity generated for a known concentration of Cel3a-N′His that can be used to determine the concentration of Cel3a of a sample with an unknown concentration of Cel3a.
  • FIG. 7 is a graph showing that specific activity of recombinant Cel3a compared to endogenous cellobiase from T. Reesei (L4196).
  • FIG. 8 is a graph showing the yield of glucose product from a saccharification reaction performed with a standard enzyme mix compared to the standard enzyme mix (L331 control) with the addition of aglycosylated cellobiase Cel3a (L331 (0.8 mg/ml Cel3a).
    •  DETAILED DESCRIPTION Definitions
  • Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains.
  • The term “a” and “an” refers to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.
  • The term “aglycosylated”, as used herein, refers to a molecule, e.g., a polypeptide, that is not glycosylated (i.e., it comprises a hydroxyl group or other functional group that is not attached to a glycosylate group) at one or more sites which has a glycan attached when the molecule is produced in its native environment. For example, a Cel3A enzyme is aglycosylated when one or more site in the protein that normally has a glycan group attached to it when the Cel3A enzyme is produced in T. reesei does not have a glycan attached at that site. In some embodiments, the aglycosylated molecule does not have any attached glycans. In one embodiment, the molecule has been altered or mutated such that the molecule cannot be glycosylated, e.g., one or more glycosylation site is mutated such that a glycan cannot be attached to the glycosylation site. In another embodiment, an attached glycan can be removed from the molecule, e.g., by an enzymatic process, e.g., by incubating with enzymes that remove glycans or have deglycosylating activity. In yet another embodiment, glycosylation of the molecule can be inhibited, e.g., by use of a glycosylation inhibitor (that inhibits a glycosylating enzyme). In another embodiment, the molecule, e.g., the polypeptide, can be produced by a host cell that does not glycosylate, e.g., E. coli.
  • The term “biomass”, as used herein, refers to any non-fossilized, organic matter. Biomass can be a starchy material and/or a cellulosic, hemicellulosic, or lignocellulosic material. For example, the biomass can be an agricultural product, a paper product, forestry product, or any intermediate, byproduct, residue or waste thereof, or a general waste. The biomass may be a combination of such materials. In an embodiment, the biomass is processed, e.g., by a saccharification and/or a fermentation reaction described herein, to produce products, such as sugars, alcohols, organic acids, or biofuels.
  • The term “biomass degrading enzymes”, as used herein, refers to enzymes that break down components of the biomass matter described herein into intermediates or final products. For example, biomass-degrading enzymes include at least amylases, e.g., alpha, beta or gamma amylases, cellulases, hemicellulases, ligninases, endoglucancases, cellobiases, xylanases, and cellobiohydrolases. Biomass-degrading enzymes are produced by a wide variety of microorganisms, and can be isolated from the microorganisms, such as T. reesei. The biomass degrading enzyme can be endogenously expressed or heterologously expressed.
  • The term “cellobiase”, as used herein, refers to an enzyme that catalyzes the hydrolysis of a dimer, trimer, tetramer, pentamer, hexamer, heptamer, octamer, or an oligomer of glucose, or an oligomer of glucose and xylose, to glucose and/or xylose. For example, the cellobiase is beta-glucosidase, which catalyzes beta-1,4 bonds in cellobiose to release two glucose molecules.
  • The term “cellobiase activity”, as used herein, refers to activity of a category of cellulases that catalyze the hydrolysis of cellobiose to glucose, e.g., catalyzes the hydrolysis of beta-D-glucose residues to release beta-D-glucose. Cellobiase activity can be determined according to the assays described herein, e.g., in Example 6. One unit of cellobiase activity can be defined as [glucose] g/L/[Cel3a] g/L/30 minutes.
  • The term “cellobiohydrolase” as used herein, refers to an enzyme that hydrolyzes glycosidic bonds in cellulose. For example, the cellobiohydrolase is 1,4-beta-D-glucan cellobiohydrolase, which catalyzes the hydrolysis of 1,4-beta-D-glucosidic linkages in cellulose, cellooligosaccharides, or any beta-1,4-linked glucose containing polymer, releasing oligosaccharides from the polymer chain.
  • The term “endoglucanase” as used herein, refers to an enzyme that catalyzes the hydrolysis of internal β-1,4 glucosidic bonds of cellulose. For example, the endoglucanase is endo-1,4-(1,3; 1,4)-beta-D-glucan 4-glucanohydrolase, which catalyses endohydrolysis of 1,4-beta-D-glycosidic linkages in cellulose, cellulose derivatives (such as carboxymethyl cellulose and hydroxyethyl cellulose), lichenan, beta-1,4 bonds in mixed beta-1, 3 glucans such as cereal beta-D-glucans or xyloglucans, and other plant material containing cellulosic components.
  • The term “enzyme mixture” as used herein, refers to a combination of at least two different enzymes, or at least two different variants of an enzyme (e.g., a glycosylated and an aglycosylated version of an enzyme). The enzyme mixture referred to herein includes at least the aglycosylated polypeptide having cellobiase activity described herein. In one embodiment, the enzyme mixture includes one or more of a cellobiase, an endoglucanase, a cellobiohydrolase, a ligninase, and/or a xylanase. In some embodiments, the enzyme mixture includes a cell, e.g., a microorganism, which expresses and, e.g., secretes, one or more of the enzymes. For example, the enzyme mixture can include an aglycosylated polypeptide described herein and a cell, e.g., a microorganism, which expresses and, e.g., secretes, one or more additional enzymes and/or variants of the polypeptide.
  • The term “ligninase” as used herein, refers to an enzyme that catalyzes the breakdown of lignin, commonly found in the cell walls of plants, such as by an oxidation reaction.
  • The terms “nucleic acid” or “polynucleotide” are used interchangeable, and refer to deoxyribonucleic acids (DNA) or ribonucleic acids (RNA) and polymers thereof in either single- or double-stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).
  • The term “operably linked”, as used herein, refers to a configuration in which a control or regulatory sequence is placed at a position relative to a nucleic acid sequence that encodes a polypeptide, such that the control sequence influences the expression of a polypeptide (encoded by the DNA sequence). In an embodiment, the control or regulatory sequence is upstream of a nucleic acid sequence that encodes a polypeptide with cellobiase activity. In an embodiment, the control or regulatory sequence is downstream of a nucleic acid sequence that encodes a polypeptide with cellobiase activity.
  • The terms “peptide,” “polypeptide,” and “protein” are used interchangeably, and refer to a compound comprised of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that can comprise a protein's or peptide's sequence. Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. “Polypeptides” include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others. A polypeptide includes a natural peptide, a recombinant peptide, or a combination thereof.
  • The term “promoter”, as used herein, refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a polynucleotide sequence.
  • The term “regulatory sequence” or “control sequence”, as used interchangeably herein, refers to a nucleic acid sequence which is required for expression of a nucleic acid product. In some instances, this sequence may be a promoter sequence and in other instances, this sequence may also include an enhancer sequence and other regulatory elements which are required for expression of the gene product. The regulatory/control sequence may, for example, be one which expresses the nucleic acid product in a regulated manner, e.g., inducible manner.
  • The term “constitutive” promoter refers to a nucleotide sequence which, when operably linked with a polynucleotide which encodes a polypeptide, causes the polypeptide to be produced in a cell under most or all physiological conditions of the cell. In an embodiment, the polypeptide is a polypeptide having cellobiase activity.
  • The term “inducible” promoter refers to a nucleotide sequence which, when operably linked with a polynucleotide which encodes a polypeptide, causes the polypeptide to be produced in a cell substantially only when an inducer which corresponds to the promoter is present in the cell. In an embodiment, the polypeptide is a polypeptide having cellobiase activity.
  • The term “repressible” promoter refers to a nucleotide sequence, which when operably linked with a polynucleotide which encodes a polypeptide, causes the polypeptide to be produced in a cell substantially only until a repressor which corresponds to the promoter is present in the cell. In an embodiment, the polypeptide is a polypeptide having cellobiase activity.
  • The term “xylanase” as used herein, refers to enzymes that hydrolyze xylan-containing material. Xylan is polysaccharide comprising units of xylose. A xylanase can be an endoxylanase, a beta-xylosidase, an arabinofuranosidase, an alpha-glucuronidase, an acetylxylan esterase, a feruloyl esterase, or an alpha-glucuronyl esterase.
    • Description
  • Glycosylation is thought to play a critical role in enzyme structure and function, such as enzyme activity, solubility, stability, folding, and/or secretion. Accordingly, processes for converting biomass into biofuels and other products have focused on producing and utilizing glycosylated enzymes, e.g., cellobiases, for use in saccharification of cellulosic and/or lignocellulosic materials. Enzymes for use in saccharification are typically produced in eukaryote host cell lines that properly glycosylate, fold, and secrete the proteins, such as Pichia pastoris.
  • The present invention is based, at least in part, on the surprising discovery that a cellobiase from T. reesei that was expressed in a non-fungal cell line and isolated from a host cell that does not significantly glycosylate the enzyme had higher specific activity on pure substrate than the endogenous cellobiase (glycosylated and secreted) from T. reesei. Furthermore, when the aglycosylated cellobiase was used in a saccharification reaction with an enzyme mixture containing other saccharifying enzymes, a substantial increase in yield of sugar products was observed compared to the reaction without the aglycosylated cellobiase. Therefore, provided herein are, an aglycosylated polypeptide having enzymatic activity, e.g., cellobiase activity, compositions comprising the aglycosylated polypeptide and methods for producing and using the compositions described herein.
    • Polypeptides and Variants
  • The present disclosure provides an aglycosylated polypeptide with cellobiase activity. In an embodiment, the aglycosylated polypeptide is a cellobiase. A cellobiase is an enzyme that hydrolyzes beta-1,4 bonds in its substrate, cellobiose, to release two glucose molecules. Cellobiose is a water soluble 1,4-linked dimer of glucose.
  • Cel3a (also known as BglI) is a cellobiase that was identified in Trichoderma reesei. The amino acid sequence for Cel3a (GenBank Accession No. NW_006711153) is provided below:
  • (SEQ ID NO: 1)
    MGDSHSTSGASAEAVVPPAGTPWGTAYDKAKAALAKLNLQDKVGIVSGVG
    WNGGPCVGNTSPASKISYPSLCLQDGPLGVRYSTGSTAFTPGVQAASTWD
    VNLIRERGQFIGEEVKASGIHVILGPVAGPLGKTPQGGRNWEGFGVDPYL
    TGIAMGQTINGIQSVGVQATAKHYILNEQELNRETISSNPDDRTLHELYT
    WPFADAVQANVASVMCSYNKVNTTWACEDQYTLQTVLKDQLGFPGYVMTD
    WNAQHTTVQSANSGLDMSMPGTDFNGNNRLWGPALTNAVNSNQVPTSRVD
    DMVTRILAAWYLTGQDQAGYPSFNISRNVQGNHKTNVRAIARDGIVLLKN
    DANILPLKKPASIAVVGSAAIIGNHARNSPSCNDKGCDDGALGMGWGSGA
    VNYPYFVAPYDAINTRASSQGTQVTLSNTDNTSSGASAARGKDVAIVFIT
    ADSGEGYITVEGNAGDRNNLDPWHNGNALVQAVAGANSNVIVVVHSVGAI
    ILEQILALPQVKAVVWAGLPSQESGNALVDVLWGDVSPSGKLVYTIAKSP
    NDYNTRIVSGGSDSFSEGLFIDYKHFDDANITPRYEFGYGLSYTKFNYSR
    LSVLSTAKSGPATGAVVPGGPSDLFQNVATVTVDIANSGQVTGAEVAQLY
    ITYPSSAPRTPPKQLRGFAKLNLTPGQSGTATFNIRRRDLSYWDTASQKW
    VVPSGSFGISVGASSRDIRLTSTLSVAGSGS
  • The present disclosure also provides functional variants of an aglycosylated polypeptide having cellobiase activity described herein, e.g., Cel3a. In an embodiment, a functional variant has an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a Cel3a described herein, or a functional fragment thereof, e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a Cel3a described herein, or a functional fragment thereof. In an embodiment, a functional variant has an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91% identity, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to SEQ ID NO: 1, or a functional fragment thereof.
  • Percent identity in the context of two or more amino acid or nucleic acid sequences, refers to two or more sequences that are the same. Two sequences are “substantially identical” if two sequences have a specified percentage of amino acid residues or nucleotides that are the same (e.g., 60% identity, optionally 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity over a specified region, or, when not specified, over the entire sequence), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Optionally, the identity exists over a region that is at least about 50 nucleotides, 100 nucleotides, 150 nucleotides, in length. More preferably, the identity exists over a region that is at least about 200 or more amino acids, or at least about 500 or 1000 or more nucleotides, in length.
  • For sequence comparison, one sequence typically acts as a reference sequence, to which one or more test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters. Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman, (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch, (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman, (1988) Proc. Nat'l. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection (see, e.g., Brent et al., (2003) Current Protocols in Molecular Biology).
  • Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., (1977) Nuc. Acids Res. 25:3389-3402; and Altschul et al., (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.
  • Functional variants may comprise one or more mutations, such that the variant retains cellobiase activity that is better, e.g., increased in comparison to, than the cellobiase activity of an ezyme of SEQ ID NO:1 produced by T. reesei. In an embodiment, the functional variant has at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, or at least 99%) of the cellobiase activity as an aglycosylated version of SEQ ID NO: 1 as produced by E. coli. Cellobiase activity can be tested using the functional assays described herein.
  • In another embodiment, the aglycosylated polypeptide differs by no more than 1, no more than 2, no more than 3, no more than 4, no more than 5, no more than 6, no more than 7, no more than 8, no more than 9, no more than 10, no more than 15, no more than 20, no more than 30, no more than 40, or no more than 50 amino acids from a reference amino acid sequence, e.g., the amino acid sequence of SEQ ID NO: 1.
  • The mutations present in a functional variant include amino acid substitutions, additions, and deletions. Mutations can be introduced by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. The mutation may be a conservative amino acid substitution, in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues within the polypeptide having cellobiase activity of the disclosure can be replaced with other amino acids from the same side chain family, and the resultant polypeptide retains cellobiase activity comparable (e.g., at least 80%, 85%, 90%, 95%, or 99% of the cellobiase activity) to that of the wild-type polypeptide. Alternatively, the mutation may be an amino acid substitution in which an amino acid residue is replaced with an amino acid residue having a different side chain.
  • Such mutations may alter or affect various enzymatic characteristics of the cellobiase. For example, such mutations may alter or affect the cellobiase activity, thermostability, optimal pH for reaction, enzyme kinetics, or substrate recognition of the cellobiase. In some embodiments, a mutation increases the cellobiase activity of the variant in comparison to the cellobiase produced by T. reesei and/or SEQ ID NO:1 produced in E.coli. In some embodiments, a mutation increases or decreases the thermostability of the variant in comparison to wild-type cellobiase and/or SEQ ID NO:1 produced in E.coli. In an embodiment, a mutation changes the pH range at which the variant optimally performs the cellobiase reaction in comparison to wild-type cellobiase and/or SEQ ID NO:1 produced in E.coli. In an embodiment, a mutation increases or decreases the kinetics of the cellobiase reaction (e.g., kcat, KM or KD) in comparison to wild-type cellobiase and/or SEQ ID NO:1 produced in E.coli. In an embodiment, a mutation increases or decreases the ability of the cellobiase to recognize or bind to the substrate (e.g., cellobiose) in comparison to wild-type cellobiase and/or SEQ ID NO:1 produced in E.coli.
  • The present invention also provides functional fragments of a polypeptide having cellobiase activity as described herein, e.g., Cel3a or SEQ ID NO: 1. One of ordinary skill in the art could readily envision that a fragment of a polypeptide having cellobiase activity as described herein that contains the functional domains responsible for enzymatic activity would retain functional activity, e.g., cellobiase activity, and therefore, such fragments are encompassed in the present invention. In an embodiment, the functional fragment is at least 700 amino acids, at least 650 amino acids, at least 600 amino acids, at least 550 amino acids, at least 500 amino acids, at least 450 amino acids, at least 400 amino acids, at least 350 amino acids, at least 300 amino acids, at least 250 amino acids, at least 200 amino acids, at least 150 amino acids, at least 100 amino acids, or at least 50 amino acids in length. In an embodiment, the functional fragment is 700 to 744 amino acids, 650 to 699 amino acids, 600 to 649 amino acids, 550 to 599 amino acids, 500 to 549 amino acids, 450 to 499 amino acids, 400 to 449 amino acids, 350 to 399 amino acids, 300 to 349 amino acids, 250 to 299 amino acids, 200 to 249 amino acids, 150 to 199 amino acids, 100 to 149 amino acids, or 50 to 99 amino acids. With regard to the ranges of amino acid length described above, the lowest and highest values of amino acid length are included within each disclosed range. In an embodiment, the functional fragment has at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% of the cellobiase activity as wild-type Cel3a or the polypeptide comprising SEQ ID NO: 1 produced in E.coli.
  • Assays for detecting cellobiase activity are known in the art. For example, detection of the amount of glucose released from cellobiose can be determined by incubating purified cellobiase with substrate, e.g., cellobiose, D-(+)-cellobiose, and detecting the resultant amount of free glucose after completion of the reaction. The amount of free glucose can be determined using a variety of methods known in the art. For example, dilutions of purified cellobiase are prepared in a buffer containing 50 mM sodium citrate monobasic, pH 5.0 NaOH. The cellobiose substrate is added to the purified cellobiase in an amount such that the final concentration of cellobiose in the reaction mixture is 30 mM. The reaction mixture is incubated under conditions suitable for the reaction to occur, e.g., in a shaker (700 rpm) at 48° C. for 30 minutes. To stop the reaction, the reaction mixture is heated for 5 minutes at 100° C. The reaction mixture is filtered through a 0.45 μm filter and the filtrate is analyzed to quantify the amount of glucose and/or cellobiase. A YSI instrument that measures analytes such as glucose can be used to determine the concentration of glucose produced from the reaction. Alternatively, UPLC (Ultra Performance Liquid Chromatography) can be used to determine the concentration of glucose and cellobiose from the reaction. This assay can be formatted in a single reaction or in multiple reaction formats, e.g., 96 well format. In some embodiments, the multiple reaction format may be preferred to generate an activity curve representing cellobiase activity with respect to different concentrations of the purified cellobiase. The concentration of the purified cellobiase can be determined using a standard Bradford assay. Dilutions of the purified cellobiase assay are prepared, e.g., 2-fold dilutions, and are aliquoted into a 96 well plate, e.g., 12 wells of 2-fold dilutions. Cellobiose substrate is added as previously described, such that the final concentration of cellobiase in the reaction is 30 mM. The plate is sealed and treated under conditions sufficient for the cellobiase reaction to occur, and then under conditions to stop the reaction. The reaction is then filtered through a 96 well format 0.45 μm membrane (e.g., Durapore) and analyzed by YSI and/or HPLC methods, e.g., UPLC.
  • This activity assay can also be used to determine the concentration, or titer, of a Cel3a in a sample by generating a standard curve of activity of dilutions of a Cel3a sample with a known concentration. The activity of dilutions of the sample with unknown concentration is determined and compared with the standard curve to identify an approximate concentration based on the standard curve. This method is described in further detail in Example 6.
  • In other embodiments, a colorimetric/fluorometric assay can be used. The purified cellobiase is incubated with substrate cellobiose under conditions for the reaction to occur. Detection of the product glucose is as follows. Glucose oxidase is added to the mixture, which oxidizes glucose (the product) to gluconic acid and hydrogen peroxide. Peroxidase and o-dianisidine is then added. O-dianisidine reacts with the hydrogen peroxide in the presence of peroxidase to form a colored product. Sulfuric acid is added, which reacts with the oxidized o-dianisidine reacts to form a more stable colored product. The intensity of the color when measured, e.g., by spectrophotometer or colorimeter, e.g., at 540 nm, is directly proportional to the glucose concentration. Such colorimetric/fluorometric glucose assays are commercially available, for example from Sigma Aldrich, Catalog No. GAGO-20.
  • For all of the polypeptides having cellobiase activity described above, the polypeptides are aglycosylated using the methods for producing aglycosylated polypeptides described herein.
  • Glycosylation is the enzymatic process by which a carbohydrate is attached to a glycosyl acceptor, e.g., the nitrogen of arginine or asparginine side chains or the hydroxyl oxygen of serine, threonine, or tyrosine side chains. There are two types of glycosylation: N-linked and O-linked glycosylation. N-linked glycosylation occurs at consensus site Asn-X-Ser/Thr, wherein the X can be any amino acid except a proline. O-linked glycosylation occurs at Ser/Thr residues. Glycosylation sites can be predicted using various algorithms known in the art, such as Prosite, publicly available by the Swiss Institute of Bioinformatics, and NetNGlyc 1.0 or NetOGlyc 4.0, publicly available by the Center for Biological Sequence Analysis.
  • In embodiments, the functional variant contains one or more mutations wherein one or more glycoslyation sites present in the Cel3a polypeptide expressed by a nucleic acid sequence described herein that has been mutated such that a glycan can no longer be attached or linked to the glycosylation site. In another embodiment, the functional variant contains one or more mutations proximal to one or more glycosylation sites present in the Cel3a polypeptide expressed by a nucleic acid sequence described herein that has been mutated such that a glycan can no longer be attached or linked to the glycosylation site. For example, the mutation proximal to a glycosylation site mutates the consensus motif recognized by the glycosylating enzyme, or changes the conformation of the polypeptide such that the polypeptide cannot be glycosylated, e.g., the glycoslation site is hidden or steric hindrance due to the new conformation prevents the glycosylating enzymes from accessing the glycosylation site. A mutation proximal to a glycosylation site in the Cel3a polypeptide is directly adjacent to, or at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 30 or at least 40 amino acids from the glycosylation site that, as a result of the proximal mutation, will not be glycosylated.
  • In an embodiment, one or more of the following glycosylation sites of Cel3a, or SEQ ID NO: 1, are mutated: the threonine at amino acid position 78, the threonine at amino acid position 241, the serine at amino acid position 343, the serine at amino acid position 450, the threonine at amino acid position 599, the serine at amino acid position 616, the threonine at amino acid position 691, the serine at amino acid position 21, the threonine at amino acid position 24, the serine at amino acid position 25, the serine at amino acid position 28, the threonine at amino acid position 38, the threonine at amino acid position 42, the threonine at amino acid position 303, the serine at amino acid position at 398, the at serine amino acid position 435, the serine at amino acid position 436, the threonine at amino acid position 439, threonine at amino acid position 442, the threonine at amino acid position 446, the serine at amino acid position 451, the serine at amino acid position 619, the serine at amino acid position 622, the threonine at amino acid position 623, the serine at amino acid position 626, or the threonine at amino acid position 630, or any combination thereof. In embodiments, the glycosylation site is mutated from a serine or threonine to an alanine. For example, the aglycosylated polypeptide described herein has one or more of the following mutations: T78A, T241A, S343A, S450A, T599A, S616A, T691A, S21A, T24A, S25A, S28A, T38A, T42A, T303A, T398A, S435A, S436A, T439A, T442A, T446A, S451A, S619A, S622A, T623A, S626A, or T630A, or any combination thereof. Alternatively, one or more amino acids proximal to the glycosylation sites described above is mutated.
  • Assays to detect whether a polypeptide is modified by a glycan (e.g., whether the polypeptide is glycosylated or aglycosylated) are known in the art. The polypeptide can be purified or isolated and can be stained for detection and quantification of glycan moieties, or the polypeptide can be analyzed by mass spectrometry, and compared to a corresponding reference polypeptide. The reference polypeptide has the same primary sequence as the test polypeptide (of which the glycosylation state is to be determined), but is either glycosylated or aglycosylated.
  • The aglycosylated polypeptides described herein have increased cellobiase activity compared to a corresponding glycosylated polypeptide, e.g., glycosylated Cel3a polypeptide. For example, the aglycosylated polypeptide having cellobiase activity has at least 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or 200% cellobiase activity compared to the glyocyosylated polypeptide.
    • Nucleic Acids
  • The present invention also provides a nucleic acid sequence encoding a polypeptide having cellobiase activity of the present invention. In an embodiment, the nucleic acid sequence encodes a Cel3a enzyme or a functional fragment thereof with the amino acid sequence described herein.
  • In an embodiment, the nucleic acid sequence that encodes Cel3a is provided below:
  • (SEQ ID NO: 2)
    ATGCGTTACCGAACAGCAGCTGCGCTGGCACTTGCCAC
    TGGGCCCTTTGCTAGGGCAGACAGTCACTCAACATCGG
    GGGCCTCGGCTGAGGCAGTTGTACCTCCTGCAGGGACT
    CCATGGGGAACCGCGTACGACAAGGCGAAGGCCGCATT
    GGCAAAGCTCAATCTCCAAGATAAGGTCGGCATCGTGA
    GCGGTGTCGGCTGGAACGGCGGTCCTTGCGTTGGAAAC
    ACATCTCCGGCCTCCAAGATCAGCTATCCATCGCTATG
    CCTTCAAGACGGACCCCTCGGTGTTCGATACTCGACAG
    GCAGCACAGCCTTTACGCCGGGCGTTCAAGCGGCCTCG
    ACGTGGGATGTCAATTTGATCCGCGAACGTGGACAGTT
    CATCGGTGAGGAGGTGAAGGCCTCGGGGATTCATGTCA
    TACTTGGTCCTGTGGCTGGGCCGCTGGGAAAGACTCCG
    CAGGGCGGTCGCAACTGGGAGGGCTTCGGTGTCGATCC
    ATATCTCACGGGCATTGCCATGGGTCAAACCATCAACG
    GCATCCAGTCGGTAGGCGTGCAGGCGACAGCGAAGCAC
    TATATCCTCAACGAGCAGGAGCTCAATCGAGAAACCAT
    TTCGAGCAACCCAGATGACCGAACTCTCCATGAGCTGT
    ATACTTGGCCATTTGCCGACGCGGTTCAGGCCAATGTC
    GCTTCTGTCATGTGCTCGTACAACAAGGTCAATACCAC
    CTGGGCCTGCGAGGATCAGTACACGCTGCAGACTGTGC
    TGAAAGACCAGCTGGGGTTCCCAGGCTATGTCATGACG
    GACTGGAACGCACAGCACACGACTGTCCAAAGCGCGAA
    TTCTGGGCTTGACATGTCAATGCCTGGCACAGACTTCA
    ACGGTAACAATCGGCTCTGGGGTCCAGCTCTCACCAAT
    GCGGTAAATAGCAATCAGGTCCCCACGAGCAGAGTCGA
    CGATATGGTGACTCGTATCCTCGCCGCATGGTACTTGA
    CAGGCCAGGACCAGGCAGGCTATCCGTCGTTCAACATC
    AGCAGAAATGTTCAAGGAAACCACAAGACCAATGTCAG
    GGCAATTGCCAGGGACGGCATCGTTCTGCTCAAGAATG
    ACGCCAACATCCTGCCGCTCAAGAAGCCCGCTAGCATT
    GCCGTCGTTGGATCTGCCGCAATCATTGGTAACCACGC
    CAGAAACTCGCCCTCGTGCAACGACAAAGGCTGCGACG
    ACGGGGCCTTGGGCATGGGTTGGGGTTCCGGCGCCGTC
    AACTATCCGTACTTCGTCGCGCCCTACGATGCCATCAA
    TACCAGAGCGTCTTCGCAGGGCACCCAGGTTACCTTGA
    GCAACACCGACAACACGTCCTCAGGCGCATCTGCAGCA
    AGAGGAAAGGACGTCGCCATCGTCTTCATCACCGCCGA
    CTCGGGTGAAGGCTACATCACCGTGGAGGGCAACGCGG
    GCGATCGCAACAACCTGGATCCGTGGCACAACGGCAAT
    GCCCTGGTCCAGGCGGTGGCCGGTGCCAACAGCAACGT
    CATTGTTGTTGTCCACTCCGTTGGCGCCATCATTCTGG
    AGCAGATTCTTGCTCTTCCGCAGGTCAAGGCCGTTGTC
    TGGGCGGGTCTTCCTTCTCAGGAGAGCGGCAATGCGCT
    CGTCGACGTGCTGTGGGGAGATGTCAGCCCTTCTGGCA
    AGCTGGTGTACACCATTGCGAAGAGCCCCAATGACTAT
    AACACTCGCATCGTTTCCGGCGGCAGTGACAGCTTCAG
    CGAGGGACTGTTCATCGACTATAAGCACTTCGACGACG
    CCAATATCACGCCGCGGTACGAGTTCGGCTATGGACTG
    TCTTACACCAAGTTCAACTACTCACGCCTCTCCGTCTT
    GTCGACCGCCAAGTCTGGTCCTGCGACTGGGGCCGTTG
    TGCCGGGAGGCCCGAGTGATCTGTTCCAGAATGTCGCG
    ACAGTCACCGTTGACATCGCAAACTCTGGCCAAGTGAC
    TGGTGCCGAGGTAGCCCAGCTGTACATCACCTACCCAT
    CTTCAGCACCCAGGACCCCTCCGAAGCAGCTGCGAGGC
    TTTGCCAAGCTGAACCTCACGCCTGGTCAGAGCGGAAC
    AGCAACGTTCAACATCCGACGACGAGATCTCAGCTACT
    GGGACACGGCTTCGCAGAAATGGGTGGTGCCGTCGGGG
    TCGTTTGGCATCAGCGTGGGAGCGAGCAGCCGGGATAT
    CAGGCTGACGAGCACTCTGTCGGTAGCG
  • The nucleic acid sequence encoding the polypeptide with cellobiase activity described herein can be codon-optimized for increased expression in host cells. Codon optimization includes changing the nucleic acid sequence to take into consideration factors including codon usage bias, cryptic splicing sites, mRNA secondary structure, premature polyA sites, interaction of codon and anti-codon, and RNA instability motifs, to increase expression of the encoded polypeptide in the host. Various algorithms and commercial services for codon-optimization are known and available in the art.
  • The codon-optimized nucleic acid sequence that encodes Cel3a is provided below:
  • (SEQ ID NO: 3)
    ATGCGTTATCGTACAGCCGCAGCCCTGGCACTGGCCAC
    AGGTCCGTTCGCACGTGCCGATAGTCACAGTACCAGCG
    GTGCCAGCGCAGAAGCCGTGGTTCCGCCGGCAGGCACA
    CCGTGGGGCACAGCCTATGATAAAGCCAAAGCCGCCCT
    GGCCAAGCTGAATCTGCAGGATAAAGTGGGCATCGTGA
    GTGGCGTGGGCTGGAACGGTGGTCCGTGCGTTGGCAAC
    ACCAGCCCGGCAAGCAAGATCAGCTATCCGAGCTTATG
    CCTGCAGGATGGTCCGCTGGGCGTGCGCTATAGCACCG
    GTAGTACCGCCTTTACACCTGGTGTGCAGGCCGCCAGT
    ACCTGGGACGTTAACCTGATCCGCGAACGTGGCCAATT
    TATCGGCGAAGAAGTTAAAGCCAGCGGCATTCATGTTA
    TTCTGGGTCCGGTGGCCGGTCCTCTGGGTAAAACCCCG
    CAGGGCGGCCGTAATTGGGAAGGCTTCGGCGTTGATCC
    GTATTTAACCGGCATCGCAATGGGCCAGACCATTAATG
    GCATCCAGAGCGTGGGTGTTCAAGCCACCGCCAAACAC
    TACATATTAAACGAACAGGAACTGAATCGTGAAACCAT
    CAGCAGCAATCCGGATGATCGCACCCTGCATGAGCTGT
    ATACATGGCCTTTTGCCGACGCAGTTCAGGCCAACGTG
    GCAAGTGTGATGTGTAGCTATAACAAGGTGAACACCAC
    CTGGGCCTGCGAAGACCAGTACACCCTGCAGACCGTTT
    TAAAAGACCAACTGGGCTTCCCTGGTTACGTGATGACA
    GATTGGAATGCCCAGCACACAACCGTTCAGAGCGCAAA
    CAGTGGCCTGGATATGAGCATGCCGGGCACCGACTTCA
    ACGGCAATAATCGTCTGTGGGGTCCGGCACTGACCAAT
    GCCGTTAACAGCAACCAGGTGCCGACCAGTCGTGTGGA
    CGATATGGTTACCCGTATTCTGGCCGCCTGGTACCTGA
    CAGGTCAAGACCAGGCCGGCTACCCGAGCTTCAACATC
    AGCCGCAACGTGCAGGGTAATCACAAGACCAACGTTCG
    CGCAATCGCACGCGATGGTATCGTGCTGTTAAAGAACG
    ATGCCAACATTCTGCCGCTGAAAAAACCGGCCAGCATC
    GCCGTTGTTGGTAGCGCAGCCATCATTGGCAACCACGC
    CCGTAACAGTCCGAGCTGCAATGATAAAGGCTGTGACG
    ACGGTGCCCTGGGCATGGGTTGGGGTAGTGGTGCCGTG
    AACTACCCGTATTTCGTGGCCCCGTACGACGCCATTAA
    CACCCGTGCAAGTAGCCAGGGTACCCAGGTTACCCTGA
    GCAACACCGACAACACAAGCAGCGGTGCCAGTGCAGCA
    CGTGGTAAGGATGTGGCCATCGTGTTCATCACCGCCGA
    CAGCGGCGAAGGCTACATTACCGTGGAGGGTAATGCCG
    GTGATCGCAATAATCTGGACCCGTGGCATAACGGCAAC
    GCCCTGGTTCAGGCAGTGGCAGGCGCAAATAGCAACGT
    GATCGTTGTGGTGCATAGCGTGGGTGCCATCATTCTGG
    AGCAGATCCTGGCCCTGCCGCAAGTTAAGGCAGTTGTG
    TGGGCAGGTCTGCCGAGCCAAGAAAGTGGCAATGCCCT
    GGTGGACGTTCTGTGGGGCGATGTTAGTCCGAGCGGCA
    AGCTGGTGTATACAATCGCCAAGAGCCCGAACGACTAT
    AACACCCGCATCGTTAGCGGCGGCAGTGATAGCTTCAG
    CGAGGGCCTGTTTATCGACTACAAGCATTTCGATGATG
    CCAATATTACCCCGCGCTACGAATTTGGTTATGGCCTG
    AGCTATACCAAGTTCAACTACAGCCGCCTGAGCGTTTT
    AAGTACCGCCAAGAGTGGTCCGGCAACAGGTGCCGTGG
    TTCCTGGTGGTCCGAGTGATCTGTTTCAGAATGTGGCC
    ACCGTGACCGTGGATATCGCCAACAGTGGTCAGGTTAC
    CGGCGCCGAAGTGGCACAGCTGTACATCACCTATCCGA
    GCAGTGCACCGCGCACCCCGCCGAAACAGCTGCGTGGC
    TTCGCCAAATTAAACCTGACCCCGGGCCAGAGCGGTAC
    AGCAACCTTCAATATTCGCCGCCGTGATCTGAGCTATT
    GGGACACCGCCAGCCAAAAATGGGTGGTGCCGAGCGGC
    AGCTTTGGCATTAGTGTGGGTGCAAGTAGCCGCGACAT
    TCGCTTAACAAGCACCCTGAGTGTTGCC
  • In an embodiment, the nucleic acid sequence encoding a Cel3a enzyme or functional variant thereof comprises at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to SEQ ID NO: 2. In an embodiment, the nucleic acid sequence encoding a Cel3a enzyme or functional variant thereof comprises at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to SEQ ID NO:2 or SEQ ID NO: 3.
  • Provided herein is a nucleic acid sequence encoding an aglycosylated polypeptide, e.g., Cel3a polypeptide, as described above, in which one or more glycoslyation sites present in the polypeptide has been mutated such that a glycan can no longer be attached or linked to the glycosylation site. In another embodiment, the nucleic acid sequence described herein encoding an aglycosylated polypeptide, e.g., a Cel3a polypeptide, as described above, in which one or more mutations proximal to one or more glycosylation sites present in the polypeptide has been mutated such that a glycan can no longer be attached or linked to the glycosylation site, as previously described. In an embodiment, the nucleic acid sequence encodes a polypeptide comprising one or more mutations at one or more of the following glycosylation sites of Cel3a, or SEQ ID NO: 1: the threonine at amino acid position 78, the threonine at amino acid position 241, the serine at amino acid position 343, the serine at amino acid position 450, the threonine at amino acid position 599, the serine at amino acid position 616, the threonine at amino acid position 691, the serine at amino acid position 21, the threonine at amino acid position 24, the serine at amino acid position 25, the serine at amino acid position 28, the threonine at amino acid position 38, the threonine at amino acid position 42, the threonine at amino acid position 303, the serine at amino acid position at 398, the at serine amino acid position 435, the serine at amino acid position 436, the threonine at amino acid position 439, threonine at amino acid position 442, the threonine at amino acid position 446, the serine at amino acid position 451, the serine at amino acid position 619, the serine at amino acid position 622, the threonine at amino acid position 623, the serine at amino acid position 626, or the threonine at amino acid position 630, or any combination thereof. In embodiments, the glycosylation site is mutated from a serine or threonine to an alanine. For example, the nucleic acid sequence of the invention encodes an aglycosylated polypeptide comprising one or more of the following mutations: T78A, T241A, S343A, S450A, T599A, S616A, T691A, S21A, T24A, S25A, S28A, T38A, T42A, T303A, T398A, S435A, S436A, T439A, T442A, T446A, S451A, S619A, S622A, T623A, S626A, or T630A, or any combination thereof. The ordinarily skilled artisan could readily modify the nucleic acid sequence of wild-type Cel3a (SEQ ID NO: 2) to encode a polypeptide with one or more glycosylation site mutation by using methods known in the art, such as site-directed mutagenesis.
  • The techniques used to isolate or clone a nucleic acid sequence encoding a polypeptide are known in the art and include isolation from genomic DNA, preparation from cDNA, or a combination thereof. The cloning of the nucleic acid sequences of the present invention from such genomic DNA can be effected, e.g., by using the well known polymerase chain reaction (PCR) or antibody screening of expression libraries to detect cloned DNA fragments with shared structural features. See, e.g., Innis et al., 1990, PCR: A Guide to Methods and Application, Academic Press, New York. Other amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and nucleotide sequence-based amplification (NASBA) may be used. The nucleic acid sequence may be cloned from a strain of Trichoderma reesei, e.g., wild-type T. reesei, or T. reesei RUTC30, or another or related organism and thus, for example, may be an allelic or species variant of the polypeptide encoding region of the nucleic acid sequence.
  • The nucleic acid sequence may be obtained by standard cloning procedures used in genetic engineering to relocate the nucleic acid sequence from its natural location to a different site where it will be reproduced. The cloning procedures may involve excision and isolation of a desired fragment comprising the nucleotide sequence encoding the polypeptide, insertion of the fragment into a vector molecule, and incorporation of the recombinant vector into a host cell where multiple copies or clones of the nucleotide sequence will be replicated. The nucleotide sequence may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.
    • Expression Vectors and Host Cells
  • The present invention also provides nucleic acid constructs comprising a nucleic acid sequence encoding the polypeptide having cellobiase activity described herein operably linked to one or more control sequences that direct the expression, secretion, and/or isolation of the expressed polypeptide.
  • As used herein, an “expression vector” is a nucleic acid construct for introducing and expressing a nucleic acid sequence of interest into a host cell. In some embodiments, the vector comprises a suitable control sequence operably linked to and capable of effecting the expression of the polypeptide encoded in the nucleic acid sequence of interest. The control sequence may be an appropriate promoter sequence, recognized by a host cell for expression of the nucleic acid sequence. In an embodiment, the nucleic acid sequence of interest is a nucleic acid sequence encoding a polypeptide having cellobiase activity as described herein.
  • A promoter in the expression vector of the invention can include promoters obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell, mutant promoters, truncated promoters, and hybrid promoters.
  • Examples of suitable promoters for directing transcription of the nucleic acid constructs of the present invention in a bacterial host cell are the promoters obtained from the E. coli lac operon, E. coli tac promoter (hybrid promoter, DeBoer et al, PNAS, 1983, 80:21-25), E. coli rec A, E. coli araBAD, E. coli tetA, and prokaryotic beta-lactamase. Other examples of suitable promoters include viral promoters, such as promoters from bacteriophages, including a T7 promoter, a T5 promoter, a T3 promoter, an M13 promoter, and a SP6 promoter. In some embodiments, more than one promoter controls the expression of the nucleic acid sequence of interest, e.g., an E. coli lac promoter and a T7 promoter. Further promoters that may be suitable for use in the present invention are described in “Useful proteins from recombinant bacteria” in Scientific American, 1980, 242:74-94, and Sambrook et al., Molecular Cloning: A Laboratory Manual, 1989. In some preferred embodiments, the promoter is inducible, where the addition of a molecule stimulates the transcription and expression of the downstream reading frame.
  • Examples of suitable promoters for directing transcription of the nucleic acid constructs of the present invention in a eukaryotic host cell, e.g., in a fungal or yeast cell are promoters obtained from the genes of Trichoderma Reesei, methanol-inducible alcohol oxidase (AOX promoter), Aspergillus nidulans tryptophan biosynthesis (trpC promoter), Aspergillus niger var. awamori flucoamylase (glaA), Saccharomyces cerevisiae galactokinase (GAL1), or Kluyveromyces lactis Plac4-PBI promoter.
  • A control sequence present in the expression vector of the present invention may also be a signal sequence that codes for an amino acid sequence linked to the amino terminus of a polypeptide and directs the encoded polypeptide into the cell's secretory pathway, e.g., a secretion signal sequence. The signal sequence may be an endogenous signal sequence, e.g., where the signal sequence is present at the N-terminus of the wild-type polypeptide when endogenously expressed by the organism from which the polypeptide of interest originates from. The signal sequence may be a foreign, or heterologous, signal peptide, in which the signal sequence is from a different organism or a different polypeptide than that of the polypeptide of interest being expressed. Any signal sequence which directs the expressed polypeptide into the secretory pathway of a host cell may be used in the present invention. Typically, signal sequences are composed of between 6 and 136 basic and/or hycrophobic amino acids.
  • Examples of signal sequences suitable for the present invention include the signal sequence from Saccharomyces cerevisiae alpha-factor.
  • Fusion tags may also be used in the expression vector of the present invention to facilitate the detection and purification of the expressed polypeptide. Examples of suitable fusion tags include His-tag (e.g., 3× His, 6× His (SEQ ID NO: 6), or 8× His (SEQ ID NO: 7)), GST-tag, HSV-tag, S-tag, T7 tag. Other suitable fusion tags include myc tag, hemagglutinin (HA) tag, and fluorescent protein tags (e.g., green fluorescent protein). The fusion tag is typically operably linked to the N or C terminus of the polypeptide to be expressed. In some embodiments, there may be a linker region between the fusion tag sequence and the N-terminus or C-terminus of the polypeptide to be expressed. In an embodiment, the linker region comprises a sequence between 1 to 20 amino acids, that does not affect or alter the expression or function of the expressed polypeptide.
  • Utilization of the fusion tags described herein allows detection of the expressed protein, e.g., by western blot by using antibodies that specifically recognize the tag. The tags also allows for purification of the expressed polypeptide from the host cell, e.g., by affinity chromatography. For example, an expressed polypeptide fused to a His-tag can be purified by using nickel affinity chromatography. The His tag has affinity for the Nickel ions, and a nickel column will retain the his-tagged polypeptide, while allowing all other proteins and cell debris to flow through the column. Elution of the His-tagged polypeptide using an elution buffer, e.g., containing imidazole, releases the His-tagged polypeptide from the column, resulting in substantially purified polypeptide.
  • The expression vector of the invention may further comprise a selectable marker gene to enable isolation of a genetically modified microbe transformed with the construct as is commonly known to those of skill in the art. The selectable marker gene may confer resistance to an antibiotic or the ability to grow on medium lacking a specific nutrient to the host organism that otherwise could not grow under these conditions. The present invention is not limited by the choice of selectable marker gene, and one of skill in the art may readily determine an appropriate gene. For example, the selectable marker gene may confer resistance to ampicillin, chloramphenicol, tetracycline, kanamycin, hygromycin, phleomycin, geneticin, or G418, or may complement a deficiency of the host microbe in one of the trp, arg, leu, pyr4, pyr, ura3, ura5, his, or ade genes or may confer the ability to grow on acetamide as a sole nitrogen source.
  • The expression vector of the invention may further comprise other nucleic acid sequences, e.g., additional control sequences, as is commonly known to those of skill in the art, for example, transcriptional terminators, synthetic sequences to link the various other nucleic acid sequences together, origins of replication, ribosome binding sites, a multiple cloning site (or polylinker site), a polyadenylation signal and the like. The ribosomal binding site suitable for the expression vector depends on the host cell used, for example, for expression in a prokaryotic host cell, a prokaryotic RBS, e.g., a T7 phage RBS can be used. A multiple cloning site, or polylinker site, contains one or more restriction enzyme sites that are preferably not present in the remaining sequence of the expression vector. The restriction enzyme sites are utilized for the insertion of a nucleic acid sequence encoding a polypeptide having cellobiase activity or other desired control sequences. The practice of the present invention is not limited by the presence of any one or more of these other nucleic acid sequences, e.g., other control sequences.
  • Examples of suitable expression vectors for use in the present invention include vectors for expression in prokaryotes, e.g., bacterial expression vectors. A bacterial expression vector suitable for use in the present invention in the pET vector (Novagen), which contains the following: a viral T7 promoter which is specific to only T7 RNA polymerase (not bacterial RNA polymerase) and also does not occur anywhere in the prokaryotic genome, a lac operator comprising a lac promoter and coding sequence for the lac repressor protein (lacI gene), a polylinker, an f1 origin of replication (so that a single-stranded plasmid can be produced when co-infected with M13 helper phage), an ampicillin resistance gene, and a ColE1 origin of replication (Blaber, 1998). Both the promoter and the lac operator are located 5′, or upstream, of the polylinker in which the nucleic acid sequence encoding a polypeptide described herein is inserted. The lac operator confers inducible expression of the nucleic acid sequence encoding a polypeptide having cellobiase activity. Addition of IPTG (Isopropyl β-D-1-thiogalactopyranoside), a lactose metabolite, triggers transcription of the lac operon and induces protein expression of the nucleic acid sequence under control of the lac operator. Use of this system requires the addition of T7 RNA polymerase to the host cell for vector expression. The T7 RNA polymerase can be introduced via a second expression vector, or a host cell strain that is genetically engineered to express T7 RNA polymerase can be used.
  • An exemplary expression vector for use with the invention is a pET vector, commercially available from Novagen. The pET expression system is described in U.S. Pat. Nos. 4,952,496; 5,693,489; and 5,869,320. In one embodiment, the pET vector is a pET-DUET vector, e.g., pET-Duet1, commercially available from Novagen. Other vectors suitable for use in the present invention include vectors containing His-tag sequences, such as those described in U.S. Pat. Nos. 5,310,663 and 5,284,933; and European Patent No. 282042.
  • The present invention also relates to a host cell comprising the nucleic acid sequence or expression vector of the invention, which are used in the recombinant production of the polypeptides having cellobiase activity.
  • An expression vector comprising a nucleic acid sequence of the present invention is sintroduced into a host cell so that the vector is maintained (e.g., by chromosomal integration or as a self-replicating extra-chromosomal vector) such that the polypeptide is expressed.
  • The host cell may be a prokaryote or a eukaryote. The host cell may be a bacteria, such as an E. coli strain, e.g., K12 strains NovaBlue, NovaBlue T1R, JM109, and DH5α. Preferably, the bacteria cell has the capability to fold, or partially fold, exogenously expressed proteins, such as E. coli Origami strains, e.g., Origami B, Origami B (DE3), Origami 2, and Origami 2(DE3) strains. In some embodiments, it may be preferred to use a host cell that is deficient for glycosylation, or has an impaired glycosylation pathway such that proteins expressed by the host cell are not significantly glycosylated.
  • The host cell may be a yeast or a filamentous fungus, particularly those classified as Ascomycota. Genera of yeasts useful as host microbes for the expression of modified TrCel3A beta-glucosidases of the present invention include Saccharomyces, Pichia, Hansenula, Kluyveromyces, Yarrowia, and Arxula. Genera of fungi useful as microbes for the expression of the polypeptides of the present invention include Trichoderma, Hypocrea, Aspergillus, Fusarium, Humicola, Neurospora, Chrysosporium, Myceliophthora, Thielavia, Sporotrichum and Penicillium. For example, the host cell may be Pichia pastoris. For example, the host cell may be an industrial strain of Trichoderma reesei, or a mutant thereof, e.g., T. reesei RUTC30. Typically, the host cell is one which does not express a parental cellobiase or Cel3a.
  • The selection of the particular host cell, e.g., bacterial cell or a fungal cell, depends on the expression vector (e.g., the control sequences) and/or the method utilized for producing an aglycosylated polypeptide of the invention, as described in further detail below.
  • The expression vector of the invention may be introduced into the host cell by any number of methods known by one skilled in the art of microbial transformation, including but not limited to, transformation, treatment of cells with CaCl2, electroporation, biolistic bombardment, lipofection, and PEG-mediated fusion of protoplasts (e.g. White et al., WO 2005/093072, which is incorporated herein by reference). After selecting the recombinant host cells containing the expression vector (e.g., by selection utilizing the selectable marker of the expression vector), the recombinant host cells may be cultured under conditions that induce the expression of the polypeptide having cellobiase activity of the invention.
    • Methods for Producing Aglycosylated Polypeptides
  • The present invention further provides methods for producing an aglycosylated polypeptide having cellobiase activity, as described herein. The method comprises culturing the recombinant host cell expressing the polypeptide of the present invention under conditions suitable for the expression of the polypeptide. The method may also comprise recovering the aglycosylated polypeptide from the recombinant host cell.
  • Methods for recovering polypeptides expressed from prokaryote and eukaryote cells are known in the art. In embodiments, the method for recovering the polypeptide comprises lysing the cells, e.g., by mechanical, chemical, or enzymatic means. For example, cells can be physically broken apart, e.g., by sonication, milling (shaking with beads), or shear forces. Cell membranes can be treated such that they are permeabilized such that the contents of the cells are released, such as treatment with detergents, e.g., Triton, NP-40, or SDS. Cells with cell walls, e.g., bacterial cells, can be permeabilized using enzymes, such as a lysozyme or lysonase. Any combination of the mechanical, chemical, and enzymatic techniques described above are also suitable for recovering expressed polypeptides of interest from the host cell in the context of this invention. For example, when expressing an aglycosylated polypeptide having cellobiase activity described herein in a bacterial cell, e.g., an E. coli cell, the cell is typically lysed by centrifuging and pelleting the cell culture, and resuspending in a lysis buffer containing lysozyme. To ensure complete lysis, the resuspended cells are subjected to one of the following methods: sonication, milling, or homogenization.
  • In one embodiment, the expressed aglycosylated polypeptides having cellobiase activity described herein are not lysed before addition to the biomass for the saccharification reaction. In some instances, the methods for lysing host cells can result in protein denaturation and/or decreased enzyme activity, which leads to increased cost of downstream processing. Thus, the present invention also provides methods for directly adding the host cells expressing an aglycosylated polypeptide having cellobiase activity described herein to the biomass prior to the saccharification step.
  • In an embodiment, the host cell, e.g., the E. coli cell, expressing the aglycosylated polypeptide having cellobiase activity described herein is isolated, e.g., by centrifugation, and added to the saccharification reaction, e.g., the saccharification reactor containing biomass. The cells are lysed by a combination of shear from the biomass, the impellers, and the increased temperature. In an embodiment, the culture of host cell, e.g., the E. coli cell, expressing the aglycosylated polypeptide having cellobiase activity described herein is added directly from the fermentation tank directly to the saccharification tank and eliminating the need to pellet cells by centrifugation.
  • Using a Host Cell Deficient for Glycosylation
  • In embodiments, the expression vector comprises a nucleic acid sequence encoding a polypeptide having cellobiase activity described herein operably linked to a fusion tag is introduced to and expressed in a cell that does not significantly glycosylate proteins expressed in the cell, e.g., a bacterial host cell. The recombinant host cell is cultured under conditions for expression of the polypeptide, resulting in the production of an aglycosylated polypeptide having cellobiase activity. The aglycosylated polypeptide can be purified or isolated from the host cell using affinity chromatography methods for the fusion tag as described herein.
  • For example, in this embodiment, the expression vector contains a lac operator and a T7 promoter upstream of the nucleic acid sequence encoding a polypeptide having cellobiase activity, and the host cell has the capacity to express T7 RNA polymerase. Expression of the polypeptide having cellobiase activity is induced by addition of IPTG. Preferably, the host cell is an E. coli cell, preferably an E. coli Origami cell. In this embodiment, the fusion tag is a His-tag, and the purification of the expressed aglycosylated polypeptide comprises nickel affinity chromatography.
  • Using a Host Cell with the Capacity for Glycosylation
  • In another embodiment, an expression vector comprising a nucleic acid sequence encoding a polypeptide comprising one or more glycosylation site mutations such that the polypeptide is not glyscosylated, as described herein, is expressed in a host cell, wherein the host cell is capable of glycosylating proteins expressed within the cell, e.g., a yeast or fungal host cell. Alternatively, the host cell is not capable of glycosylating proteins expressed within the cell, e.g., a bacterial host cell. In this embodiment, the polypeptide is operably linked to a fusion tag. The aglycosylated polypeptide can be purified or isolated from the bacterial host cell using affinity chromatography methods for the fusion tag as described herein.
  • In yet another embodiment, an expression vector comprising a nucleic acid sequence encoding a polypeptide having cellobiase activity described herein is expressed in a host cell, wherein the host cell is capable of glycosylating proteins expressed within the cell. The cells are cultured under conditions sufficient for expression and glycosylation of the polypeptide. In this embodiment, the polypeptide is operably linked to a fusion tag. The glycosylated polypeptide can be purified or isolated from the bacterial host cell using affinity chromatography methods for the fusion tag as described herein. After purification from the host cells and other endogenous host enzymes, e.g., glycosylation enzymes, the glycans of the isolated glycosylated polypeptide can be removed by incubation with deglycosylating enzymes. Deglycosylating enzymes include PNGase F, PNGase A, EndoH (endoglycosidase H), EndoS (endoglycosidase S), EndoD (endoglycosidase D), EndoF (endoglycosidase F), EndoF1 (endoglycosidase F1), or EndoF2 (endoglycosidase F2). Protein deglycosylation mixes containing enzymes sufficient for the complete removal of glycans are commercially available, e.g., from New England Biolabs. The isolated polypeptide is incubated with one or more deglycosylating enzyme under conditions sufficient for the removal of all of the glycans from the polypeptide. Other methods are known in the art for removing glycans from a polypeptide, e.g., β-elimination with mild alkali or mild hydrazinolysis. Assessment of the glycosylation state of the polypeptide can be determined using methods for staining and visualization of glycans known in the art, or mass spectrometry.
  • In yet another embodiment, an expression vector comprising a nucleic acid sequence encoding a polypeptide having cellobiase activity described herein is expressed in a host cell, wherein the host cell is capable of glycosylating proteins expressed within the cell. The cells are cultured under conditions sufficient for expression of the polypeptide, but in the presence of glycosylation inhibitors. The glycosylation inhibitors are present at a concentration and for a sufficient time such that the expressed polypeptides are not glycosylated. In this embodiment, the polypeptide is operably linked to a fusion tag. The resulting aglycosylated polypeptide can be purified or isolated from the bacterial host cell using affinity chromatography methods for the fusion tag as described herein.
  • Examples of suitable glycosylation inhibitors for use in this embodiment include tunicamycin, Benzyl-GalNAc (Benzyl 2-acetamido-2-deoxy-α-D-galactopyranoside), 2-Fluoro-2-deoxy-D-glucose, and 5′CDP (5′ cytidylate diphosphate). In some embodiments, a combination of glycosylation inhibitors is used. Preferably, the concentration of glycosylation inhibitors used in this embodiment is sufficient to inhibit glycosylation of the polypeptide, but do not cause cytotoxicity or inhibition of protein expression of the host cell.
    • Methods of Producing Products Using Aglycosylated Polypeptides
  • The present invention provides methods and compositions for converting or processing a biomass into products, using an aglycosylated polypeptide having cellobiase activity, as described herein. Methods for converting a biomass to products, such as sugar products, are known in the art, for example, as described in US Patent Application 2014/0011258, the contents of which are incorporated by reference in its entirety. Briefly, a biomass is optimally pretreated, e.g., to reduce the recalcitrance, and saccharified by a saccharification process that involves incubating the treated biomass with biomass-degrading, or cellulolytic, enzymes to produce sugars (e.g., glucose and/or xylose). The sugar products can then be further processed to produce a final product, e.g., by fermentation or distillation. Final products include alcohols (e.g., ethanol, isobutanol, or n-butanol), sugar alcohols (e.g., erythritol, xylitol, or sorbitol), or organic acids (e.g., lactic acid, pyurvic acid, succinic acid).
  • Using the processes described herein, the biomass material can be converted to one or more products, such as energy, fuels, foods and materials. Specific examples of products include, but are not limited to, hydrogen, sugars (e.g., glucose, xylose, arabinose, mannose, galactose, fructose, cellobiose, disaccharides, oligosaccharides and polysaccharides), alcohols (e.g., monohydric alcohols or dihydric alcohols, such as ethanol, n-propanol, isobutanol, sec-butanol, tert-butanol or n-butanol), hydrated or hydrous alcohols (e.g., containing greater than 10%, 20%, 30% or even greater than 40% water), biodiesel, organic acids, hydrocarbons (e.g., methane, ethane, propane, isobutene, pentane, n-hexane, biodiesel, bio-gasoline and mixtures thereof), co-products (e.g., proteins, such as cellulolytic proteins (enzymes) or single cell proteins), and mixtures of any of these in any combination or relative concentration, and optionally in combination with any additives (e.g., fuel additives). Other examples include carboxylic acids, salts of a carboxylic acid, a mixture of carboxylic acids and salts of carboxylic acids and esters of carboxylic acids (e.g., methyl, ethyl and n-propyl esters ketones (e.g., acetone), aldehydes (e.g., acetaldehyde), alpha and beta unsaturated acids (e.g., acrylic acid) and olefins (e.g., ethylene). Other alcohols and alcohol derivatives include propanol, propylene glycol, 1,4-butanediol, 1,3-propanediol, sugar alcohols and polyols (e.g., glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol, and polyglycitol and other polyols), and methyl or ethyl esters of any of these alcohols. Other products include methyl acrylate, methylmethacrylate, lactic acid, citric acid, formic acid, acetic acid, propionic acid, butyric acid, succinic acid, valeric acid, caproic acid, 3-hydroxypropionic acid, palmitic acid, stearic acid, oxalic acid, malonic acid, glutaric acid, oleic acid, linoleic acid, glycolic acid, gamma-hydroxybutric acid, and mixtures thereof, salts of any of these acids, mixtures of any of the acids and their respective salts.
  • Biomass
  • The biomass to be processed using the methods described herein is a starchy material and/or a cellulosic material comprising cellulose, e.g., a lignocellulosic material. The biomass may also comprise hemicellulose and/or lignin. The biomass can comprise one or more of an agricultural product or waste, a paper product or waste, a forestry product, or a general waste, or any combination thereof. An agricultural product or waste comprises material that can be cultivated, harvested, or processed for use or consumption, e.g., by humans or animals, or any intermediate, byproduct, or waste that is generated from the cultivation, harvest, or processing methods. Agricultural products or waste include, but are not limited to, sugar cane, jute, hemp, flax, bamboo, sisal, alfalfa, hay, arracacha, buckwheat, banana, barley, cassava, kudzu, oca, sago, sorghum, potato, sweet potato, taro, yams, beans, favas, lentils, peas, grasses, switchgrass, miscanthus, cord grass, reed canary grass, grain residues, canola straw, wheat straw, barley straw, oat straw, rice straw, corn cobs, corn stover, corn fiber, coconut hair, beet pulp, bagasse, soybean stover, grain residues, rice hulls, oat hulls, wheat chaff, barley hulls, or beeswing, or a combination thereof. A paper product or waste comprises material that is used to make a paper product, any paper product, or any intermediate, byproduct or waste that is generated from making or breaking down the paper product. Paper products or waste include, but are not limited to, paper, pigmented papers, loaded papers, coated papers, corrugated paper, filled papers, magazines, printed matter, printer paper, polycoated paper, cardstock, cardboard, paperboard, or paper pulp, or a combination thereof. A forestry product or waste comprises material that is produced by cultivating, harvesting, or processing of wood, or any intermediate, byproduct, or waste that is generated from the cultivation, harvest, or processing of the wood. Forestry products or waste include, but are not limited to, aspen wood, wood from any genus or species of tree, particle board, wood chips, or sawdust, or a combination thereof. A general waste includes, but is not limited to, manure, sewage, or offal, or a combination thereof.
  • In an embodiment, the biomass comprises agriculture waste, such as corn cobs, e.g., corn stover. In another embodiment, the biomass comprises grasses.
  • In one embodiment, the biomass is treated prior to contact with the compositions described herein. For example, the biomass is treated to reduce the recalcitrance of the biomass, to reduce its bulk density, and/or increase its surface area. Suitable biomass treatment process may include, but are not limited to: bombardment with electrons, sonication, oxidation, pyrolysis, steam explosion, chemical treatment, mechanical treatment, and freeze grinding. Preferably, the treatment method is bombardment with electrons.
  • In some embodiments, electron bombardment is performed until the biomass receives a total dose of at least 0.5 Mrad, e.g. at least 5, 10, 20, 30, or at least 40 Mrad. In some embodiments, the treatment is performed until the biomass receives a dose a of from about 0.5 Mrad to about 150 Mrad, about 1 Mrad to about 100 Mrad, about 5 Mrad to about 75 Mrad, about 2 Mrad to about 75 Mrad, about 10 Mrad to about 50 Mrad, e.g., about 5 Mrad to about 50 Mrad, about 20 Mrad to about 40 Mrad, about 10 Mrad to about 35 Mrad, or from about 20 Mrad to about 30 Mrad. In some implementations, a total dose of 25 to 35 Mrad is preferred, applied ideally over a couple of seconds, e.g., at 5 Mrad/pass with each pass being applied for about one second. Applying a dose of greater than 7 to 9 Mrad/pass can in some cases cause thermal degradation of the feedstock material.
  • The biomass material (e.g., plant biomass, animal biomass, paper, and municipal waste biomass) can be used as feedstock to produce useful intermediates and products such as organic acids, salts of organic acids, anhydrides, esters of organic acids and fuels, e.g., fuels for internal combustion engines or feedstocks for fuel cells. Systems and processes are described herein that can use as feedstock cellulosic and/or lignocellulosic materials that are readily available, but often can be difficult to process, e.g., municipal waste streams and waste paper streams, such as streams that include newspaper, kraft paper, corrugated paper or mixtures of these.
  • In order to convert the biomass to a form that can be readily processed, the glucan- or xylan-containing cellulose in the feedstock can be hydrolyzed to low molecular weight carbohydrates, such as sugars, by a saccharifying agent, e.g., an enzyme or acid, a process referred to as saccharification. The low molecular weight carbohydrates can then be used, for example, in an existing manufacturing plant, such as a single cell protein plant, an enzyme manufacturing plant, or a fuel plant, e.g., an ethanol manufacturing facility.
  • The biomass can be hydrolyzed using an enzyme, e.g., a biomass degrading enzyme, by combining the materials and the enzyme in a solvent, e.g., in an aqueous solution. The enzymes can be made/induced according to the methods described herein.
  • Specifically, the biomass degrading enzyme can be supplied by organisms, e.g., a microorganism, that are capable of breaking down biomass (such as the cellulose and/or the lignin portions of the biomass), or that contain or manufacture various cellulolytic enzymes (cellulases), ligninases or various small molecule biomass-degrading metabolites. These enzymes may be a complex of enzymes that act synergistically to degrade crystalline cellulose or the lignin portions of biomass. Examples of cellulolytic enzymes include: endoglucanases, cellobiohydrolases, and cellobiases (beta-glucosidases).
  • During saccharification a cellulosic substrate can be initially hydrolyzed by endoglucanases at random locations producing oligomeric intermediates. These intermediates are then substrates for exo-splitting glucanases such as cellobiohydrolase to produce cellobiose from the ends of the cellulose polymer. Cellobiose is a water-soluble 1,4-linked dimer of glucose. Finally, cellobiase cleaves cellobiose to yield glucose. The efficiency (e.g., time to hydrolyze and/or completeness of hydrolysis) of this process depends on the recalcitrance of the cellulosic material.
  • Saccharification
  • The reduced-recalcitrance biomass is treated with the biomass-degrading enzymes discussed above, generally by combining the reduced-recalcitrance biomass and the biomass-degrading enzymes in a fluid medium, e.g., an aqueous solution. In some cases, the feedstock is boiled, steeped, or cooked in hot water prior to saccharification, as described in U.S. Pat. App. Pub. 2012/0100577 A1 by Medoff and Masterman, published on Apr. 26, 2012, the entire contents of which are incorporated herein.
  • Provided herein are mixtures of enzymes that are capable of degrading the biomass, e.g., an enzyme mixture of biomass-degrading enzymes, for use in the saccharification process described herein.
  • The saccharification process can be partially or completely performed in a tank (e.g., a tank having a volume of at least 4000, 40,000, or 500,000 L) in a manufacturing plant, and/or can be partially or completely performed in transit, e.g., in a rail car, tanker truck, or in a supertanker or the hold of a ship. The time required for complete saccharification will depend on the process conditions and the biomass material and enzyme used. If saccharification is performed in a manufacturing plant under controlled conditions, the cellulose may be substantially entirely converted to sugar, e.g., glucose in about 12-96 hours. If saccharification is performed partially or completely in transit, saccharification may take longer.
  • In a preferred embodiment, the saccharification reaction occurs at a pH optimal for the enzymatic reactions to occur, e.g., at the pH optimal for the activity of the biomass-degrading enzymes. Preferably, the pH of the saccharification reaction is at pH 4-4.5. In a preferred embodiment, the saccharification reaction occurs at a temperature optimal for the enzymatic reactions to occur, e.g., at the temperature optimal for the activity of the biomass-degrading enzymes. Preferably, the temperature of the saccharification reaction is at 42° C.-52° C.
  • It is generally preferred that the tank contents be mixed during saccharification, e.g., using jet mixing as described in International App. No. PCT/US2010/035331, filed May 18, 2010, which was published in English as WO 2010/135380 and designated the United States, the full disclosure of which is incorporated by reference herein.
  • The addition of surfactants can enhance the rate of saccharification. Examples of surfactants include non-ionic surfactants, such as a Tween® 20 or Tween® 80 polyethylene glycol surfactants, ionic surfactants, or amphoteric surfactants.
  • It is generally preferred that the concentration of the sugar solution resulting from saccharification be relatively high, e.g., greater than 40%, or greater than 50, 60, 70, 80, 90 or even greater than 95% by weight. Water may be removed, e.g., by evaporation, to increase the concentration of the sugar solution. This reduces the volume to be shipped, and also inhibits microbial growth in the solution.
  • Alternatively, sugar solutions of lower concentrations may be used, in which case it may be desirable to add an antimicrobial additive, e.g., a broad spectrum antibiotic, in a low concentration, e.g., 50 to 150 ppm. Other suitable antibiotics include amphotericin B, ampicillin, chloramphenicol, ciprofloxacin, gentamicin, hygromycin B, kanamycin, neomycin, penicillin, puromycin, streptomycin. Antibiotics will inhibit growth of microorganisms during transport and storage, and can be used at appropriate concentrations, e.g., between 15 and 1000 ppm by weight, e.g., between 25 and 500 ppm, or between 50 and 150 ppm. If desired, an antibiotic can be included even if the sugar concentration is relatively high. Alternatively, other additives with anti-microbial of preservative properties may be used. Preferably the antimicrobial additive(s) are food-grade.
  • A relatively high concentration solution can be obtained by limiting the amount of water added to the biomass material with the enzyme. The concentration can be controlled, e.g., by controlling how much saccharification takes place. For example, concentration can be increased by adding more biomass material to the solution. In order to keep the sugar that is being produced in solution, a surfactant can be added, e.g., one of those discussed above. Solubility can also be increased by increasing the temperature of the solution. For example, the solution can be maintained at a temperature of 40-50° C., 60-80° C., or even higher.
  • In the processes described herein, for example after saccharification, sugars (e.g., glucose and xylose) can be isolated. For example, sugars can be isolated by precipitation, crystallization, chromatography (e.g., simulated moving bed chromatography, high pressure chromatography), centrifugation, extraction,any other isolation method known in the art, and combinations thereof.
  • Enzyme Mixtures for Saccharification
  • The present invention provides an enzyme mixture comprising a glycosylated polypeptide comprising at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 1, and an aglycosylated polypeptide comprising at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 1, wherein both the glycosylated polypeptide and the aglyscosylated polypeptide have cellobiase activity. The aglycosylated polypeptide having cellobiase activity is any of the aglycosylated polypeptides described herein, e.g., produced using the methods described herein. The glycosylated polypeptide comprising at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 1 can be isolated or obtained from a microorganism that endogenously expresses the polypeptide.
  • In an embodiment, the glysocylated polypeptide and the aglycosylated polypeptide are both the Cel3A enzyme from wild-type T. reesei, e.g., comprising SEQ ID NO: 1.
  • In embodiments, the enzyme mixture further comprises at least one additional enzyme derived from a microorganism, wherein the additional enzyme has biomass or cellulose-based material-degrading activity, e.g., the additional enzyme is a cellulolytic enzyme, e.g., a cellulase. For example, the additional enzyme is a ligninase, an endoglucanase, a cellobiohydrolase, a xylanase, and a cellobiase. In an embodiment, the mixture further comprises one or more ligninase, one or more endogluconase, one or more cellobiohydrolase, and one or more xylanase. In embodiments, the additional biomass-degrading enzyme is glycosylated. In embodiments, the enzyme mixture further comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 additional biomass-degrading enzymes described herein. For example, the enzyme mixture further comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or all of the enzymes listed in Table 1.
  • For example, the enzyme mixture further comprises a mixture of additional biomass-degrading enzymes produced by a microorganism, e.g., a fungal cell, such as wild-type T. reesei, or a mutant thereof, e.g., T. Reesei RUTC30. In an embodiment, the additional biomass-degrading enzymes are isolated from the microorganisms. In an embodiment, the mixture comprises one or more of the following biomass-degrading enzymes: B2AF03, CIP1, CIP2, Cel1a, Cel3a, Cel5a, Cel6a, Cel7a, Cel7b, Cel12a, Cel45a, Cel74a, paMan5a, paMan26a, or Swollenin, or any combination thereof. The additional biomass-degrading enzymes, e.g., listed above, can be endogenously expressed and isolated from the microorganism, e.g., fungal cell, from which the enzyme originates from (listed below in Table 1). Alternatively, the additional biomass-degrading enzymes, e.g., listed above, can be heterologously expressed using similar methods of expression in a host cell described herein, and isolated from the host cells. In an embodiment, the heterologously expressed additional biomass-degrading enzymes are tagged with a His tag at the C or N terminus of the enzyme and are isolated using nickel affinity chromatography techniques known in the art. For example, the additional biomass-degrading enzymes can be selected from Table 1 below.
  • TABLE 1
    Examples of Additional Biomass-Degrading Enzymes
    Protein MW, kDa no AA's th. pl no. Cysteines Organism
    B2AF03-C′His 88.6 813 6.3 10 Podospora anserina
    CIP1-C′His 32.5 311 5.6 8 Trichoderma reesei
    CIP2-C′His 48.0 457 7.0 12 Trichoderma reesei
    Cel1a-C′His 53.6 478 5.8 5 Trichoderma reesei
    Cel3a-C′His 78.0 739 6.3 6 Trichoderma reesei
    Cel3a-N′His 78.0 739 6.3 6 Trichoderma reesei
    Cel5a-N′His 43.7 411 5.7 12 Trichoderma reesei
    Cel6a-C′His 48.8 461 6.0 12 Trichoderma reesei
    Cel7a-C′His 53.8 511 4.8 24 Trichoderma reesei
    Cel7b-C′His 47.6 451 5.3 22 Trichoderma reesei
    Cel12a-C′His 25.1 232 6.9 2 Trichoderma reesei
    Cel45a-C′His 24.4 239 5.4 16 Trichoderma reesei
    Cel74a-C′His 86.7 832 5.7 4 Trichoderma reesei
    paMan5a-C′His 41.0 370 7.0 6 Podospora anserina
    paMan26a-C′His 51.4 463 5.2 1 Podospora anserina
    Swollenin-N′His 51.5 491 5.3 28 Trichoderma reesei
  • The amino acid sequences for the biomass-degrading enzymes listed in Table 1 are provided below.
  • B2AF03 (Podospora anserina)
    (SEQ ID NO: 9)
            MKSSVFWGASLTSAVVRAIDLPFQFYPNCVDDLLSTNQVCNTTLSPPERAAALVAALTPEE
    KLQNIVSKSLGAPRIGLPAYNWWSEALHGVAYAPGTQFWQGDGPFNSSTSFPMPLLMAATFDDELLEKI
    AEVIGIEGRAFGNAGFSGLDYWTPNVNPFKDPRWGRGSETPGEDVLLVKRYAAAMIKGLEGPVPEKERR
    VVATCKHYAANDFEDWNGATRHNFNAKISLQDMAEYYFMPFQQCVRDSRVGSIMCAYNAVNGVPSCASP
    YLLQTILREHWNWTEHNNYITSDCEAVLDVSLNHKYAATNAEGTAISFEAGMDTSCEYEGSSDIPGAWS
    QGLLKESTVDRALLRLYEGIVRAGYFDGKQSLYSSLGWADVNKPSAQKLSLQAAVDGTVLLKNDGTLPL
    SDLLDKSRPKKVAMIGFWSDAKDKLRGGYSGTAAYLHTPAYAASQLGIPFSTASGPILHSDLASNQSWT
    DNAMAAAKDADYILYFGGIDTSAAGETKDRYDLDWPGAQLSLINLLTTLSKPLIVLQMGDQLDNTPLLS
    NPKINAILWANWPGQDGGTAVMELVTGLKSPAGRLPVTQYPSNFTELVPMTDMALRPSAGNSQLGRTYR
    WYKTPVQAFGFGLHYTTFSPKFGKKFPAVIDVDEVLEGCDDKYLDTCPLPDLPVVVENRGNRTSDYVAL
    AFVSAPGVGPGPWPIKTLGAFTRLRGVKGGEKREGGLKWNLGNLARHDEEGNTVVYPGKYEVSLDEPPK
    ARLRFEIVRGGKGKGKVKGKGKAAQKGGVVLDRWPKPPKGQEPPAIERV
    CIP1 (Trichoderma reesei)
    (SEQ ID NO: 10)
            MVRRTALLALGALSTLSMAQISDDFESGWDQTKWPISAPDCNQGGTVSLDTTVAHSGSNSM
    KVVGGPNGYCGHIFFGTTQVPTGDVYVRAWIRLQTALGSNHVTFIIMPDTAQGGKHLRIGGQSQVLDYN
    RESDDATLPDLSPNGIASTVTLPTGAFQCFEYHLGTDGTIETWLNGSLIPGMTVGPGVDNPNDAGWTRA
    SYIPEITGVNFGWEAYSGDVNTVWFDDISIASTRVGCGPGSPGGPGSSTTGRSSTSGPTSTSRPSTTIP
    PPTSRTTTATGPTQTHYGQCGGIGYSGPTVCASGTTCQVLNPYYSQCL
    CIP2 (Trichoderma reesei)
    (SEQ ID NO: 11)
            MASRFFALLLLAIPIQAQSPVWGQCGGIGWSGPTTCVGGATCVSYNPYYSQCIPSTQASSS
    IASTTLVTSFTTTTATRTSASTPPASSTGAGGATCSALPGSITLRSNAKLNDLFTMFNGDKVTTKDKFS
    CRQAEMSELIQRYELGTLPGRPSTLTASFSGNTLTINCGEAGKSISFTVTITYPSSGTAPYPAIIGYGG
    GSLPAPAGVAMINFNNDNIAAQVNTGSRGQGKFYDLYGSSHSAGAMTAWAWGVSRVIDALELVPGARID
    TTKIGVTGCSRNGKGAMVAGAFEKRIVLTLPQESGAGGSACWRISDYLKSQGANIQTASEIIGEDPWFS
    TTFNSYVNQVPVLPFDHHSLAALIAPRGLFVIDNNIDWLGPQSCFGCMTAAHMAWQALGVSDHMGYSQI
    GAHAHCAFPSNQQSQLTAFVQKFLLGQSTNTAIFQSDFSANQSQWIDWTTPTLS
    Cel1a (Trichoderma reesei)
    (SEQ ID NO: 12)
            MLPKDFQWGFATAAYQIEGAVDQDGRGPSIWDTFCAQPGKIADGSSGVTACDSYNRTAEDI
    ALLKSLGAKSYRFSISWSRIIPEGGRGDAVNQAGIDHYVKFVDDLLDAGITPFITLFHWDLPEGLHQRY
    GGLLNRTEFPLDFENYARVMFRALPKVRNWITFNEPLCSAIPGYGSGTFAPGRQSTSEPWTVGHNILVA
    HGRAVKAYRDDFKPASGDGQIGIVLNGDFTYPWDAADPADKEAAERRLEFFTAWFADPIYLGDYPASMR
    KQLGDRLPTFTPEERALVHGSNDFYGMNHYTSNYIRHRSSPASADDTVGNVDVLFTNKQGNCIGPETQS
    PWLRPCAAGFRDFLVWISKRYGYPPIYVTENGTSIKGESDLPKEKILEDDFRVKYYNEYIRAMVTAVEL
    DGVNVKGYFAWSLMDNFEWADGYVTRFGVTYVDYENGQKRFPKKSAKSLKPLFDELIAAA
    Cel3a (Trichoderma reesei)
    (SEQ ID NO: 13)
            MRYRTAAALALATGPFARADSHSTSGASAEAVVPPAGTPWGTAYDKAKAALAKLNLQDKVG
    IVSGVGWNGGPCVGNTSPASKISYPSLCLQDGPLGVRYSTGSTAFTPGVQAASTWDVNLIRERGQFIGE
    EVKASGIHVILGPVAGPLGKTPQGGRNWEGFGVDPYLTGIAMGQTINGIQSVGVQATAKHYILNEQELN
    RETISSNPDDRTLHELYTWPFADAVQANVASVMCSYNKVNTTWACEDQYTLQTVLKDQLGFPGYVMTDW
    NAQHTTVQSANSGLDMSMPGTDFNGNNRLWGPALTNAVNSNQVPTSRVDDMVTRILAAWYLTGQDQAGY
    PSFNISRNVQGNHKTNVRAIARDGIVLLKNDANILPLKKPASIAVVGSAAIIGNHARNSPSCNDKGCDD
    GALGMGWGSGAVNYPYFVAPYDAINTRASSQGTQVTLSNTDNTSSGASAARGKDVAIVFITADSGEGYI
    TVEGNAGDRNNLDPWHNGNALVQAVAGANSNVIVVVHSVGAIILEQILALPQVKAVVWAGLPSQESGNA
    LVDVLWGDVSPSGKLVYTIAKSPNDYNTRIVSGGSDSFSEGLFIDYKHFDDANITPRYEFGYGLSYTKF
    NYSRLSVLSTAKSGPATGAVVPGGPSDLFQNVATVTVDIANSGQVTGAEVAQLYITYPSSAPRTPPKQL
    RGFAKLNLTPGQSGTATFNIRRRDLSYWDTASQKWVVPSGSFGISVGASSRDIRLTSTLSVA
    Cel5a (Trichoderma reesei)
    (SEQ ID NO: 14)
            MNKSVAPLLLAASILYGGAAAQQTVWGQCGGIGWSGPTNCAPGSACSTLNPYYAQCIPGAT
    TITTSTRPPSGPTTTTRATSTSSSTPPTSSGVRFAGVNIAGFDFGCTTDGTCVTSKVYPPLKNFTGSNN
    YPDGIGQMQHFVNDDGMTIFRLPVGWQYLVNNNLGGNLDSTSISKYDQLVQGCLSLGAYCIVDIHNYAR
    WNGGIIGQGGPTNAQFTSLWSQLASKYASQSRVWFGIMNEPHDVNINTWAATVQEVVTAIRNAGATSQF
    ISLPGNDWQSAGAFISDGSAAALSQVTNPDGSTTNLIFDVHKYLDSDNSGTHAECTTNNIDGAFSPLAT
    WLRQNNRQAILTETGGGNVQSCIQDMCQQIQYLNQNSDVYLGYVGWGAGSFDSTYVLTETPTGSGNSWT
    DTSLVSSCLARK
    Cel6a (Trichoderma reesei)
    (SEQ ID NO: 15)
            MIVGILTTLATLATLAASVPLEERQACSSVWGQCGGQNWSGPTCCASGSTCVYSNDYYSQC
    LPGAASSSSSTRAASTTSRVSPTTSRSSSATPPPGSTTTRVPPVGSGTATYSGNPFVGVTPWANAYYAS
    EVSSLAIPSLTGAMATAAAAVAKVPSFMWLDTLDKTPLMEQTLADIRTANKNGGNYAGQFVVYDLPDRD
    CAALASNGEYSIADGGVAKYKNYIDTIRQIVVEYSDIRTLLVIEPDSLANLVTNLGTPKCANAQSAYLE
    CINYAVTQLNLPNVAMYLDAGHAGWLGWPANQDPAAQLFANVYKNASSPRALRGLATNVANYNGWNITS
    PPSYTQGNAVYNEKLYIHAIGPLLANHGWSNAFFITDQGRSGKQPTGQQQWGDWCNVIGTGFGIRPSAN
    TGDSLLDSFVWVKPGGECDGTSDSSAPRFDSHCALPDALQPAPQAGAWFQAYFVQLLTNANPSFL
    Cel7a(Trichoderma reesei)
    (SEQ ID NO: 16)
            MYRKLAVISAFLATARAQSACTLQSETHPPLTWQKCSSGGTCTQQTGSVVIDANWRWTHAT
    NSSTNCYDGNTWSSTLCPDNETCAKNCCLDGAAYASTYGVTTSGNSLSIGFVTQSAQKNVGARLYLMAS
    DTTYQEFTLLGNEFSFDVDVSQLPCGLNGALYFVSMDADGGVSKYPTNTAGAKYGTGYCDSQCPRDLKF
    INGQANVEGWEPSSNNANTGIGGHGSCCSEMDIWEANSISEALTPHPCTTVGQEICEGDGCGGTYSDNR
    YGGTCDPDGCDWNPYRLGNTSFYGPGSSFTLDTTKKLTVVTQFETSGAINRYYVQNGVTFQQPNAELGS
    YSGNELNDDYCTAEEAEFGGSSFSDKGGLTQFKKATSGGMVLVMSLWDDYYANMLWLDSTYPTNETSST
    PGAVRGSCSTSSGVPAQVESQSPNAKVTFSNIKFGPIGSTGNPSGGNPPGGNPPGTTTTRRPATTTGSS
    PGPTQSHYGQCGGIGYSGPTVCASGTTCQVLNPYYSQCL
    Cel7b (Trichoderma reesei)
    (SEQ ID NO: 17)
            MAPSVTLPLTTAILAIARLVAAQQPGTSTPEVHPKLTTYKCTKSGGCVAQDTSVVLDWNYR
    WMHDANYNSCTVNGGVNTTLCPDEATCGKNCFIEGVDYAASGVTTSGSSLTMNQYMPSSSGGYSSVSPR
    LYLLDSDGEYVMLKLNGQELSFDVDLSALPCGENGSLYLSQMDENGGANQYNTAGANYGSGYCDAQCPV
    QTWRNGTLNTSHQGFCCNEMDILEGNSRANALTPHSCTATACDSAGCGFNPYGSGYKSYYGPGDTVDTS
    KTFTIITQFNTDNGSPSGNLVSITRKYQQNGVDIPSAQPGGDTISSCPSASAYGGLATMGKALSSGMVL
    VFSIWNDNSQYMNWLDSGNAGPCSSTEGNPSNILANNPNTHVVFSNIRWGDIGSTTNSTAPPPPPASST
    TFSTTRRSSTTSSSPSCTQTHWGQCGGIGYSGCKTCTSGTTCQYSNDYYSQCL
    Cel12a (Trichoderma reesei)
    (SEQ ID NO: 18)
            MKFLQVLPALIPAALAQTSCDQWATFTGNGYTVSNNLWGASAGSGFGCVTAVSLSGGASWH
    ADWQWSGGQNNVKSYQNSQIAIPQKRTVNSISSMPTTASWSYSGSNIRANVAYDLFTAANPNHVTYSGD
    YELMIWLGKYGDIGPIGSSQGTVNVGGQSWTLYYGYNGAMQVYSFVAQTNTTNYSGDVKNFFNYLRDNK
    GYNAAGQYVLSYQFGTEPFTGSGTLNVASWTASIN
    Cel45a (Trichoderma reesei)
    (SEQ ID NO: 19)
            MKATLVLGSLIVGAVSAYKATTTRYYDGQEGACGCGSSSGAFPWQLGIGNGVYTAAGSQAL
    FDTAGASWCGAGCGKCYQLTSTGQAPCSSCGTGGAAGQSIIVMVTNLCPNNGNAQWCPVVGGTNQYGYS
    YHFDIMAQNEIFGDNVVVDFEPIACPGQAASDWGTCLCVGQQETDPTPVLGNDTGSTPPGSSPPATSSS
    PPSGGGQQTLYGQCGGAGWTGPTTCQAPGTCKVQNQWYSQCLP
    Cel74a (Trichoderma reesei)
    (SEQ ID NO: 20)
            MKVSRVLALVLGAVIPAHAAFSWKNVKLGGGGGFVPGIIFHPKTKGVAYARTDIGGLYRLN
    ADDSWTAVTDGIADNAGWHNWGIDAVALDPQDDQKVYAAVGMYTNSWDPSNGAIIRSSDRGATWSFTNL
    PFKVGGNMPGRGAGERLAVDPANSNIIYFGARSGNGLWKSTDGGVTFSKVSSFTATGTYIPDPSDSNGY
    NSDKQGLMWVTFDSTSSTTGGATSRIFVGTADNITASVYVSTNAGSTWSAVPGQPGKYFPHKAKLQPAE
    KALYLTYSDGTGPYDGTLGSVWRYDIAGGTWKDITPVSGSDLYFGFGGLGLDLQKPGTLVVASLNSWWP
    DAQLFRSTDSGTTWSPIWAWASYPTETYYYSISTPKAPWIKNNFIDVTSESPSDGLIKRLGWMIESLEI
    DPTDSNHWLYGTGMTIFGGHDLTNWDTRHNVSIQSLADGIEEFSVQDLASAPGGSELLAAVGDDNGFTF
    ASRNDLGTSPQTVWATPTWATSTSVDYAGNSVKSVVRVGNTAGTQQVAISSDGGATWSIDYAADTSMNG
    GTVAYSADGDTILWSTASSGVQRSQFQGSFASVSSLPAGAVIASDKKTNSVFYAGSGSTFYVSKDTGSS
    FTRGPKLGSAGTIRDIAAHPTTAGTLYVSTDVGIFRSTDSGTTFGQVSTALTNTYQIALGVGSGSNWNL
    YAFGTGPSGARLYASGDSGASWTDIQGSQGFGSIDSTKVAGSGSTAGQVYVGTNGRGVFYAQGTVGGGT
    GGTSSSTKQSSSSTSSASSSTTLRSSVVSTTRASTVTSSRTSSAAGPTGSGVAGHYAQCGGIGWTGPTQ
    CVAPYVCQKQNDYYYQCV
    paMan5a (Podospora anserina)
    (SEQ ID NO: 21)
            MKGLFAFGLGLLSLVNALPQAQGGGAAASAKVSGTRFVIDGKTGYFAGTNSYWIGFLTNNR
    DVDTTLDHIASSGLKILRVWGFNDVNNQPSGNTVWFQRLASSGSQINTGPNGLQRLDYLVRSAETRGIK
    LIIALVNYWDDFGGMKAYVNAFGGTKESWYTNARAQEQYKRYIQAVVSRYVNSPAIFAWELANEPRCKG
    CNTNVIFNWATQISDYIRSLDKDHLITLGDEGFGLPGQTTYPYQYGEGTDFVKNLQIKNLDFGTFHMYP
    GHWGVPTSFGPGWIKDHAAACRAAGKPCLLEEYGYESDRCNVQKGWQQASRELSRDGMSGDLFWQWGDQ
    LSTGQTHNDGFTIYYGSSLATCLVTDHVRAINALPA
    paMan26a (Podospora anserina)
    (SEQ ID NO: 22)
            MVKLLDIGLFALALASSAVAKPCKPRDGPVTYEAEDAILTGTTVDTAQVGYTGRGYVTGFD
    EGSDKITFQISSATTKLYDLSIRYAAIYGDKRTNVVLNNGAVSEVFFPAGDSFTSVAAGQVLLNAGQNT
    IDIVNNWGWYLIDSITLTPSAPRPPHDINPNLNNPNADTNAKKLYSYLRSVYGNKIISGQQELHHAEWI
    RQQTGKTPALVAVDLMDYSPSRVERGTTSHAVEDAIAHHNAGGIVSVLWHWNAPVGLYDTEENKWWSGF
    YTRATDFDIAATLANPQGANYTLLIRDIDAIAVQLKRLEAAGVPVLWRPLHEAEGGWFWWGAKGPEPAK
    QLWDILYERLTVHHGLDNLIWVWNSILEDWYPGDDTVDILSADVYAQGNGPMSTQYNELIALGRDKKMI
    AAAEVGAAPLPGLLQAYQANWLWFAVWGDDFINNPSWNTVAVLNEIYNSDYVLTLDEIQGWRS
    Swollenin (Trichoderma reesei)
    (SEQ ID NO: 23)
    MAGKLILVALASLVSLSIQQNCAALFGQCGGIGWSGTTCCVAGAQCSFVNDWYSQCLASTGGNPPNGTT
    SSSLVSRTSSASSSVGSSSPGGNSPTGSASTYTTTDTATVAPHSQSPYPSIAASSCGSWTLVDNVCCPS
    YCANDDTSESCSGCGTCTTPPSADCKSGTMYPEVHHVSSNESWHYSRSTHFGLTSGGACGFGLYGLCTK
    GSVTASWTDPMLGATCDAFCTAYPLLCKDPTGTTLRGNFAAPNGDYYTQFWSSLPGALDNYLSCGECIE
    LIQTKPDGTDYAVGEAGYTDPITLEIVDSCPCSANSKWCCGPGADHCGEIDFKYGCPLPADSIHLDLSD
    IAMGRLQGNGSLTNGVIPTRYRRVQCPKVGNAYIWLRNGGGPYYFALTAVNTNGPGSVTKIEIKGADTD
    NWVALVHDPNYTSSRPQERYGSWVIPQGSGPFNLPVGIRLTSPTGEQIVNEQAIKTFTPPATGDPNFYY
    IDIGVQFSQN
  • The ratio between the aglycosylated polypeptide described herein to the other biomass-degrading enzymes in the mixture can be, for example, at least 1:1; 1:2; 1:4; 1:8; 1:16; 1:32; 1:50; 1:75; 1:100, 1:150; 1:200; 1:300, 1:400 or 1:500. In an embodiment, the ratio of aglycosylated polypeptide described herein to the other enzymes in the mixture is 1:32. The ratio between the aglycosylated polypeptide described herein to the glycosylated polypeptide is, for example, at least 1:1; 1:2; 1:4; 1:8; 1:16; 1:32; 1:50; 1:75; 1:100, 1:150; 1:200; 1:300, 1:400, or 1:500.
  • Other examples of suitable biomass-degrading enzymes for use in the enzyme mixture of the present invention include the enzymes from species in the genera Bacillus, Coprinus, Myceliophthora, Cephalosporium, Scytalidium, Penicillium, Aspergillus, Pseudomonas, Humicola, Fusarium, Thielavia, Acremonium, Chrysosporium and Trichoderma, especially those produced by a strain selected from the species Aspergillus (see, e.g., EP Pub. No. 0 458 162), Humicola insolens (reclassified as Scytalidium thermophilum, see, e.g., U.S. Pat. No. 4,435,307), Coprinus cinereus, Fusarium oxysporum, Myceliophthora thermophila, Meripilus giganteus, Thielavia terrestris, Acremonium sp. (including, but not limited to, A. persicinum, A. acremonium, A. brachypenium, A. dichromosporum, A. obclavatum, A. pinkertoniae, A. roseogriseum, A. incoloratum, and A. furatum). Preferred strains include Humicola insolens DSM 1800, Fusarium oxysporum DSM 2672, Myceliophthora thermophila CBS 117.65, Cephalosporium sp. RYM-202, Acremonium sp. CBS 478.94, Acremonium sp. CBS 265.95, Acremonium persicinum CBS 169.65, Acremonium acremonium AHU 9519, Cephalosporium sp. CBS 535.71, Acremonium brachypenium CBS 866.73, Acremonium dichromosporum CBS 683.73, Acremonium obclavatum CBS 311.74, Acremonium pinkertoniae CBS 157.70, Acremonium roseogriseum CBS 134.56, Acremonium incoloratum CBS 146.62, and Acremonium furatum CBS 299.70H. Biomass-degrading enzymes may also be obtained from Chrysosporium, preferably a strain of Chrysosporium lucknowense. Additional strains that can be used include, but are not limited to, Trichoderma (particularly T. viride, T. reesei, and T. koningii), alkalophilic Bacillus (see, for example, U.S. Pat. No. 3,844,890 and EP Pub. No. 0 458 162), and Streptomyces (see, e.g., EP Pub. No. 0 458 162).
  • In embodiments, the microorganism is induced to produce the biomass-degrading enzymes described herein under conditions suitable for increasing production of biomass-degrading enzymes compared to an uninduced microorganism. For example, an induction biomass sample comprising biomass as described herein is incubated with the microorganism to increase production of the biomass-degrading enzymes. Further description of the induction process can be found in US 2014/0011258, the contents of which are hereby incorporated by reference in its entirety.
  • The biomass-degrading enzymes produced and/or secreted by the aforementioned microorganisms can be isolated and added to the enzyme mixture of the present invention. Alternatively, in one embodiment, the aforementioned microorganisms or host cells expressing the biomass-degrading enzymes described herein and above are not lysed before addition to the saccharification reaction.
  • In an embodiment, the enzyme mixture comprises the host cell expressing an aglycosylated polypeptide having cellobiase activity as described herein, and one or more additional biomass-degrading enzymes described herein. In an embodiment, the enzyme mixture comprises a host cell expressing an aglycosylated polypeptide having cellobiase activity as described herein, and one or more host cells expressing one or more additional biomass-degrading enzymes described herein. For example,
  • Use of the enzyme mixture described herein comprising an aglycosylated polypeptide having cellobiase activity results in increased yield of sugar products from saccharification compared to the yield of sugar products from saccharification using the standard mixture of biomass-degrading enzymes (e.g., RUTC30 cocktail, e.g., without addition of an aglycosylated polypeptide having cellobiase activity). The yield of sugar products increases at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100% when an aglycosylated polypeptide having cellobiase activity is added to the saccharification process.
  • Further Processing
  • Further processing steps may be performed on the sugars produced by saccharification to produce alternative products. For example, the sugars can be hydrogenated, fermented, or treated with other chemicals to produce other products.
  • Glucose can be hydrogenated to sorbitol. Xylose can be hydrogenated to xylitol. Hydrogenation can be accomplished by use of a catalyst (e.g., Pt/gamma-Al2O3, Ru/C, Raney Nickel, or other catalysts know in the art) in combination with H2 under high pressure (e.g., 10 to 12000 psi). The sorbitol and/or xylitol products can be isolated and purified using methods known in the art.
  • Sugar products from saccharification can also be fermented to produce alcohols, sugar alcohols, such as erythritol, or organic acids, e.g., lactic, glutamic or citric acids or amino acids.
  • Yeast and Zymomonas bacteria, for example, can be used for fermentation or conversion of sugar(s) to alcohol(s). Other microorganisms are discussed below. The optimum pH for fermentations is about pH 4 to 7. For example, the optimum pH for yeast is from about pH 4 to 5, while the optimum pH for Zymomonas is from about pH 5 to 6. Typical fermentation times are about 24 to 168 hours (e.g., 24 to 96 hrs) with temperatures in the range of 20° C. to 40° C. (e.g., 26° C. to 40° C.), however thermophilic microorganisms prefer higher temperatures.
  • In some embodiments, e.g., when anaerobic organisms are used, at least a portion of the fermentation is conducted in the absence of oxygen, e.g., under a blanket of an inert gas such as N2, Ar, He, CO2 or mixtures thereof. Additionally, the mixture may have a constant purge of an inert gas flowing through the tank during part of or all of the fermentation. In some cases, anaerobic conditions can be achieved or maintained by carbon dioxide production during the fermentation and no additional inert gas is needed.
  • In some embodiments, all or a portion of the fermentation process can be interrupted before the low molecular weight sugar is completely converted to a product (e.g., ethanol). The intermediate fermentation products include sugar and carbohydrates in high concentrations. The sugars and carbohydrates can be isolated via any means known in the art. These intermediate fermentation products can be used in preparation of food for human or animal consumption. Additionally or alternatively, the intermediate fermentation products can be ground to a fine particle size in a stainless-steel laboratory mill to produce a flour-like substance.
  • Jet mixing may be used during fermentation, and in some cases saccharification and fermentation are performed in the same tank.
  • Nutrients for the microorganisms may be added during saccharification and/or fermentation, for example the food-based nutrient packages described in U.S. Pat. App. Pub. 2012/0052536, filed Jul. 15, 2011, the complete disclosure of which is incorporated herein by reference.
  • “Fermentation” includes the methods and products that are disclosed in U.S. Prov. App. No. 61/579,559, filed Dec. 22, 2012, and U.S. Prov. App. No. 61/579,576, filed Dec. 22, 2012, the contents of both of which are incorporated by reference herein in their entirety.
  • Mobile fermenters can be utilized, as described in International App. No. PCT/US2007/074028 (which was filed Jul. 20, 2007, was published in English as WO 2008/011598 and designated the United States), the contents of which is incorporated herein in its entirety. Similarly, the saccharification equipment can be mobile. Further, saccharification and/or fermentation may be performed in part or entirely during transit.
  • The microorganism(s) used in fermentation can be naturally-occurring microorganisms and/or engineered microorganisms. For example, the microorganism can be a bacterium (including, but not limited to, e.g., a cellulolytic bacterium), a fungus, (including, but not limited to, e.g., a yeast), a plant, a protist, e.g., a protozoa or a fungus-like protest (including, but not limited to, e.g., a slime mold), or an algae. When the organisms are compatible, mixtures of organisms can be utilized.
  • Suitable fermenting microorganisms have the ability to convert carbohydrates, such as glucose, fructose, xylose, arabinose, mannose, galactose, oligosaccharides or polysaccharides into fermentation products. Fermenting microorganisms include strains of the genus Saccharomyces spp. (including, but not limited to, S. cerevisiae (baker's yeast), S. distaticus, S. uvarum), the genus Kluyveromyces, (including, but not limited to, K. marxianus, K. fragilis), the genus Candida (including, but not limited to, C. pseudotropicalis, and C. brassicae), Pichia stipitis (a relative of Candida shehatae), the genus Clavispora (including, but not limited to, C. lusitaniae and C. opuntiae), the genus Pachysolen (including, but not limited to, P. tannophilus), the genus Bretannomyces (including, but not limited to, e.g., B. clausenii (Philippidis, G. P., 1996, Cellulose bioconversion technology, in Handbook on Bioethanol: Production and Utilization, Wyman, C. E., ed., Taylor & Francis, Washington, D.C., 179-212)). Other suitable microorganisms include, for example, Zymomonas mobilis, Clostridium spp. (including, but not limited to, C. thermocellum (Philippidis, 1996, supra), C. saccharobutylacetonicum, C. saccharobutylicum, C. Puniceum, C. beijernckii, and C. acetobutylicum), Moniliella pollinis, Moniliella megachiliensis, Lactobacillus spp. Yarrowia lipolytica, Aureobasidium sp., Trichosporonoides sp., Trigonopsis variabilis, Trichosporon sp., Moniliellaacetoabutans sp., Typhula variabilis, Candida magnoliae, Ustilaginomycetes sp., Pseudozyma tsukubaensis, yeast species of genera Zygosaccharomyces, Debaryomyces, Hansenula and Pichia, and fungi of the dematioid genus Torula.
  • For instance, Clostridium spp. can be used to produce ethanol, butanol, butyric acid, acetic acid, and acetone. Lactobacillus spp. can be used to produce lactic acid.
  • Many such microbial strains are publicly available, either commercially or through depositories such as the ATCC (American Type Culture Collection, Manassas, Va., USA), the NRRL (Agricultural Research Sevice Culture Collection, Peoria, Ill., USA), or the DSMZ (Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH, Braunschweig, Germany), to name a few.
  • Commercially available yeasts include, for example, Red Star®/Lesaffre Ethanol Red (available from Red Star/Lesaffre, USA), FALI® (available from Fleischmann's Yeast, a division of Burns Philip Food Inc., USA), SUPERSTART® (available from Alltech, now Lalemand), GERT STRAND® (available from Gert Strand AB, Sweden) and FERMOL® (available from DSM Specialties).
  • Many microorganisms that can be used to saccharify biomass material and produce sugars can also be used to ferment and convert those sugars to useful products.
  • After fermentation, the resulting fluids can be distilled using, for example, a “beer column” to separate ethanol and other alcohols from the majority of water and residual solids. The vapor exiting the beer column can be, e.g., 35% by weight ethanol and can be fed to a rectification column. A mixture of nearly azeotropic (92.5%) ethanol and water from the rectification column can be purified to pure (99.5%) ethanol using vapor-phase molecular sieves. The beer column bottoms can be sent to the first effect of a three-effect evaporator. The rectification column reflux condenser can provide heat for this first effect. After the first effect, solids can be separated using a centrifuge and dried in a rotary dryer. A portion (25%) of the centrifuge effluent can be recycled to fermentation and the rest sent to the second and third evaporator effects. Most of the evaporator condensate can be returned to the process as fairly clean condensate with a small portion split off to waste water treatment to prevent build-up of low-boiling compounds.
  • Other types of chemical transformation of the products from the processes described herein can be used, for example, production of organic sugar derived products such (e.g., furfural and furfural-derived products). Chemical transformations of sugar derived products are described in U.S. Prov. App. No. 61/667,481, filed Jul. 3, 2012, the disclosure of which is incorporated herein by reference in its entirety.
    • EXAMPLES
  • The invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.
  • Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples specifically point out various aspects of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.
    • Example 1 Cloning of Cel3a-C′His into an Expression Vector
  • The mature sequence for Cel3a (amino acids 20-744) was synthesized and codon-optimized for E. coli expression by Genewiz. The Cel3a-C′His referred to in the following examples refers to the codon-optimized mature sequence for Cel3a (aas 20-744) with an 8× His (SEQ ID NO: 7) tag at the C-terminus. The below primers were used to clone the Cel3a-C′His into pET-Duet (Novagen, Catalog No. 71146):
  • Forward
    (SEQ ID NO: 4)
    5′-CATGCCATG GGCGATAGTCACAGTACCAGC
    Reverse
    (SEQ ID NO: 5)
    3′-CCCAAGCTT TCATTA GTGATGATGATGATGATGATGATGGCTGCCGC
    TGCCGGCAACACTCAGGGTGC

    (NcoI and HindIII sites are underlined; start and stop codons are in bold; the polyhistidine (8-His (SEQ ID NO: 7)) tag; and glycine-serine (GSGS) linker (SEQ ID NO: 8) are italized.) The Amplification reaction was performed using PfuUltra II Fusion HS Polymerase (Agilent, Catalog No. 600672).
  • The amplified DNA was cloned by restriction digestion using NcoI restriction enzyme (New England Biolabs, R3193) and HindIII restriction enzyme (New England Biolabs, R3104) under conditions suggested by the manufacturer. The digested amplified DNA was ligated into the NcoI-HindIII sites in the pETDuet vector using T4 DNA ligase (New England Biolabs, M0202), followed by transformation of E. coli cloning host Top10 One Shot (Invitrogen). Plasmid purification was carried out using Qiagen's plasmid purification kit.
    • Example 2 Expression and Purification of Cel3a-C′His
  • The Cel3A-C′His constructs were transformed into the E. coli expression host Origami B (DE3) (EMD Millipore, Catalog No. 70837) and streaked on plates containing LB medium and 100 μg/ml ampicillin (Fisher Scientific, Catalog No. BP1760), 15 μg/ml kanamysin (Fisher Scientific, Catalog No. BP906) and 12.5 μg/ml tetracycline (Fisher Scientified, Catalog No. BP912). Colonies carrying the recombinant DNA were picked from plates for the inoculation of 2 ml starter cultures, and grown overnight at 37° C., then subsequently used to inoculate 100 ml of LB media containing the appropriate antibiotics. Cultures were grown at 37° C. until OD600 reached 0.8.
  • To induce protein expression, 500 μM IPTG (Isopropyl-b-D-thiogalactopyranoside; Fisher Scientific, Catalog No. BP1755) was added. The expression culture was further grown for another 4 hours at 37° C. The cells were harvested by centrifugation at 4000 g at room temperature (RT) for 20 minutes using the Sorvall St16 rotor TX400; and the pellet was stored at −80° C.
  • For protein extraction, the cell pellet was thawed on ice and resuspended in 2 ml of native lysis buffer containing 50 mM Tris-HCl pH 7.5, 0.1% Triton X-100, 5 mM imidazole (Fisher Scientific, Catalog No. 03196), and 1 mg/ml lysozyme (Fisher Scientific, Catalog No. BP535), then incubated on ice for 20 minutes. To digest the DNA in the sample, 2 μl of lysonase (EMD Millipore, Catalog No. 71230) was added and incubated for another 10 minutes. The sample was then spun in a microcentrifuge at maximum speed for 10 minutes at 4° C. The clarified lysate was transferred to a fresh tube containing 100 μl of pre-equilibrated Profinity (Biorad) Ni-charged IMAC resin slurry (Biorad, Catalog No. 732-4614). The native binding buffer consisted of 50 mM Tris HCl pH 7.5, 150 mM NaCl, 0.1% Triton X-100, and 5 μM imidazole. The protein was batch-bound for 1 hour at RT, and then washed with native buffer containing 25 μM imidazole. The protein was eluted in 300 ml of native buffer containing 200 μM imidazole. Purified Cel3a protein from the expression and purification process described above is shown in FIG. 1.
    • Example 3 Expression of Cel3a-C′His in Bioreactors
  • In this example, the expression and purification of Cel3a is scaled up to 3 liter and 5 liter bioreactors. The skilled artisan could readily use the process described herein to scale the production further, for example, to 3 L and 7 L bioreactors.
  • For each bioreactor run, the pET Duet-1 Cel3a-C′His construct is transformed into E. Coli Origami B (DE3) host cell line, and streaked on plates containing LB medium and 100 μg/ml ampicillin (Fisher Scientific, Catalog No. BP1760), 15 μg/ml kanamysin (Fisher Scientific, Catalog No. BP906) and 12.5 μg/ml tetracycline (Fisher Scientific, Catalog No. BP912).
  • On Day 1, colonies carrying the recombinant DNA were picked from plates for the inoculation of 200 ml starter cultures, and grown overnight at 37° C. The bioreactors were prepared, e.g., 1.5 L of LB media was added to each 3 L reactor, and 4 L of LB media was added to each 5 L reactor, with the appropriate antibiotics. Each reactor has a pH probe, a dissolved oxygen (DO) probe, and a condenser.
  • On Day 2, the OD of the overnight inoculums was measured by a spectrophotometer at 600 nM. The spectrophotometer can be blanked by using LB media. The bioreactors were set to 37° C., 300 rpm, and 2.5 vvm. Once the bioreactors reach 37° C., the appropriate mls of overnight inoculums was added to each 1.5 L and to each 4 L culture for a target starting OD value of 0.05. The OD of the reactors were measured occasionally by sampling out of the top with ethanol and a sterile pipet. As the OD approaches 0.8, samples were taken more frequently.
  • When the OD of the reactors reached 0.7-0.8 (approximately 2-4 hours after inoculation), the temperature of the bioreactors was reduced to 20° C., and the cultures were induced with IPTG for Cel3a-C′His protein expression. 750 ml of IPTG was added to each 1.5 L reactor and 1.5 ml of IPTG was added to each 5 L reactor. The reactors were run overnight.
  • On Day 3, in the morning, the cells were harvested into clean 2 L centrifuge bottles and spun at 4200 rpm for 45 minutes. The supernatant was discarded, and the pellet was saved and the weight of the pellet was recorded. Using PBS buffer, the pellet was transferred to 50 mL conical centrifuge tubes. The 50 mL tubes were spun at 4500 rpm for 45 minutes in the Sorvall St-16 tabletop centrifuge. Supernatant was discarded and the pellet was frozen at −20° C. until ready for purification, or processed immediately for purification.
    • Example 4 Protein Extraction from Cells
  • Lysis Buffer with EDTA was prepared, containing the following: 50 mM Tris-HCl pH 7.5, 0.1% Triton X-100, 1% Glycerol, 5 mM imidazole, 1 mg/mL Lysozyme, and 1 mM EDTA in de-ionized water. The cell pellet was resuspended in 5 mL volume of Lysis Buffer with EDTA. 10 μl of Lysonase (DNAse) was added to the sample. Samples were then incubated for 1 hour at room temperature.
  • Then, samples were sonicated on ice for three 1 minute intervals (e.g., for 3 minutes total, Sorvall sonicator at setting 17).
  • At this point, 1000 μl aliquots were e reserved from each fraction of the extraction process to analyze the yield and activity of the Cel3a-C′His protein from the extraction and purification process. An aliquot was taken from sonicated sample (sample A) to represent the total protein isolated. The sample was then centrifuged at 13000 rpm for 5 minutes, and the supernatant was removed. An aliquot was taken from the supernatant (sample D), representing the soluble fraction. The remaining pellet was resuspended in 1000 μl of Lysis Buffer+EDTA, and then centrifuged at 13000 rpm for 5 minutes. The supernatant was removed, and an aliquot was taken from the supernatant (sample E), representing the soluble wash fraction. The remaining pellet was reserved (sample C), representing the insoluble fraction. All samples were stored in the refrigerator (e.g., 4° C.) until analysis.
  • A cellobiase activity assay was performed using the total protein aliquot (sample A), for example, as described in Example 6.
  • The samples A, C, D, and E were also analyzed by SDS-PAGE and western blotting. Samples were diluted to 2.00 OD to normalize. 17.5 μl of LDS sample buffer (375 μl LDS buffer and 150 μl of NuPAGE reducing agent were mixed to prepare 525 μl of LDS sample buffer) was added to 32.5 μl of each sample. Samples were boiled for 5 minutes and 20 μl of each sample was loaded into each gel well. A standard (molecular weight ladder) was also loaded into a gel well.
    • Example 5 Mass Spectrometry Analysis of Purified Cel3a-N′His
  • Cel3a with a His-tag at the N-terminus (Cel3a-N′His) was cloned, expressed in E. coli, and harvested using methods similar to those described above in Examples 1-4. Cel3a-N′His was cloned into pET-Duet1 vector. The expressed Cel3a-N′His was purified with an affinity column containing Profinity Ni-charge IMAC resin slurry and eluted using elution buffer containing 200 mM imidazole in the lysis buffer.
  • The purified Cel3a-N′His was dialyzed in buffer containing 50mM Tris-HCl and 0.5M EDTA. The dialyzed protein was then submitted for liquid chromatography-mass spectrometry (LCMS) intact mass analysis.
  • Sample concentration was determined, e.g., by Bradford assay and by Nanodrop assay. Sample concentration was at about 4 mg/mL. A 10× and 100× dilution sample was prepared for LCMS, with 0.1% formic acid in de-ionized water to provide 0.4 mg/mL and 0.04 mg/mL samples.
  • LC conditions were as follows:
      • Acquity UPLC H-Class Bio System: BEH300 C4 column, 1.7 m, 2.1×150 mm (p/n: 186004497)
      • Column Temp: 45° C.
      • MPA: 0.1% FA in Water
      • MPB: 0.1% FA in ACN
  • Mass Spectrometer conditions were as follows:
      • Source Temp: 125° C.
      • Desolvation Temp: 450° C.
      • Cone Voltage: 40V
      • Calibration: Csl (500-5000 Da)
      • Lockmass: Csl
  • The chromatographic profile of the sample is shown in FIG. 2. The profile shows three areas of interest: a large peak at 31 minutes, a cluster of peaks between 38 and 40 minutes, and a smaller peak at about 45 minutes. Manual deconvolution of the mass spectrum of peak at about 45 minutes and the peak cluster at about 39 minutes shows that the main peaks are not part of a charge state envelope, but rather a polymer series (with 44 amu as the repeating unit), and were thus attributed to possibly being from the Triton-X used in the lysis buffer.
  • Analysis of the mass spectral region for the peak detected at 31 minutes indicates a protein charge state envelope, and importantly, with no evidence of glycosylation (FIG. 3). Expansion of the charge state envelope indicates the presence of 2-3 minor proteins slightly larger than the major component. Deconvolution of the charge state envelope indicated that the major component had a molecular weight of 78,052 (FIG. 4), which corresponds to the expected molecular weight of Cel3a-N′His. The minor components had the following molecular weights: 78,100, 78,182, and 78,229 (FIG. 4), therefore indicating minor modifications to the Cel3a-N′His protein.
  • Among the charge states for the main component were several signals corresponding to smaller peptide fragments. These are distinguished by the more widely spaced isotope peaks. Some of the fragments identified have molecular weights of 8,491, 9,261, and 11,629. These fragments may be generated in the MS source, or may originate from the sample.
  • The results from this experiment demonstrate that an aglycosylated cellobiase, Cel3a-N′His was cloned, expressed, and isolated using the methods encompassed by the present invention.
    • Example 6 Cellobiase Activity Assay
  • His-tagged Cel3a (e.g., Cel3a with a His-tag at the N or C-terminus) were purified using IMAC techniques. The amount (titer) of purified His-tagged Cel3a was determined using Bradford assay and/or the nanodrop. For nanodrop quantification, the molar extinction coefficient was estimated by inserting the amino acid sequence of the target form of Cel3a into the ExPASy ProtParam online tool.
  • For the activity assay, two fold serial dilutions of samples containing Cel3a-N′His were performed in a 96 well plate format. Dilutions were incubated with a D-(+)-Cellobiose (Fluka) substrate solution in 50 mM sodium citrate monobasic buffer at pH 5.0, at 48° C. for 30 minutes. After 30 minutes, the samples were heated to 100° C. for 10 minutes to stop the reaction. Samples were analysed for glucose and cellobiose using the YSI Biochemistry analyser (YSI Life Sciences) and/or HPLC methods. The protein activity of the purified Cel3a-N′His was recorded as percent conversion of cellobiose to glucose per 30 minutes (FIG. 5).
  • For samples where the amount of Cel3a cannot be assayed by using a Bradford assay and/or the nanodrop, e.g., crude lysate sample, the activity assay can be used to determine the titer of Cel3a. A standard curve of cellobiase activity of a sample of purified Cel3a-N′His with a known concentration is generated. Two-fold serial dilutions of Cel3a-N′His with a known concentration were prepared in one row of a 96 well plate, e.g., 12 two-fold serial dilutions. The other rows contained two-fold serial dilutions of other remaining samples whose titer is to be determined, e.g., the crude lysate sample. The dilutions were incubated with a D-(+)-Cellobiose (Fluka) substrate solution in 50 mM sodium citrate monobasic buffer at pH 5.0, at 48° C. for 30 minutes. After 30 minutes, the samples were heated to 100° C. for 10 minutes to stop the reaction. Samples were analysed for glucose and cellobiose using the YSI Biochemistry analyser (YSI Life Sciences) and/or HPLC methods. Using Cel3a-N′His samples of known concentration, a standard curve is generated using the data points within the linear range of the assay (FIG. 6). The cellobiase activity detected from the samples with unknown Cel3a titer can be compared to the standard curve to determine the titer of Cel3a in the sample.
  • Units of activity are only relative if calculated using values within the linear range of the assay. The linear range of the assay is defined as using glucose values that are less than 30% of the original soluble substrate load. In addition, glucose values lower than 0.05 g/L are omitted due to instrumentation reporting levels. One unit of cellobiase activity is defined as the amount of glucose per the amount of Cel3a per 30 minutes: [Glucose]g/L/[Cel3a]g/L/30 min.
  • A comparison of the activity between aglycosylated Cel3a purified from E. coli and endogenous (glycosylated) cellobiase Cel3a from T. reesei was performed, using the cellobiase activity described herein. The results are shown in FIG. 7, which show that the recombinant Cel3a (aglycosylated Cel3a purified from E. coli; labeled Cel3a in FIG. 7) demonstrated higher specific activity for converting cellobiose to glucose compared to the endogenous Cel3a (labeled L4196 in FIG. 7). Specifically, at concentrations lower than 0.2 mg/mL of cellobiase, the recombinant Cel3a was able to produce a larger amount of glucose after 30 minutes than the endogenous Cel3a.
    • Example 7 Addition of Aglycosylated Cellobiase Increases Product from Saccharification Process
  • In this example, the glucose yield was compared between two saccharification reactions. In one saccharification reaction, an enzyme mixture comprising the enzymes described in Table 1 was added to a biomass. In a second saccharification reaction, 0.8 mg/ml of aglycosylated Cel3a purified from E. coli was added to the enzyme mixture comprising the enzymes described in Table 1, and was added to a biomass. The saccharification reactions were run under the conditions as described herein, with samples taken at multiple timepoints between 0 and 80 minutes of the reaction. The resulting glucose was measured and quantified using methods in the art, such as by YSI instrument or HPLC, and plotted over time, as shown in FIG. 8. These results show that addition of aglycosylated Cel3a increased the yield of sugar product, e.g., glucose, in a saccharification reaction.
    • EQUIVALENTS
  • The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety. While this invention has been disclosed with reference to specific aspects, it is apparent that other aspects and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such aspects and equivalent variations.

Claims (53)

What is claimed is:
1. An aglycosylated polypeptide having cellobiase activity comprising at least 90% identity to SEQ ID NO: 1, or a functional fragment thereof.
2. The aglycosylated polypeptide of claim 1, wherein the polypeptide comprises a Cel3A enzyme from wild-type T. reesei, or a functional variant or fragment thereof.
3. The aglycosylated polypeptide of claim 2, wherein the Cel3A enzyme comprises (e.g., consists of) the amino acid sequence SEQ ID NO: 1.
4. The aglycosylated polypeptide of any one of claims 1-3, wherein the polypeptide is encoded by a nucleic acid sequence comprising (e.g., consisting of) SEQ ID NO: 2.
5. The aglycosylated polypeptide of any one of claims 1-4, wherein the polypeptide comprises a mutation proximal to or at one or more glycosylation sites, wherein the mutation prevents glycosylation at the one or more glycosylation sites.
6. The aglycosylated polypeptide of claim 5, wherein the mutation is at one or more of the threonine at amino acid position 78, the threonine at amino acid position 241, the serine at amino acid position 343, the serine at amino acid position 450, the threonine at amino acid position 599, the serine at amino acid position 616, the threonine at amino acid position 691, the serine at amino acid position 21, the threonine at amino acid position 24, the serine at amino acid position 25, the serine at amino acid position 28, the threonine at amino acid position 38, the threonine at amino acid position 42, the threonine at amino acid position 303, the serine at amino acid position at 398, the at serine amino acid position 435, the serine at amino acid position 436, the threonine at amino acid position 439, threonine at amino acid position 442, the threonine at amino acid position 446, the serine at amino acid position 451, the serine at amino acid position 619, the serine at amino acid position 622, the threonine at amino acid position 623, the serine at amino acid position 626, or the threonine at amino acid position 630 of SEQ ID NO: 1.
7. The aglycosylated polypeptide of any one of the preceding claims, wherein the aglycosylated polypeptide has increased cellobiase activity as compared to glycosylated Cel3A enzyme from wild-type T. reesei.
8. The aglycosylated polypeptide of any one of the preceding claims, wherein the aglycosylated polypeptide has increased substrate recognition, a more active substrate recognition site, or reduced steric hindrance as compared to glycosylated Cel3A enzyme from wild-type T. reesei.
9. The aglycosylated polypeptide of any one of the preceding claims, wherein the aglycosylated polypeptide hydrolyzes a carbohydrate such as cellobiose into one or more monosaccharides, e.g., glucose.
10. The aglycosylated polypeptide of any one of the preceding claims, wherein the cellobiase activity comprises hydrolysis of a beta 1,4 glycosidic linkage of cellobiose.
11. A nucleic acid sequence encoding the polypeptide of claims 1-10.
12. A nucleic acid sequence encoding a Cel3A enzyme or functional variant thereof, wherein the nucleic acid sequence comprises (e.g., consists of) at least 90% identity to SEQ ID NO: 2 or SEQ ID NO: 3.
13. A nucleic acid molecule comprising a nucleic acid sequence of any of claims 11 and 12.
14. The nucleic acid molecule of claim 13, further comprising a promoter, e.g., a promoter for prokaryotic cell expression, e.g., bacterial cell expression, e.g., expression in E. coli.
15. The nucleic acid molecule of claim 14, wherein the promoter sequence is a constitutive promoter sequence, inducible promoter sequence, or a repressible promoter sequence.
16. The nucleic acid molecule of claim 14 or 15, wherein the promoter is a T7 promoter.
17. The nucleic acid molecule of any one of claims 13-16, further comprising a nucleic acid sequence encoding a tag, e.g., a tag for detection and/or purification and/or for linkage to another molecule, e.g., a His tag.
18. The nucleic acid molecule of any one of claims 13-17, further comprising a nucleic acid encoding one or more signal sequences, e.g., a secretion signal sequence.
19. An expression vector comprising the nucleic acid sequence of any of claims 11-18.
20. The expression vector of claim 18, further comprising a nucleic acid sequence encoding a selection marker, e.g., a kanamycin or an ampicillin marker.
21. A cell comprising the vector of any one of claims 13-20.
22. A prokaryotic cell or bacterial cell comprising the vector of any one of claims 13-20.
23. A cell expressing a polypeptide of any one of claims 1-10.
24. A prokaryotic cell or bacterial cell expressing a polypeptide of any one of claims 1-10.
25. The bacterial cell of claim 22 or 24 wherein the bacterial cell is impaired for glycosylation.
26. The bacterial cell of claim 25, wherein the bacterial cell is an E. coli cell.
27. The bacterial cell of claim 26, wherein the E. coli cell is an origami E. coli cell.
28. A method for producing the aglycosylated polypeptide of any one of claim 1, 2, 3, 4, 7, 8, 9 or 10, comprising culturing a cell expressing a polypeptide of any one of claim 1, 2, 3, 4, 7, 8, 9 or 10, under conditions suitable for the expression of the polypeptide, wherein the cell does not glycosylate the polypeptide, e.g., a bacterial cell, e.g., an E. coli cell, e.g., an origami E. coli cell.
29. A method for producing the aglycosylated polypeptide of any of claim 1, 2, 3, 4, 7, 8, 9 or 10, comprising treating a polypeptide comprising an amino acid with at least 90% identity to SEQ ID NO: 1 with a deglycosylating enzyme.
30. The method of claim 29, wherein the deglycosylating enzyme is selected from PGNase and EndoH.
31. A method for producing the aglycosylated polypeptide of any one of claim 1, 2, 3, 4, 7, 8, 9 or 10, comprising culturing a cell that comprises a nucleic acid sequence encoding a polypeptide of any one of claim 1, 2, 3, 4, 7, 8, 9 or 10, wherein the nucleic acid sequence has one or more mutations which prevent glycosylation of the encoded polypeptide.
32. A method for culturing a cell expressing the aglycosylated polypeptide of any one of claim 1, 2, 3, 4, 7, 8, 9 or 10 in the presence of a glycosylation inhibitor, e.g., tunicamycin.
33. An enzyme mixture comprising a glycosylated polypeptide comprising an amino acid sequence with at least 90% identity to SEQ ID NO: 1 and an aglycosylated polypeptide comprising an amino acid sequence with at least 90% identity to SEQ ID NO: 1, wherein both of the glycosylated polypeptide and the aglycosylated peptide have cellobiase activity.
34. The enzyme mixture of claim 33, wherein the aglycosylated polypeptide is the aglycosylated polypeptide of any one of claims 1-10.
35. The enzyme mixture of claim 33 or 34, wherein the glycosylated polypeptide and the aglycosylated polypeptide both comprise Cel3A enzyme from wild-type T. reesei.
36. The enzyme mixture of any one of claims 33-35, further comprising at least one additional enzyme derived from a microorganism, wherein the additional enzyme has a biomass-degrading activity of a cellulose based material.
37. The enzyme mixture of claim 36, wherein the additional enzyme is selected from a ligninase, an endoglucanase, a cellobiohydrolase, xylanase, and a cellobiase.
38. The enzyme mixture of claim 33 or 34, wherein the mixture further comprises one or more ligninase, one or more endoglucanase, one or more cellobiohydrolase, one or more xylanase.
39. The enzyme mixture of any one of claims 33-38, wherein the ratio between the aglycosylated polypeptide to the remaining enzymes in the mixture is at least 1:32, e.g., 1:32 to 1:300.
40. The enzyme mixture of any of claims 33-38, wherein the ratio of the aglycosylated polypeptide to a glycosylated polypeptide is at least 1:32, e.g., 1:32 to 1:300.
41. A method of producing a product (e.g., a hydrogen, sugar, alcohol, etc.) from a biomass (or converting a biomass to a product) comprising contacting a biomass, e.g., by treatment with an electron beam, with an aglycosylated polypeptide of any one of claims 1-10 and a microorganism (mixture) that produces one or more biomass-degrading enzyme or an enzyme mixture comprising biomass-degrading enzymes under conditions suitable for the production of the sugar product.
42. A method of producing a product (e.g., a hydrogen, a sugar, an alcohol) from a biomass comprising contacting a biomass with an enzyme mixture of any one of claims 33-40 under conditions suitable for the production of the product.
43. The method of claim 41 or 42, wherein said product is a sugar product.
44. The method of any one of claims 41-43, further comprising isolating the sugar product.
45. The method of claim 44, wherein the isolating of the sugar product comprises precipitation, crystallization, chromatography, centrifugation, and/or extraction.
46. The method of any one of claims 43-45, wherein the sugar product is glucose and/or xylose.
47. The method of any one of claims 41-46, wherein the enzyme mixture comprises at least two of the enzymes selected from the group consisting of B2AF03, CIP1, CIP2, Cel1a, Cel3a, Cel5a, Cel6a, Cel7a, Cel7b, Cel12a, Cel45a, Cel74a, paMan5a, paMan26a, Swollenin, and the enzymes listed in Table 1.
48. The method of any one of claims 41-47, wherein the biomass comprises one or more of an agricultural product or waste, a paper product or waste, a forestry product, or a general waste, or any combination thereof; wherein:
a) an agricultural product or waste comprises sugar cane jute, hemp, flax, bamboo, sisal, alfalfa, hay, arracacha, buckwheat, banana, barley, cassava, kudzu, oca, sago, sorghum, potato, sweet potato, taro, yams, beans, favas, lentils, peas, grasses, switchgrass, miscanthus, cord grass, reed canary grass, grain residues, canola straw, wheat straw, barley straw, oat straw, rice straw, corn cobs, corn stover, corn fiber, coconut hair, beet pulp, bagasse, soybean stover, grain residues, rice hulls, oat hulls, wheat chaff, barley hulls, or beeswing, or a combination thereof;
b) a paper product or waste comprises paper, pigmented papers, loaded papers, coated papers, filled papers, magazines, printed matter, printer paper, polycoated paper, cardstock, cardboard, paperboard, or paper pulp, or a combination thereof;
c) a forestry product comprises aspen wood, particle board, wood chips, or sawdust, or a combination thereof; and
d) a general waste comprises manure, sewage, or offal, or a combination thereof.
49. The method of any one of claims 41-48, further comprising a step of treating the biomass prior to introducing the microorganism or the enzyme mixture to reduce the recalcitrance of the biomass, wherein the treating comprises bombardment with electrons, sonication, oxidation, pyrolysis, steam explosion, chemical treatment, mechanical treatment, or freeze grinding.
50. The method of any one of claims 41-49 wherein the microorganism that produces a biomass-degrading enzyme is from species in the genera selected from Bacillus, Coprinus, Myceliophthora, Cephalosporium, Scytalidium, Penicillium, Aspergillus, Pseudomonas, Humicola, Fusarium, Thielavia, Acremonium, Chrysosporium or Trichoderma.
51. The method of any one of claims 41-50, wherein the microorganism that produces a biomass-degrading enzyme is selected from Aspergillus, Humicola insolens (Scytalidium thermophilum) Coprinus cinereus, Fusarium oxysporum, Myceliophthora thermophila, Meripilus giganteus, Thielavia terrestris, Acremonium persicinum, Acremonium acremonium, Acremonium brachypenium, Acremonium dichromosporum, Acremonium obclavatum, Acremonium pinkertoniae, Acremonium roseogriseum, Acremonium incoloratum, Acremonium furatum, Chrysosporium lucknowense, Trichoderma viride, Trichoderma reesei, or Trichoderma koningii.
52. The method of any one of claims 41-51, wherein the microorganism has been induced to produce a biomass-degrading enzyme by combining the microorganism with an induction biomass sample under conditions suitable for increasing production of a biomass-degrading enzyme compared to an uninduced microorganism.
53. The method of any of claim 52, wherein said induction biomass sample comprises paper, paper products, paper waste, paper pulp, pigmented papers, loaded papers, coated papers, filled papers, magazines, printed matter, printer paper, polycoated paper, card stock, cardboard, paperboard, cotton, wood, particle board, forestry wastes, sawdust, aspen wood, wood chips, grasses, switchgrass, miscanthus, cord grass, reed canary grass, grain residues, rice hulls, oat hulls, wheat chaff, barley hulls, agricultural waste, silage, canola straw, wheat straw, barley straw, oat straw, rice straw, jute, hemp, flax, bamboo, sisal, abaca, corn cobs, corn stover, soybean stover, corn fiber, alfalfa, hay, coconut hair, sugar processing residues, bagasse, beet pulp, agave bagasse, algae, seaweed, manure, sewage, offal, agricultural or industrial waste, arracacha, buckwheat, banana, barley, cassava, kudzu, oca, sago, sorghum, potato, sweet potato, taro, yams, beans, favas, lentils, peas, or any combination thereof.
US16/151,690 2014-08-08 2018-10-04 Aglycosylated enzyme and uses thereof Abandoned US20190024068A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/151,690 US20190024068A1 (en) 2014-08-08 2018-10-04 Aglycosylated enzyme and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462035346P 2014-08-08 2014-08-08
US14/768,126 US10131894B2 (en) 2014-08-08 2015-08-07 Aglycosylated enzyme and uses thereof
PCT/US2015/044136 WO2016022878A1 (en) 2014-08-08 2015-08-07 Aglycosylated enzyme and uses thereof
US16/151,690 US20190024068A1 (en) 2014-08-08 2018-10-04 Aglycosylated enzyme and uses thereof

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2015/044136 Continuation WO2016022878A1 (en) 2014-08-08 2015-08-07 Aglycosylated enzyme and uses thereof
US14/768,126 Continuation US10131894B2 (en) 2014-08-08 2015-08-07 Aglycosylated enzyme and uses thereof

Publications (1)

Publication Number Publication Date
US20190024068A1 true US20190024068A1 (en) 2019-01-24

Family

ID=55264604

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/768,126 Active US10131894B2 (en) 2014-08-08 2015-08-07 Aglycosylated enzyme and uses thereof
US16/151,690 Abandoned US20190024068A1 (en) 2014-08-08 2018-10-04 Aglycosylated enzyme and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/768,126 Active US10131894B2 (en) 2014-08-08 2015-08-07 Aglycosylated enzyme and uses thereof

Country Status (16)

Country Link
US (2) US10131894B2 (en)
EP (1) EP3177719A4 (en)
JP (1) JP2017524363A (en)
KR (1) KR20170040246A (en)
CN (1) CN106536730A (en)
AP (1) AP2016009640A0 (en)
AU (1) AU2015300897A1 (en)
BR (1) BR112017002391A2 (en)
CA (1) CA2955960A1 (en)
CU (1) CU20170011A7 (en)
EA (1) EA201790054A1 (en)
IL (1) IL250272A0 (en)
MX (1) MX2017001596A (en)
PH (1) PH12016502604A1 (en)
SG (1) SG11201610894UA (en)
WO (1) WO2016022878A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017002391A2 (en) 2014-08-08 2017-11-28 Xyleco Inc aglycosylated enzyme and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110171674A1 (en) * 2008-09-12 2011-07-14 IFP Energies Nouvelles Beta-Glucosidase Variants Having Improved Activity, and Uses Thereof
US10131894B2 (en) * 2014-08-08 2018-11-20 Xyleco, Inc. Aglycosylated enzyme and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5028515B2 (en) 1971-09-30 1975-09-16
US5997913A (en) * 1990-12-10 1999-12-07 Genencor International, Inc. Method enhancing flavor and aroma in foods by overexpression of β-glucosidase
WO2001036586A2 (en) 1999-11-19 2001-05-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Aspegillus niger beta-glucosidase gene, protein and uses thereof
US6946277B2 (en) 2001-01-31 2005-09-20 Council Of Scientific And Industrial Research Method for enhancing cellobiase activity of termitomyces clypeatus using a glycosylation inhibitor
FI120045B (en) * 2005-12-22 2009-06-15 Roal Oy Treatment of cellulose materials and enzymes useful therein
ES2538360T3 (en) * 2006-07-21 2015-06-19 Novozymes, Inc. Methods to increase the secretion of polypeptides that have biological activity
EP3279329A1 (en) 2006-07-21 2018-02-07 Xyleco, Inc. Conversion systems for biomass
EP2037274A1 (en) 2007-09-11 2009-03-18 GALAB Technologies GmbH Lectin based glycane assay
MX344902B (en) 2009-05-20 2017-01-11 Xyleco Inc Processing hydrocarbon-containing materials.
IN2012DN03825A (en) * 2009-11-20 2015-08-28 Danisco Us Inc
SG10201604060SA (en) 2010-07-19 2016-07-28 Xyleco Inc Processing biomass
NZ609261A (en) 2010-10-20 2015-04-24 Xyleco Inc Method for treating lignocellulosic material by irradiating with an electron beam
US20140073017A1 (en) * 2011-03-17 2014-03-13 Danisco Us Inc. Cellulase compositions and methods of using the same for improved conversion of lignocellulosic biomass into fermentable sugars
SG11201402953SA (en) 2011-12-22 2014-08-28 Xyleco Inc Processing of biomass materials
FR2994981B1 (en) * 2012-09-05 2014-09-12 Centre Nat Rech Scient POLYPEPTIDE WITH BETA-GLUCOSIDASE ACTIVITY REINFORCED AT LOW TEMPERATURE
WO2014086706A1 (en) 2012-12-07 2014-06-12 Novozymes A/S Method for generating site-specific mutations in filamentous fungi

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110171674A1 (en) * 2008-09-12 2011-07-14 IFP Energies Nouvelles Beta-Glucosidase Variants Having Improved Activity, and Uses Thereof
US10131894B2 (en) * 2014-08-08 2018-11-20 Xyleco, Inc. Aglycosylated enzyme and uses thereof

Also Published As

Publication number Publication date
AU2015300897A1 (en) 2017-01-05
SG11201610894UA (en) 2017-01-27
CA2955960A1 (en) 2016-02-11
MX2017001596A (en) 2017-05-15
CU20170011A7 (en) 2017-08-08
EP3177719A4 (en) 2018-04-04
KR20170040246A (en) 2017-04-12
PH12016502604A1 (en) 2017-04-24
CN106536730A (en) 2017-03-22
JP2017524363A (en) 2017-08-31
WO2016022878A1 (en) 2016-02-11
AP2016009640A0 (en) 2016-12-31
US20170137797A1 (en) 2017-05-18
US10131894B2 (en) 2018-11-20
IL250272A0 (en) 2017-03-30
EP3177719A1 (en) 2017-06-14
BR112017002391A2 (en) 2017-11-28
EA201790054A1 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
US20190161772A1 (en) Methods for improving the efficiency of simultaneous saccharification and fermentation reactions
US9080163B2 (en) Cellobiohydrolase variants
US9260705B2 (en) Cellobiohydrolase variants
US8906689B2 (en) Endoglucanase variants
US20200190462A1 (en) Compositions for enhanced enzyme production
US20190316108A1 (en) Solubilized enzyme and uses thereof
US20190024068A1 (en) Aglycosylated enzyme and uses thereof
OA18211A (en) Aglycosylated enzyme and uses thereof.
AU2015261652B2 (en) Methods for improving the efficiency of simultaneous saccharification and fermentation reactions
CN111094562A (en) Polypeptides having trehalase activity and their use in methods of producing fermentation products
WO2018069499A1 (en) Method for processing lignocellulosic biomass
OA18252A (en) Solubilized enzyme and uses thereof.
MEDOFF et al. Patent 2981059 Summary

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION